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Background: Cardiovascular disease (CVD) is still the leading cause of death 
in the developed as well as developing country. Atherosclerosis and 
neointima formation considered as chronic inflammatory diseases, in which 
many cells including inflammatory smooth muscle cell (iSMC) were involved. 
ISMC differentiation from vascular adventitia stem/progenitor cells 
(AdSPCs) has been recently recognised as a critical determinant in 
cardiovascular diseases. One study have recently reported an important 
role for microRNA-214 (miR-214) in mature vascular SMC functions and 
injury-induced neointima formation. However, little is known about the 
functional involvements of miR-214 in iSMC differentiation from AdSPCs 
and its contribution to adverse arterial remodelling. 
Purpose: In this PhD study, I aimed to study the functional importance of 
miR-214 and its target gene in iSMC differentiation from AdSPCs and 
neointima SMC hyperplasia. 
Results: miR-214 expression was significantly increased during SMC 
differentiation from AdSPCs in response to TGFβ1. miR-214 gain/loss-of-
function assays showed that miR-214 plays an important role in SMC 
differentiation from AdSPCs. By co-incubating AdSPCs with TGFβ1 and TNFα, 
AdSPCs were induced to differentiate toward iSMCs as evident by a 
decreased expression level of SMC-specific genes, but an increased level of 
inflammatory genes in iSMCs. Importantly, such phenotype could be 
reverted by miR-214 over-expression. I observed that sonic hedgehog-
glioma-associated oncogene 1 (Shh-GLI1) signal was closely modulated 
during iSMC differentiation, and demonstrated that Suppressor of Fused 
(SuFu) is the functional target of miR-214 controlling iSMC generation from 
AdSPCs. Further mechanistic studies revealed that increased amount of the 
GLI1 protein was translocalized into nuclei in miR-214 over-expressing or 
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SuFu knockdown cells, and the consensus sequence (GACCACCCA) of GLI1 
within gene promoters of smooth muscle alpha-actin (SMαA) and serum 
response factor (SRF) was required for their regulation by miR-214 and SuFu. 
Additionally, Sufu also functions as a positive regulator for inflammatory 
gene regulations in iSMCs. In vivo, I demonstrated that locally enforced 
expression of miR-214 in the injured vessels significantly reduced SuFu 
expression level, iSMC generation, and inhibited neointima SMC 
hyperplasia after injury. Importantly, I observed that perivascularly 
transplanted AdSPCs significant contribute to neointima SMC hyperplasia 
by differentiating to iSMCs, and miR-214 over-expression could reverse 
such an effect. Finally, a decreased expression level of miR-214, but 
increased expression level of Sufu was observed in diseased human arteries.  
Conclusions/Implications: This thesis reports an unexplored role for miR-
214 in iSMC differentiation from AdSPCs and controlling neointima iSMC 
hyperplasia. These findings provide new insights into the therapeutic effect 
of miR-214 in vascular diseases. 
 
Key words:  Adventitia stem cells; Progenitor cells,  Arterial remodelling; 
Neointima formation; Atherosclerosis; Inflammatory smooth muscle cell; 
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Although huge improvement on treating and researching into 
cardiovascular disease (CVD) has been successfully achieved in the past 
several decades, CVD is still the leading cause of death around the world 
(Benjamin et al. 2017). A recent report on CVD in Europe, of all the deaths 
registered in 15 EU countries, one third of deaths were caused by CVDs 
(Townsend et al. 2016). According to statistical analyses by the World 
Health Organization (WHO), more than 17.3 million people died from CVDs 
in 2013 all around the world, a 41% increase since 1990  (Roth et al. 2015). 
A rapid increase in world population growth and number of aging people, 
are considered the two major contributing factors to this increase. 
Additionally, the composition of CVD patients in recent years has changed 
over time. Increasingly more and more young patients present with signs of 
severe CVD onset. In 2002, The WHO reported that more than 46% of 
deaths due to CVD were in patients under 70 (Guilbert 2003). These global 
statistical analyses reveal the serious threat that CVD presents to human’s 
future.  
 
Raised blood pressure, tobacco, excess alcohol consumption, cholesterol 
and being overweight are the major risk factors of CVD. For instance, 
tobacco smoking results in endothelial cell dysfunction, which plays a 
critical role during the atherosclerosis process, a precursor to CVD onset.  
Evidence from clinical and pre-clinical studies supports that smoking 
tobacco promotes endothelial cell dysfunction which not only initiates 
atherosclerosis but also accelerates it (American Heart Association 
Statistics 2004). Atherosclerotic plaque formation and/or growth will lead 
to the blood vessel narrowing or even complete occlusion, resulting oxygen 
depletion and cell death in tissues and organs further downstream. 
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Atherosclerosis is the main pathophysiological process of most ischemic 
CVDs. According to investigations in 2013, ischemic heart disease is the 
main cause of increased death in CVDs (Roth et al. 2015).  
 
Atherosclerosis is considered as a chronic inflammatory disease, with a 
series of pathological changes and rampant cell proliferation occurring at 
the lesion site resulting in a narrowed artery or complete blockage, leading 
to diminished blood flow to the myocardium. Coronary artery disease is one 
of the most serious consequences of atherosclerosis. Surgical operations 
like angioplasty, Percutaneous transluminal coronary angioplasty (PTCA) 
with stenting, atherectomy and coronary artery bypass grafting (CABG) are 
widely used in the clinic to treat patients who are suffering from the 
consequences of severe, end-stage coronary atherosclerosis (Weintraub 
2007). PTCA, first developed in 1977, is the most successful and minimally 
invasive surgery for treating patients with ischemic coronary artery disease 
(CAD). It has since become one of the most commonly used surgical 
techniques in the US, accounted  for 3.6% of all surgical procedure in US in 
2011(Weiss, et al. 2006). Although it was widely used in the clinic, PTCA is 
not flawless, as there are many side effects associated with this technique 
post-surgery. These unavoidable side effects include restenosis of the 
vessel wall. Novel research has focused on improving this procedure or 
even promoting the use of alternative non-invasive strategies, in order to 
help prevent current side effects from arising. For example, since PTCA 
requires the use of a balloon-tipped catheter, which is inserted into the 
blocked site, an anti-proliferation drug coated- balloon was developed to 
reduce the proliferating cells from blocking the site once more. One clinical 
trial used paclitaxel-coated balloons before treatment, and compared the 
therapy prognosis against the drug eluting stents treatment patients. 
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Promising data were found that this method has better outcome than using 
the foreign body replacement stent (Mohiaddin et al. 2018). Restenosis of 
the vessel wall or neointimal hyperplasia has been considered as the most 
prominent pathological issue with the patients after PTCA and stenting. In 
brief, restenosis is a maladaptive response to arterial injury and 
characterised by arterial neointimal formation. Vascular smooth muscle 
cells (VSMCs) play a critical role during this process, and it has been 
reported that VSMCs participate in restenosis and neointimal formation by 
undergoing phenotype switching, proliferation, migration as well as by 
secreting extracellular matrix (ECM) proteins into the injured intimal 
layer(ER et al. 2011). A clinical report shows that over 20-50% of patients 
after balloon angioplasty and about 10-30% who received a stent during the 
procedure experienced restenosis (Bhargava et al. 2003). The underlying 
pathophysiology of restenosis involves a very complex series of cellular and 
molecular mechanisms, which are not yet fully understood. Thus, the 
treatments for restenosis are far from satisfactory. Many cells involved into 
the atherosclerosis are also involved in neointimal formation following 
PTCA. Endothelial cells, macrophages, VSMCs and myo-fibroblasts are 
among the most important cell types to participate in neointimal formation. 
Research focusing on these cells not only reveal the exact roles that these 
cell play during the pathological process but also provide a novel 
therapeutic direction for the future clinical treatments (Gimbrone et al. 
2016; Bennett, et al. 2016; Groh et al. 2018). VSMCs are the main cellular 
component of the vascular media. Under normal physiological conditions, 
VSMCs maintain the vascular structure and rarely undergo proliferation. 
However, under specific environmental stimulation, synthetic VSMCs are 
apparent and participate in various pathological processes. Inflammatory 
SMCs (iSMCs) identified in the developing restenotic lesion were found 
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resident in the intima of the vessel, producing collagen, elastin and various 
inflammatory cytokines. Altogether, this was shown to promote 
hyperplasia of the neointima, resulting in arterial wall thickening and vessel 
narrowing and/or occlusion. Understanding the source of iSMCs during 
restenosis is of great importance for future atherosclerosis and restenosis 
therapy.  
 
Many types of the cells have been reported as capable of contributing to 
iSMC such as; mature VSMCs migrating into the intima and undergoing 
phenotype switching; endothelial cells (ECs) undergoing mesenchymal 
transition, circulating stem cells as well as the vascular stem/progenitor 
cells.  
   
Adventitial stem/ progenitor cells (AdSPCs) are considered as one of the 
cellular sources of iSMCs in atherosclerosis and restenosis. In 1997, one 
group identified a group of CD34+ endothelial progenitor cells (EPCs), in 
peripheral blood, which participate in new vessel formation (Asahara et al. 
1997). Many adult stem progenitor cells have been reported to be involved 
in CVDs. Previously, the adventitia of the blood vessel was considered to 
consist mainly of fibroblasts, connective tissue matrix as well as nerve 
ending.  In 2004, one group examined organs and tissues of ApoE deficient 
mice and found that many stem cells that were detectable through 
antibody selection were present in the adventitia of the vascular wall. These 
cells were positive for Stem cells antigen-1 (Sca-1), proto-oncogene c-kit, 
CD34 and Flk-1, but negative for the bone marrow biomarker CD133 and 
embryonic stem cell marker SSEA-1. Further experiments indicated that 
these cells could be differentiated into SMCs in vitro as well as in vivo (Hu 
et al. 2004). Interestingly, when these Sca-1 positive cells were transferred 
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to the adventitial side of the vein graft in ROSA26/ApoE-/- mice for 4 weeks, 
the cells could be traced to the neointimal of the blood vessel, which 
indicated that the Sca-1 positive progenitor cells were able to migrate from 
the adventitia to the neointima and more importantly they were able to 
differentiate into SMCs (Hu et al. 2004).  Moreover, miRNAs were found to 
play a crucial role during the differentiation of Sca-1 positive stem 
progenitor cells into SMCs (Zhao et al. 2015), suggesting that certain 
miRNAs can influence adventitial stem progenitor cells differentiation, and 
thus have an important effect on several disease processes. 
 
MiRNAs are a group of small non-coding RNAs, which are found in a variety 
organism including viruses, plants as well as metazoans. The main function 
of miRNAs is to act as post transcriptional regulators.  Mature miRNA, along 
with the relative Argonaute family protein, is loaded onto an RNA-induced 
silencing complex, which then binds to a recognised 3’UTR region of its 
target mRNAs. MiRNAs are thus able to control protein expression within 
the cell by determining the fate of its target mRNA molecule which will 
eventually undergo cleavage, degradation, or transport and storage into P 
bodies thereby inhibiting protein translation, a fundamental biological 
process. Numerous miRNAs have been proven to take part into almost 
every stage of the atherosclerotic process and neointimal formation, 
including the regulation of endothelial dysfunction, cholesterol 
homeostasis, plaque development, neo-angiogenesis, VSMC migration and 
phenotype switching, as well as iSMC differentiation during the restenosis 
(Madrigal-Matute, et al. 2013).  Future gene therapies and/or 
pharmacological compounds should take advantage of this group of non-




1.1 Cardiovascular Diseases (CVDs) 
According to statistical analyses by the WHO global status report on non-
communicable diseases (NCDs), CVD was the leading cause of NCD death in 
2012, accounting for 17.5 million deaths (Mendis, et al. 2015). It remain one 
of the most serious diseases in Europe accounting for about 4 million deaths 
in 2016, which is around 45% of total mortality in the EU (Townsend,  et al. 
2016),  Unfortunately, this phenomenon is now spreading to low and 
middle income countries as well (Lopez,  et al. 2006). According to data from 
2016, regions affected by the highest rates of CVD were recorded in the 
central Asia and Eastern Europe (Thomas, et al. 2018), with nearly 70% of 
deaths attributed to CVDs occurring in low and middle income 
countries(Figure 1) (Benziger, et al.  2016).  
 
Figure 1. Eastern Europe and Central Asia region contribute to the highest per capita CVDs 
burden. According to the data of change in CVDs disability adjusted life years (DALYs) in every 
100,000 people in 21 global region investigation between 2000 and 2016 (Benziger, Roth, and 
Moran 2016) (Thomas, et al. 2018).  
 
Risk factors attributable to besides gender, age, ethnicity, family history and 
genetic makeup, include; high systolic blood pressure, diet, high total 
cholesterol, air pollution, tobacco, high body mass index, high fasting 
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plasma glucose, impaired kidney function, low physical activity, alcohol and 
drug use, and other environmental and occupational risks. 
 
Diet, high blood pressure and tobacco are the top three leading risk factors 
for CVDs (Figure 2), whilst the remaining CVD risk factors vary from region 
to region. For example air pollution presents a much greater risk in East 
Asian and South Asian countries while alcohol consumption appears to be 
a more critical risk factor in Eastern Europe(Benziger, et al.  2016).  
 
Figure 2. CVDs risk factors contribute to the number of DALYs, between 2000 and 2016 including 
both sexes, all around the world (Thomas, et al. 2018). 
The cardiovascular system is one of the most complex systems in the human 
body, and many diseases are linked to CVD. In the clinic, a number of 
diseases are classed as CVDs including; coronary heart disease, heart failure, 
cardiac arrest, ventricular arrhythmias, sudden cardiac death, rheumatic 
heart disease and transient ischemic attack, subarachnoid ischemic stroke, 
intracerebral haemorrhage, abdominal aortic aneurysm, peripheral artery 
disease and congenital heart disease (Wong, et al. 2014). Ischemic heart 
diseases, belonging to the coronary heart diseases (CHD) category, 
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contributed to approximately 46% of CVD deaths in males and 38% of 
deaths in females in 2011(Shanthi Mendis. 2011). In 2016, the number of 
people suffering from ischemic heart disease was estimated to be about 49% 
of CVD cases (Thomas, et al. 2018).  CHD occurs when the coronary arteries 
carrying oxygenated blood and nutrients to the heart (or myocardium) 
become blocked or narrowed by an atheroma, a process caused by the 
clinically defined process of ‘atherosclerosis’. 
 
1.2 Atherosclerosis and restenosis   
Atherosclerosis is the leading cause of ischemic CVDs. It is recognized as a 
chronic inflammatory disease within the arterial wall. Atherosclerosis 
lesions normally develop in large and medium size arteries which can lead 
to ischemia of the heart, brain as well as extremities of the body (Ross. 
1999). The exact triggers for atherosclerosis are still unknown, but similar 
to all the CVDs, tobacco smoking, dietary risks, high blood pressure, obesity 
and high total cholesterol including high or low-density lipoprotein 
cholesterol and low level of high-density lipoprotein in the blood system are 
known to be associated with an increased risk of atherosclerosis. Health 
behaviour plays an important role in delaying or preventing atherosclerosis. 
For example, a group tracked about 9776 adults in US for an average of 19 
years, and they concluded that a higher intake of dietary fibre could reduce 
the risk of CHD in most cases (Bazzano, et al. 2003). Based on the 
histological analysis, the stages of atherosclerotic lesion formation can be 
classified into six different morphological types: 1) initial lesion which 
predominantly consists of macrophages and scattered foam cells 
surrounding the atherogenic lipoprotein  (Stary, et al. 1992). 2) progression-
prone type II lesion; with the macrophage foam cells and lipid laden smooth 
muscle cell (SMC) as the key feature, and a fatty streak as the primary lesion 
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structure. 3) Intermediate lesion, this is the stage between type II and type 
III, which is similar to type II but contains scattered extracellular lipid drops 
and the SMC coherence were blocked by some particles (Stary, et al. 1994). 
4) Extracellular lipids are extensively distributed throughout the atheroma 
in the region of the intima known as the lipid core. 5) Type V lesion 
(including V a, V b and V c type), contains new, fibrous connective tissue, 
with the presence of a fibro-atheroma known as type Va, the presence of 
lipid core calcification known as type Vb, or minimal presence (or even 
absence) of a lipid core referred to as type Vc.  6) Type VI lesion is the final 
morphology of the atherosclerosis, which usually results in disruption of the 
lesion surface, hematoma, haemorrhage and the thrombotic deposits. 
Notably, the type IV or V morphology superimposed one or more character 


















Table 1. Different types of atherosclerotic lesion and its relationship 
Nomenclature  Histological character classification Sequences in progression 










Type II lesion Progression –prone type 
II lesion (type II a lesion) 
Fatty 
steak 
Progression – resistant 
type II lesion (type II b 
lesion) 
Type III lesion Intermediate lesion 
Type IV lesion Atheromatous plaque 
Type V lesion Fibroatheroma 















(Type V c/VIII 
lesion) 
Fibrous plaque 
Type VI lesion Lesion with surface defect 
with/without hematoma 




This table displays the pathways in the progression of human atherosclerotic lesion. The arrows 
show the sequence of morphologies changes over time. With the main change pertaining to lipid 
accumulation from type I to IV. The transition between stage IV, V and VI depends on lesion 












Surgery operations like angioplasty, PTCA with stenting, atherectomy and 
coronary artery bypass grafting (CABG) are widely used in the clinic to treat 
patients who suffer from severe coronary atherosclerosis (Weintraub. 
2007). Among these surgical operations, CABG and PTCA are the most 
popular approaches in clinical treatment for revascularization. PTCA, also 
known as percutaneous coronary intervention (PCI), was first developed in 
1977 and became one of the most common surgical techniques in the US 
(Weiss, et al. 2006). In Canada, the popularity of the revascularization 
operation has increased continually to about 50% of 40,000 CHD patients  
in each year (ER, et al. 2011). Although it is widely used in the clinic, PTCA is 
not a flawless surgery and side effects like the restenosis of the vessel wall 
are inevitable. 
 
Although atherosclerosis and restenosis are defined as different clinical 
diseases, they still involve similar pathological processes such as neointima 
formation. Neointimal formation is a common pathological process in 
different cardiovascular diseases such as atherosclerosis, post angioplasty 
restenosis, coronary heart diseases and so on (Ji, et al. 2007). 
Atherosclerosis, neointimal formation and hyperplasia as well as the 
restenosis are continual problems, which hinder clinical therapy. No matter 
what stage of atherosclerosis is, the artery injury caused by surgery or 
disease itself induced the maladaptive response of the artery are likely 
develop into the restenosis. Restenosis is defined by the diameter of the 
stenosis. When the vessel diameter reaches around 50% reduction after the 
treatment this is termed as vascular restenosis (Bhargava, et al. 2003). 
Usually, the lumen loss after the revascularization can be divided into three 
different stages; such as early loss of relative elastic recoil, late loss of 
relative elastic recoil causing negative remodelling and neointimal 
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hyperplasia(Weintraub. 2007). It has been reported that about 20-50% of 
balloon angioplasty surgery patients and 10-30% stent implantation 
patients are likely to develop restenosis. Restenosis usually presents 
between one and three months following balloon angioplasty surgery, with 
angina occurring in the fourth month, but this is delayed by one to three 
months in patients who have received stents (Serruys, et al. 1988). 
Although endovascular stents are considered to delay restenosis in the 
early stages after the operation, implantation of a foreign object has the 
added risk of inducing an inflammatory response, which plays an important 
role during neointimal hyperplasia. Clinical research found that patients 
receiving stents, develop a thicker neointimal layer and display greater 
inflammatory cell infiltration  (Farb, et al. 2002). Some scientists consider 
Restenosis as the Achilles’ heel of coronary angioplasty, which may 
ultimately lead to failure of the surgical operation.  The origin and identity 
of cells types that contribute to restenosis is not well understood. SMCs are 
the most dominant cell types within the neointima. Whilst the traditional 
view is that these cells come from the medial layer of the vessel through 
vascular migration, more recent evidence suggests that the origin of the 
SMCs in restenotic lesions is much more complex than we previously 
thought. Bone marrow progenitor cells and adventitial stem progenitor 
cells are regarded as key additional contributors to SMCs during the 
restenosis besides the medial infiltration of SMCs (Bentzon, et al. 2006) 
(Tigges, et al.  2013).   
 
1.3 Risk Factors for the atherosclerosis and restenosis 
Risks factors considered to promote atherosclerosis and restenosis, include 
an unhealthy diet, physical inactivity, tobacco use and excessive alcohol 
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consumption which can lead to a set of clinical symptoms such as 
hypertension, hyperlipidaemia, diabetes, obesity and hemodynamic forces 
(Organization. 2017). Atherosclerosis leads to the development of 
atheromatous plaques in the inner layer of the arteries. Among all these 
risk factors, lipoproteins especially oxLDL levels have been recognized to 
play a central role during the pathogenesis of the atherosclerosis plaques. 
In the circulatory system, cholesterol is transported and removed from cells 
and tissues by lipoprotein. Excess lipoprotein trapped in the area where the 
blood flow is disturbed may trigger an inflammatory response and recruit 
monocytes, activate underlying ECs and VSMCs, which triggers the process 
of the atherosclerosis (Tabas, et al. 2015). This earliest lesion of 
atherosclerosis are called fatty streaks and commonly appear in children or 
during infancy (Pant, et al. 2014). In this stage, macrophages and SMCs are 
recruited to the site where lipids are trapped and attempt to scavenge the 
excess lipids. As the atherosclerosis develops, the fatty streak becomes an 
advanced atherosclerotic lesion, consists of macrophages/foam cells, SMCs 
and inflammatory cells. Lipid uptake will induce foam cell death and attract 
more macrophages to the plaque and further promote atherosclerosis 
development. As described in Table 1, the early stages of the 
atherosclerosis are mainly characterised by lipid accumulation. So obviously 
that dyslipidaemia is a critical risk factor for atherosclerosis development 
(Laffont and Rayner. 2017).   
 
Reactive oxygen species (ROS) are considered another important initiator 
of the atherosclerosis. The human body is oxygen-centric and oxidative 
phosphorylation (as well as non-respiratory oxygenation) occurs in every 
cell every minute (Miller, et al. 2011).  ROS is a by- product of the oxidation 
reaction and enzymes such as NADPH oxidases generate ROS during normal 
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aerobic metabolism in cells (Droge. 2002). As mentioned previously, 
smoking is one of the top risk factors for CVD. It has been reported that 
cigarette smoke releases a large number of free radicals into the circulatory 
system, which activates dysfunctional nitric oxide (NO) biosynthesis (Barua, 
et al. 2003). Excess free ROS can promote oxidation of LDL and promote the 
LDL induced EC and VSMC inflammation within arteries. Furthermore, it has 
been shown that ROS induces a set of inflammatory signally pathways; for 
instance, IL-4 induced MCP-1 expression in a ROS-dependent manner in ECs. 
Increased MCP-1, allows ECs to recruit a large number of monocytes into 
the site of the vessel wall and promotes migration of monocytes into the 
sub-endothelial region(Lee, et al. 2010).   
 
The restenosis depends on variety factors, including the patient’s additional 
health complications, lesion characteristics and procedural variables. The 
patient’s condition could affect restenosis development if for instance they 
present with related diseases (such as diabetes mellitus (DM)) or have 
undergone surgery for restenosis at another treated site, or have previously 
required intervention for acute coronary syndromes. DM can increase the 
likelihood of restenosis in patients, as metabolic alterations resulting from 
DM could trigger endothelial dysfunction, strengthen  the production of 
growth factors, increase the likelihood of platelet aggregation and promote 
thrombogenicity(Aronson, et al. 1996). A clinical study showed that in a 
cohort of 954 patients who received PCI surgery, over 28% of insulin-
dependent diabetes patients needed revascularization compared with 16.3% 
non-diabetic patients (Abizaid, et al. 1998). For acute coronary syndrome, 
injury to vessel wall will promote cellular proliferation and worsen the 
existing microenvironment. Lesion characteristics and procedural variables 
including the diameter of the vessel, the length of the lesion or stent, 
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minimum lumen diameter before and after the stenting, the ostial lesion, 
saphenous venous graft and total occlusion are critical in determining the 
lesion constitutions (Bhargava, et al. 2003). Similarly, the most important 
predictor of restenosis is the size of vessel diameter and the length of the 
lesion. It has been reported that a larger minimum lumen diameter after 
stent implantation decreases the risk of restenosis in patients (Moussa, et 
al. 1999). Additionally, some genetic factors such as the polymorphisms in 
genes coding for angiotensin converting enzyme, glycoprotein receptor IIIa 
PLA1/2 and haptoglobin2/2  have been reported associated with a higher 
risk of restenosis (Ribichini, et al. 1998; Di Castelnuovo, et al. 2001; Roguin 
et al. 2001).  
 
1.4 The pathology of atherosclerosis and restenosis 
Most blood vessel is composed of three distinct layers of cells, called tunica 
intima, tunica media and tunica adventitia (Gutterman. 1999).  The tunica 
intima includes a single layer of vascular ECs resting on a basement 
membrane, which is mainly composed of internal elastic lamina membrane 
along with some collagen type IV and laminin proteins. The medial layer is 
mainly composed of VSMCs embedded in the ECM. The adventitial layer is 
the outside layer of the vessel, and contains connective tissue, collagen 
fibres and fibroblasts, a vasa vasorum, fat cells as well as some inactive 
inflammatory cells (Gutterman. 1999). Interestingly, up until recently the 
primary function of adventitial layer was considered to protect and provide 
nutrition for the medial and intimal layers. However, the region of the 
adventitia facing the SMC layer, known as the ‘vasculogenic zone’,  contain 
a number of endothelial progenitor cells, as well as some multipotent stem 
and progenitor cells, and contributes to new blood vessel formation as well 
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as providing a source of inflammatory cells for a local immune response 
(Zengin, et al. 2006). These cells, as well as mesenchymal cells, work in 
concert to maintain blood vessel wall homeostasis, repair the damaged 
vessel as well as respond to inflammatory stimulation.  
 
As previously discussed, atheroma formation occurs as a result of physical 
and/or chemical abnormalities induced by hypertension, hyperlipidemia, 
hyperglycemia, elevated ROS levels,  and an activated endothelial which 
triggers an inflammatory cascade in the sub endothelial layer (Kojda et al. 
1999). Meanwhile accumulated lipoprotein also triggers the ECs to release 
inflammatory chemokines, which help to recruit a set of highly specific cells 
such as monocytes and macrophages into the site. In an attempt to engulf 
the accumulated cholesterol, macrophages become inflammatory foam 
cells and recruit more cells into the growing atheroma (Laffont et al. 2017). 
Besides, the oxidized low-density lipoproteins also promote the activated 
ECs to upregulate adhesion molecule expression which boost the 
inflammatory cell accumulation (Butini et al. 1994). Additionally, 
endothelial dysfunction also activates platelets which accumulate at the 
pathological site, releasing platelet derived growth factor (PDGF) and 
inducing SMC migration from the medial layer into sub-endothelial space, 
which then start to undergo proliferation and phenotype switching(Libby 
2002) (Mack. 2011). Once enough cells have accumulated, the lesion 
progress into a mature atheroma with the core of the atheroma consisting 
of foam cells and extracellular lipid droplets. The SMCs together with some 
collagen-rich matrix form a cap surrounding the lipid core and other cells 
including macrophages, T cells and mast cells located in the shoulder region 
of the atheroma.  This structure is not stable, and as the atherosclerosis 
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progresses, increased cell apoptosis and iSMCs accumulation results in the 
calcification of the VSMCs which further promotes atherosclerotic plaque 
growth. Also if the lipid and the inflammatory molecules keep clustering to 
the site, macrophages will replace the SMCs in the cap of the 
atherosclerosis plaque which will increase the likelihood of plaque rupture 
(Yu, et al. 2018). Angiogenesis and haemorrhage within the core of the 
lesion could drive the vulnerable plaque to rupture which may lead to 
further cardiovascular complications such as stroke and heart attack  
(Madrigal-Matute, et al. 2013).  
 
Neointimal formation and hyperplasia are complicated cellular and 
molecular responses which occur in many CVDs like atherosclerosis and 
hypertension, as well as after vascular surgery such as the PCI and CABG. 
This kind of disorder induces the arterial wall to thicken and thus cause 
further reduction of the vessel lumen size. It is widely reported that SMCs 
undergo migration, phenotype switching and abnormal proliferation in the 
intimal region, which plays a fundamental role in development of the 
neointima and restenosis. Other cell types such as myofibroblasts, ECs and 
macrophages are also involved in this process. Although numerous studies 
have been carried out on the pathogenesis of the neointima formation, the 
underlying mechanisms of neointima SMC hyperplasia are still not 
completely understood. Histological studies found that in the restenosis 
site, the inflammatory cells followed by the accumulate of the synthetic 
SMCs or iSMCs were exist,  the myofibroblast and the iSMCs secret huge 
amount of extra cellular matrix  (ER, et al. 2011). The initiation of the 
neointima formation and hypertension during the restenosis is said to start 
from the maladaptive response to arterial trauma caused during the 
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angioplasty, consisting of thrombosis, inflammation, cells migration and 
proliferation as well as the extra cellular matrix secretion, within  6 months 
of surgery (Nikol, et al. 1996). In short, about three distinct stages are used 
to classify the loss of luminal diameter after angioplasty, that is early loss 
elastic recoil of the vessel, negative remodelling, and neoinitimal formation 
and hypertension (Weintraub. 2007). Compared with the atherosclerosis 
process, neointimal formation in restenosis is much simpler and more 
efficient. Whilst atherosclerosis is initiated from a very young age and may 
develop into a serious CVD after many years, restenosis can occur within 
the space of 6 months. Elastic recoil is a dynamic phenomenon that starts 
immediately after the angioplasty operation and is characterised by instant 
luminal diameter loss. It was found upon clinical observation that in about 
34% of cases loss the lumen diameter occurred within 15min of balloon 
inflation(Caixeta, et al. 1996). Stent implantation may have a more reduced 
rate of elastic recoil, but a suboptimal stent insertion has been found to 
cause average of 60% less of the desired lumen dimension (Bermejo, et al. 
1998). In total, immediate elastic recoil causes about 50% of the restenosis 
during the angioplasty (Rozenman, et al. 1993). Platelet adhesion, 
activation and thrombosis are the key step in the next stage of the 
neointimal formation. This step also starts immediately after the 
angioplasty, with the fracture of the atherosclerotic plaque and direct 
exposure to blood flow, leading the thrombogenic contents in the plaque 
interacting with platelets and thereby inducing the platelet adhesion and as 
a result, thrombosis (Casscells, et al. 1994). Furthermore, dysfunction of the 
endothelial cells result in less express some antithrombotic factors such as 
NO and prostacyclin in the fractured site which promotes further platelet 
adhesion and aggregation after surgery (Weintraub. 2007). After that, 
activated platelets release plenty of mitogens like the PDGF, serotonin and 
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thromboxane A2 that will induce SMC proliferation and migration.  Many 
different cell types contribute to iSMC accumulation in the neointima 
including the medial SMCs, ECs, circulating stem progenitor cells and most 
importantly, adventitial stem progenitor cells. Vascular remodelling exists 
in both atherosclerosis and restenosis, but the characterisation of these 
two pathological processes differ significantly. During atherosclerotic 
plaque formation, outward vascular remodelling, namely external elastic 
membrane hyperplasia, will be triggering to maintain the structure of the 
lumen (Glagov, et al. 1987). In contrast, neointimal formation, hyperplasia 
and concentric compression in the intima layer of the vessel are the main 
processes by which restenosis occurs. As discussed previously, iSMC 
accumulation into the intimal layer and narrowing  the lumen of the vessel 
occurs at the same time as adventitial thickening and concentric 
compression possibly due to collagen secretion which replaces the original 
hyaluronic proteins (Mintz, et al. 1996). Notably, although the endovascular 
stent could reduce early elastic recoil and lumen loss in the early stage of 
the restenosis, investigations found that stent implantation induce 
inflammatory cell infiltration and triggers an inflammatory response which 
promotes neointimal hyperplasia (Farb, et al. 2002).  
 
1.5 Cells involved in atherosclerosis and restenosis 
As previously mentioned, atherosclerosis can start at a very young age but 
only begins to affect patients’ quality of life after many years. Restenosis 
usually occurs after a surgical operation, of which the main characteristic is 
neointimal hyperplasia. Numerous cells are involved in this process, 





1.5.1 Endothelial cells  
In brief, the endothelium is a cellular monolayer which acts as a perfect  
functional barrier for the blood and surrounding tissue by regulating blood 
fluidity, maintaining vessel wall integrity, controlling the vascular tone and 
regulating permeability of the vessel wall(Pober, et al. 2007). ECs also 
involved in vasoactive mediator synthesis and degradation, lipoproteins 
transport and metabolism, ECM secretion, growth factors and cytokines 
biosynthesis as well as the vascular inflammatory response(Gimbrone, et al. 
2016). Under pathological conditions, pro- inflammatory factors activate 
ECs which induce several gene activation pathways and adjust many normal 
functions in response to potentially harmful stimuli. 
 
Endothelial dysfunction is the initial trigger for the atherosclerosis and 
restenosis. Moreover, it has been proven that many pathophysiological 
processes could induce and enhance endothelial dysfunction including 
hypercholesterolemia, diabetes, hypertension, oxidative stress, ageing and 
pro-inflammatory cytokines (Gimbrone, et al. 2016). As previously 
mentioned, ROS and lipoproteins activate ECs, initiate the inflammatory 
cascade and promote pro-inflammatory cytokine expression. ECs trigger 
atherosclerosis and neointima formation through multiple cross-talking 
signalling which amplify the effect of endothelial dysfunction in 
atherosclerosis process. For example, EC damage or dysfunction will recruit 
the leukocytes and monocytes to the lesion site, meanwhile active ECs 
upregulate cells adhesion molecule expression on the surface of the cells to 
anchor the immune cells. The most important adhesion molecule is 
intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
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molecule-1 (VCAM-1). VCAM-1 was recognized as a selective adhesion 
molecule and has highly selective adhesion ability on monocytes and 
lymphocytes by interact with the VLA-4 receptor (Elices, et al. 1990). It has 
been proven that hydrogen peroxide treatment could upregulate the ICAM-
1 and VCAM-1 expression in human umbilical vein endothelial cells (HuVECs) 
within 6 hours, and neutralizing ROS during the treatment could reverse 
this elevation (Habas, et al. 2018). Another group also demonstrated that 
treatment of rabbit aortic endothelial cells with oxidized lipoproteins, like 
lysophosphatidic choline, induced ICAM-1 and VCAM-1 expression and 
further increased  the adhesion of blood monocytes (Kume, et al. 1992). In 
vivo experiments also demonstrated that reduced VCAM-1 and ICAM-1 
gene expression in ApoE-null mice could reduce aortic lesion area in a 
murine model of atherosclerosis (Cybulsky, et al. 2001; Bourdillon et al. 
2000). 
 
Endothelial activation also induces secretion of a set of chemokines such as 
IL-1, MCP-1, IL-8 and E-selectin (Libby, et al. 1986; Cushing, et al. 1990; 
Pober et al. 2007). Furthermore, EC activation causes a rise in intracellular 
Ca2+, upregulating P-selectin expression, a molecule is functionally similar 
to E-selectin, which in turn promote neutrophil trans-endothelium 
migration (Lorant, et al. 1993; Pober, et al. 2007). These intercellular 
autocrine and paracrine signalling events in the activated ECs could activate 
neighbouring ECs and recruit more circulating leukocytes into lesion site, 
triggering a more complex immune response network in the early period of 




It is worth noting that the NF-ƙB signalling pathway seems play a central 
role in the endothelial pro-inflammatory activation process. NF-ƙB 
regulates many target genes involved in atherosclerosis, including adhesion 
molecules, cytokines and chemokines. NF-ƙB also promotes cell 
proliferation and cell survival-related gene expression. Interestingly, NF-ƙB 
also upregulates expression of the antagonistic gene, IkBa, to limit or 
abolish NF-ƙB cascade and ensure that active cells return to their quiescent 
state. Many cytokines and chemokines which are expressed by active ECs 
as previously mentioned, such as  ICAM-1, VCAM-1, MCP-1, IL-8 (Linghu, et 
al. 2019) as well as the E-selectin, which is produced by type II activation of 
ECs (Pober, et al. 2007),  are  regulated by NF-ƙB signalling. VCAM-1 is a 
selective adhesion molecule that is expressed a very low level in quiescent 
ECs.  Gene structure analysis found that the promoter of the VCAM-1 gene 
contains two NF-ƙB binding sites which are critical for VCAM-1 expression 
(Collins, et al. 2001). Another experiment also shows that eucalyptol, a 
monoterpene known as an anti-inflammatory component, could reverse 
the acute inflammatory reaction in HuVECs and reduce the VCAM-1 
expression by blocking the degradation of the NF-ƙB antagonistic gene, IkBa 
(Linghu, et al. 2019). Oxidative stress and dyslipidaemia are two major 
triggers of NF-ƙB activation in endothelial dysfunction. Other factors such 
as hypertension and homocysteine also play a very important role in NF-ƙB 
activation in atherosclerosis (Collins et al. 2001).  Multiple transcription 
factors such as Krüppel-like factor 2 and 4 (KLF2/4) have also been reported 
to be involved in endothelial dysfunction, and exert an anti-inflammatory 




Endothelial dysfunction also acts as a candidate for triggering neointimal 
formation during the restenosis. In the normal circulating system, the 
endothelium not only acts as an interface between blood and the vessel 
wall, it also participates in regulating vascular wall homeostasis. 
Endothelium provides an antithrombotic surface which separates blood 
flow from matrix proteins in the sub endothelial space and interacts with 
SMCs in the medial layer to regulate cells proliferation, migration and death. 
Endothelium can release mediators like NO and prostacyclins, which can 
inhibit platelet aggregation and adhesion to the intimal surface under 
normal physiological condition (Tesfamariam. 2016). However, these 
mediators are dysregulated upon endothelial activation, causing platelet 
adhesion/aggregation, PDGF production, adhesion molecule upregulation, 
monocyte/macrophage recruitment and activation, which in turn initiate 
pro-inflammatory signal cascades and eventually promotes neointimal 
lesaion. The activated endothelium also affects the intimal ECM mass by 
controlling their turn-over through secreting proteases and relevant 
inhibitors.  
 
Intimal surface injury or endovascular device implantation can trigger 
platelet aggregation and activate an inflammatory response. Injured ECs 
recruit neutrophils and monocytes into the subendothelial space and 
release cytokines such as IL-1β, IL-6, TNFα, IL-12 and IL-23 (Chinetti-
Gbaguidi, et al. 2015). More importantly, vascular injury  break the balance 
between endothelium-derived cytokines and related inhibitors which 
attract SMCs (Otsuka, et al. 2012) and stem cells (Sata, et al. 2002) to the 
sub endothelium. The trapped cells become iSMCs under the influence of 
pro-inflammatory cytokines. It has been proven that the hematopoietic 
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stem cells have the ability to differentiate into different cells depending on 
the microenvironment. For example, under inflammatory condition stem 
cells selectively differentiate into the smooth muscle progenitor cells (Sata, 
et al. 2002). Studies using animal models demonstrate that endothelial 
dysfunction after a stenting procedure promotes bone marrow derived 
endothelial progenitor cell accumulation which promotes neointimal 
formation (Kipshidze, et al. 2004). Therefore, attempts to unravel the 
underlying molecular mechanisms of endothelial dysfunction may prove a 
better strategy for treating CVD in the future. 
 
1.5.2 Macrophage 
Macrophages regarded as phagocytic cells are widely exist in tissues and 
organs. Normally, activated macrophages act as an immune responder of 
the body’s immune system to remove apoptotic cells and debris during the 
tissue remodelling process. Endothelial dysfunction initiates the 
inflammatory response and promotes accumulation of oxidized LDL in the 
intima of the vessel wall, which subsequently recruit the inflammatory cells 
like monocytes to arterial wall (Moore, et al. 2011). Once the monocytes 
migrate into the sub endothelial layer, they differentiate into macrophages 
which uptake oxidized LDLs in the intima. After excessive LDL uptake 
macrophages are converted into foam cells, another pathological type of 
the macrophage (Chistiakov, et al. 2017).  
 
A variety of macrophage subsets with different protein expression profiles 
are found inside the atherosclerotic plaques. Based on in vitro 
investigations of cell markers and the production of the specific factors, 
macrophages can be classified into two major phenotypes, M1 pro-
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inflammatory and M2 anti-inflammatory phenotypes. M1 macrophages are 
induced by TH1 cytokines such as TNFα and IFNγ,  or interact with the 
lipopolysaccharide, meanwhile the M1 macrophage produces high levels of 
pro-inflammatory factors like IL-1β, IL-6, TNFα, IL-12 and IL-23 (Chinetti-
Gbaguidi, et al.  2015). M2 macrophages can be further divided into three 
subclasses; M2a macrophages are induced by Th2 cytokines like IL-4 and IL-
13, and M2b macrophages are polarized by treatment with the IL-1β plus 
some immune complex, IL-10, TGFβ1, while M2c macrophages are induced 
by glucocorticoids. All three subtypes of M2 macrophages produce high 
levels of IL-10 and TGFβ1, and low levels of IL-12 compared to the M1 
macrophage (Chinetti-Gbaguidi, et al. 2015). Notably, macrophages 
maintain their plasticity and can switch from M1 to M2 phenotype 
depending on their environment (Porcheray, et al. 2005).  In vivo, 
macrophages have a much more transient and heterogeneous expression 
and secretion profile due to a much more complex environment. Since 
many subtypes have been identified in atherosclerosis, it is clear that these 
macrophages could interact with each other, leading to a complex network 
in atherosclerosis lesions. Particularly macrophage subtypes play an 
important role in controlling inflammatory process. Take M1 and M2 type 
macrophages as an example, M1-like macrophages are found in both mice 
and human atherosclerosis and are regarded as pro-inflammatory 
macrophages because its role in promoting vulnerable plaques, whereas 
M2 macrophages have an anti-inflammatory character. One study found 
that in the ruptured plaque, both M1 and M2 macrophages populations 
increase, with M1 macrophages predominantly located in the most 
unstable regions of the atherosclerosis plaque (i.e  the shoulder region of 
the plaque) while the M2 macrophages located  far away from the lipid core 
of the plaque in the adventitia(Stoger, et al. 2012). Interestingly, foam cells 
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were observed to co-express M1 and M2 macrophages markers (Stoger, et 
al. 2012), raising question to the cellular origins of these cells (Porcheray, et 
al. 2005). Additionally, although the M1 and M2 macrophages were found 
to be located in different areas of the plaque, we still do not know whether 
this distribution occurs before or after macrophage polarisation. Finally, M1 
and M2 macrophages were found to be equally distributed in the fibrous 
cap (Stoger, et al. 2012). Since the M2 macrophages have pro-fibrotic 
phenotype while M1 consistently promote the inflammatory activation, the 
fibrous cap might be the outcome of M1 and M2 competition and balance 
in this region.   
 
Although SMC migration and proliferation in the intima and ECM 
accumulation are defining features of neointima formation and restenosis, 
inflammatory macrophage activation also plays a very important role in 
promoting neointima formation. EC injury or stenting implantation not only 
lead to the platelet activation and aggregation but also recruit the 
leucocytes like monocytes from the circulatory system. Leucocyte and 
platelet interactions play a key role in the initiation and progression of 
neoinitimal formation. Evidence indicates that monocyte adhesion is 
correlated with neointimal formation. Indeed, research shows that 
increased inflammation will induce more serious neointimal hyperplasia, 
and early chronic inflammation has a strong relationship with intimal 
thickening after stenting (Burke, et al. 2002). In a murine model of vascular 
injury- induced neointima formation, depletion of macrophages also results 
in the reduced neointima formation up to 30 days (Danenberg, et al. 2003). 
As discussed, macrophages release a set of cytokines, which contribute to 
SMC differentiation and proliferation, which are morphological predictors 
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of arterial remodelling in coronary atherosclerosis (Lv, et al. 2016).  It is 
worth noting that other leucocytes, such as the neutrophils, also have an 
impact on intimal thickening. Administration a monoclonal Mac-1 antibody 
into a rabbit model was found to reduce neutrophil infiltration in the 
injured vasculature, which in turn decreased SMC proliferation (Welt, et al. 
2000).  
 
Bone marrow derived monocytes are the main source of macrophages in 
atherosclerosis. After initially being generated from hematopoietic stem 
and progenitor cells in the bone marrow, monocytes were first found to be 
resident in the spleen, where they undergo proliferation and activation 
before being released into the blood and recruited into blood vessel wall in 
the early stage of atherosclerosis (Tabas, et al.  2015). Quiescent monocytes 
generally stay in the spleen and lymph node, until induced by several 
chemokines released from the lesions. One study found that CCR2 (receptor 
of CCL2) deficient mice displayed lower levels of circulating monocytes, 
suggesting that CCL2 mediates monocyte release into the blood. It should 
be noted that other chemokines might play more important role in 
recruiting the cells to the lesions. For instance, abolishing CCL5 and CXCL1 
in animal experiments directly reduced monocyte attraction to 
atherosclerotic lesions (Soehnlein, et al. 2013). Since endothelial 
dysfunction is the critical reason for monocytes accumulation in plaques, 
molecules such as the VCAM-1 and the P- selectin have also been 
demonstrated to play important roles in monocytes accumulation within 
atherosclerotic plaques. Although monocytes may contribute to a large 
number of macrophages in the plaque, other cells may also participate in 
macrophage accumulation. It is believed that although monocyte influx 
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takes place predominantly in early lesions processes, local macrophage 
proliferation accounts for most of macrophages accumulation in the 
advanced atherosclerotic plaques (Robbins, et al. 2013).  One group 
identified a group of Sca-1 positive cells in the mice adventitia. These cells 
not only expressed the progenitor markers; CD34 and c-kit, but also 
leukocyte markers; Ly6C and CD45, suggesting that these cells may 
contribute to lesion macrophages and in turn affect atherosclerosis 
development (Psaltis, et al. 2012). Of note, intimal SMC phenotype 
switching was also reported to contribute to macrophages and foam cell 
population in advanced atherosclerotic lesion (Allahverdian, et al. 2014). 
 
1.5.3 VSMC and iSMC 
In circulatory system, VSMCs are the major cell types in the vascular tunica 
media. During the early stage of blood vessel development, SMCs resident 
in the medial layer of the vessel wall secrete a huge amount of ECM 
including collage, elastin, fibronectin, cadherin and integrin. Although ECM 
is not the primary element of the blood vessel, they provide the basic 
structure for the cells resident in the early stage  of the vascular 
development (Owens. 1995).  As the blood vessel matures, SMCs begin to 
undergo phenotype switching by reducing ECM secretion while increase 
intracellular myofilament expression to allow for contraction and dilation 
of the vessel wall, thereby regulating blood pressure and flow (Rudijanto. 
2007). Because they are not terminally differentiated cells, VSMCs exhibit 
remarkable phenotypic plasticity in response to environmental stimulation 
such as vascular injury, inflammation, and lipoprotein accumulation. In the 
normal mature blood vessels, SMCs display a contractile state and act as a 
blood vessel diameter regulator to control the blood pressure and flow. In 
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this quiescent phenotype, SMCs express typical smooth muscle contractile 
proteins such as the SM-α actin, SM22α, SM myosin heavy chain(SM-MHC), 
H1 –calponin and smoothelin (Owens, et al. 2004). Under some pathological 
conditions, SMCs can undergo a phenotype switch from its contractile state 
to a synthetic state.  The cells in this latter state are much more active, and 
can migrate into the intima and renew itself by undergoing proliferation. 
Besides, synthetic SMCs also produce ECM proteins, like the collagen and 
elastin, whereas at the same time the expression of smooth muscle 
contractile proteins is reduced. Researchers have shown that SMCs migrate 
and accumulate in the sub-endothelial layer after fatty streak formation 
and further develop a new fibrous cap in plaques(Gomez, et al. 2012). 
Another study found that in human atherosclerotic plaques, SMCs display 
chondrocyte-like phenotype with reduced expression of SMαA and 
increased expression of Sox-9 (Bobryshev. 2005). 
 
During atherosclerosis, lipids and other triggers alter the endothelium 
which promotes circulating monocytes being transported into the SMCs 
layer and maturing into macrophages. Activated macrophage secrete 
growth factors as well as some inflammatory mediators, which promote 
SMC phenotype switching from quiescent state to synthetic state. Synthetic 
SMCs tend to migrate into the intima where they start to proliferate, 
produce extracellular matrix, and take part in fibrous cap formation. By 
determining telomere loss of the SMCs, scientists found that these SMCs 
from fibrous cap display monoclonal features with a higher level of 
replication compared with the cells in the medial layer. This demonstrate 
that the SMCs in the fibrous are not in the quiescent state and undergone 
proliferation when they participate into the atherosclerosis 
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development(Matthews, et al. 2006).  Interestingly, increased SMCs in the 
cap of the atherosclerotic lesion was found to increase the likelihood of 
plaque stability during the atherosclerosis (Lee, et al. 1997), but the 
mechanisms for this are still unknown. Since SMCs lost contractile marker 
expression after phenotype switching, it is hard to identify the origin of 
smooth muscle-like cells in atherosclerotic lesion. Restenosis is the re-
narrowing of the blood vascular after the revascularization procedures such 
as angioplasty and stenting. Followed the injury to the vessel wall, the 
platelets and inflammatory cells release multiple cytokines, which stimulate 
SMCs to proliferate and secrete ECM proteins in the intimal space, resulting 
in the intimal hyperplasia and narrowing the blood vessels (Chaabane,  et 
al. 2013).  
 
By using the genetic tools, studies have recently identified foam cells like 
SMCs expressing common macrophage markers in the plaque (Majesky 
2016). One study found that ApoE-/- mice, with myocardin+/- gene 
background, display worse atherosclerosis with more macrophage and 
macrophage-like cells accumulation compared with control mice (Wang, et 
al. 2001). Since the  myocardin regulates serum response factor (SRF) 
expression and VSMC contractile gene expression, loss of myocardin gene 
appears to induce the VSMC switch to a macrophage-like phenotype (Wang, 
et al. 2001). Another important phenotype is the iSMC phenotype 
generated from contractile SMCs undergoing phenotype modulation due to 
inflammatory cytokine co-stimulation. In the past 30 years, SMCs 
phenotype switching has been simply classified into the contractile and 
synthetic, however following huge progress in our understanding of the 
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molecular mechanism regulating SMC phenotypic modulation, it has 
become harder to define VSMC sub-phenotypes.  
 
Monocytes recruited from the circulatory system produce cytokines such 
as TNFα and IL-1β, creating a local inflammatory environment for medial 
SMCs. One study found that IL-1β could mediate SMC phenotype switching 
into an inflammatory state by activating the NF-ƙB signal pathway in vitro 
(Alexander, et al. 2012). lSMCs typically become less contractile, show 
enhanced proliferation and migration with increased inflammatory 
cytokines production, take on a cobblestone-like appearance and 
participate into atherosclerotic plaque and neointima formation (Sobue, et 
al. 1999; Kawai-Kowase et al. 2007). One study shows that SMCs-derived 
TGFβ1 could mediate macrophage polarization in vitro and increase 
inflammatory chemokines expression (Ostriker et al. 2014). Histological 
experiments in animal models of the atherosclerosis showed that SMCs in 
the media of the vessel wall express a number of pro-inflammatory markers 
and inflammatory transcriptional mediators, including the VCAM-1(O'Brien 
et al. 1993), ICAM-1, CXCL2 and NF-ƙB (Alexander, et al. 2012; Landry, et al. 
1997). In vitro experiments have also proven that SMCs producing these 
pro-inflammatory molecules increase monocyte adhesion and protect the 
cells from apoptosis (Cai, et al. 2004). Together the results show that there 
are a group of SMCs, which can express contractile markers of 
differentiation as well as the inflammatory genes under inflammatory 
conditions. This group of SMCs present a markedly different phenotype 
from the classical definition of SMC phenotypic modulation, whereby 
VSMCs in the contractile state express only contractile markers, and VSMCs 
in the synthetic state, mainly undergo proliferation and migration and 
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produce ECM proteins. Thus, iSMCs describe a type of SMCs present in 
atherosclerosis and restenosis, which display a similar phenotype to the 
synthetic/dedifferentiated SMCs, and co-express SMC proteins and 
inflammatory markers within the lesion. 
 
Since atherosclerosis is regarded as a chronic inflammatory disease, it has 
been widely accepted that iSMCs play an essential role in atherosclerosis 
and neiointima formation. Multiple stimulatory factors in atherosclerotic 
lesions are considered to promote iSMC production. Low-density 
lipoprotein (LDL) accumulation and deposition within the blood vessel wall 
or intima due to hypercholesterolemia and dyslipidaemia is considered as a 
critical trigger of iSMC production (Alexander, et al. 2012). Meanwhile, 
endothelial dysfunction or injury is thought to provide a pro-inflammatory 
environment for iSMC production and accumulation. ECM alteration also 
induces SMCs to undergo pro-inflammatory phenotype switching (Orr, et al. 
2009). Additionally, changes in blood pressure also affects SMCs phenotype 
switching by changing endothelial cell physiology (Mitchell, et al. 1999). 
According to the neointimal formation “response -to-injury” model 
proposed by Ross (Ross. 1993), SMCs of the tunica media contribute to the 
most part of the iSMCs in the neointimal hyperplastic process. However, 
growing evidence suggests that the medial SMCs contribution model might 
be too simple to account for the total SMC population in the atherosclerosis 
and neointima formation process, with other cells including ECs, circulating 
stem/progenitor cells and adventitial stem/progenitor cells discovered to 




Apart from medial SMCs and stem/progenitor cells, additional cellular 
origin for iSMCs in the neointima are endothelial cells. ECs also exhibit a 
variety of phenotypes in the cardiovascular system. For instance, 
endocardium cells change into mesenchymal cells to form a part of the 
atrioventricular cushion. This occurs by a process known as ‘endothelial-to-
mesenchymal transition’(End-MT) (Eisenberg, et al. 1995). By investigating 
neointimal formation and hyperplasia after the grafting veins into the 
arterial circulation, a group found that endothelial lineage-derived cells 
experience End-MT and acquire a mesenchymal or SMC-like phenotype 
(Cooley, et al. 2014).  
 
1.6 Stem and progenitor cells  
Stem cells are group of cells which have permanent potential to self-renew 
and differentiate into multiple types of cells, while the progenitor cells have 
limited capacity to differentiate into specific cell lineages related to its 
location. The exact definition for stem and progenitor cells remains 
debatable. It has been suggested that stem cells and progenitor cells are 
similar cells but present at different stages, with stem cells losing their stem 
cell characteristics and gradually becoming progenitor cells before 
committing to a mature cell phenotype. To make it simple, we termed these 
cells as stem/progenitor cells (SPCs). The SPCs in the adult body are a mixed 
pool of cells, resident in specific harbours called “SPC niches”, and exist in 
a variety of tissues and organs like the bone marrow, the peripheral blood, 
skin and the vessel wall. Accumulating evidence has suggested that these 
SPCs play an important role in atherosclerosis and restenosis, with the 





1.6.1 Circulating Stem and progenitor cells  
Mesenchymal stem cells (MSCs), one type of multipotent stem cells, were 
believed to be mainly derived from the mesenchyme, but more and more 
studies have shown that these cells could be identified and isolated from 
almost all the tissues/organs including the neuroepithelium and neural 
crest. Due to their multipotencies, MSCs can either differentiate into a 
mesodermal lineage or give rise to non-mesenchymal tissue both in vivo 
and in vitro. It has been shown that these cells participate in vascular 
neointimal formation and restenosis. Another type of circulating SPCs is 
endothelial progenitor cell (EPC) that was first reported in 1997 (Asahara, 
et al. 1997). EPCs can be isolated from bone marrow and peripheral blood, 
and contribute to in vivo angiogenesis. Five years later, a study reported a 
novel type of SPCs with the capacity to differentiate into SMCs with specific 
growth, adhesion and integrin profile exist in human blood, classified as 
smooth muscle progenitor cell (SMPCs) (Simper, et al. 2002). Another group 
also succeeded in isolating these SMPCs from human peripheral blood, 
which express SMαA, as well as CD14 and CD105. Following long-term 
culture, these SMPCs display a contractile phenotype and express typical 
SMC markers (Sugiyama, et al. 2006). Interestingly, CD14 negative SMPCs, 
which produced less proteases and inflammatory cytokines than that of 
VSMCs was reported in a later study (Simper, et al. 2010). Though these 
SPCs were proven to exist in the circulating system and have the ability to 
differentiate into the smooth muscle-like cells in vitro, debate remains over 
whether these cells participate in atherosclerosis and restenosis. By tracing 
these bone marrow derived SPCs with the eGFP, Bentzon and his group 
found that no cells, differentiated from the bone marrow cells, were in the 
atherosclerotic plaques of a mice (Bentzon, et al. 2006). Later in another 
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model of plaque disruption model, this group also demonstrated that only 
SPCs resident in vessel wall participate in the healing process (Bentzon, et 
al. 2007). These data infer an important role for the local SPC population in 
atherosclerosis and restenosis. 
 
1.6.2 Adventitial stem and progenitor cells  
In the past decades, many studies have reported that there are large 
number of SPCs in the vessel wall. Although debatable, it has been widely 
accepted that the stem cell niches in the sub endothelial layer harbour 
variety of SPCs. As aforementioned, the tunica adventitial is the outside 
layer of the vessel wall which composed with connective tissue, terminal 
nerve fibres, collagen and fibroblasts as well as some quiescent 
inflammatory cells such as the tissue macrophages (Gutterman. 1999). For 
decades, the adventitia was considered to be ‘quiescent’, and have little to 
no involvement in vessel wall homeostasis. Now, scientists believe that cells 
in the adventitia layer play more than just a structural role in vascular 
function. The cells in the adventitia, such as adventitial fibroblasts were 
reported to contribute to the sub-intimal proliferation during the 
atherosclerosis. Moreover, cells from the adventitial have also been shown 
to participate in vascular calcification in the chronic atherosclerotic lesions. 
Additionally, neurotransmitters released by the nerve in the adventitial 
could play a role in regulating the vessel tone (Gutterman. 1999).  More 
importantly, immunohistochemistry assays found that large number of 
progenitor cells were present in the adventitia of the vascular wall and 
positively expressed SPC-like markers; Sca-1, c-kit, CD34 and FLK-1 
(Campagnolo, et al. 2010; Worsdorfer, et al. 2017; Hu, et al. 2004). These 
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SPCs could differentiate into SMCs in response to injury in an attempt to 
repair the damaged tissue. 
 
Specifically, Hu et al reported that these SPCs express Sca-1, CD34, c-Kit, 
Flk1 but no the SSEA-1 as the cell surface marker, and differentiate into 
SMCs in vitro in response to PDGF-BB. After transfered to the adventitial 
side of the vein grafts ApoE-/- mice, these cells could migrate through the 
media and enhance atherosclerotic intima formation (Hu, et al. 2004). Later, 
another study found that these Sca-1+ SPCs were located closely to the vasa 
vasorum and displayed the potential to differentiate into SMCs, adipocytes, 
osteoblast and chondrocytes in vitro.  When these cells were implanted 
onto the outer layer of vein grafts of ApoE-/- mice, of the authors observed 
about 30% of neointimal SMCs were derived from transplanted SPCs (Chen, 
et al. 2013). Another pre-clinical study showed that sirolimus induced Sca-
1+ SPC migration and differentiation into SMCs in the intima, which 
promoted restenosis (Wong, et al. 2013). This thesis indirectly proved that 
these adventitial SPCs were involved into the neointima formation as well 
as restenosis. Interestingly, the origin of these Sca-1+ cells has led to some 
suggestions that some of them are derived from mature SMCs. Using two 
different genetic-fate mapping methods to trace the Sca-1 progenitor cell 
ancestors in vivo, about 8% of Sca-1+ cells were shown to come from the 
mature SMCs of the medial layer, while no cells were derived from the 
peripheral blood mononuclear cells s (Majesky, et al. 2017).  Another group 
of CD34+/CD31- progenitor cells were also found in saphenous veins, and 
were negative for the endothelial markers; vWF and CD31, but positive for 
progenitor cell markers; C-Kit and CD133 (Campagnolo, et al. 2010). Notably, 
a few of these cells were also found to be positive for NG2 and PDGFRβ 
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markers, which means these cells may have some relation with MSCs. 
Further experiments using these cells demonstrated that CD34+/CD31- cells 
were able to self-renew and differentiate into mesodermal lineages, 
although they failed to differentiate into ECs. After a few years, another 
group also succeeded in isolating CD34+/CD31- /CD146-/CD45- cells from 
human stromal adipose tissue around the vascular adventitia (Corselli, et al. 
2012). These cells displayed MSC-like features and could be induced to 
differentiate into pericyte-like cells in vitro. Moreover, one study focusing 
on cell origin during the restenosis reported that a population of NG2+/ 
CD146+ cells exist in the vascular adventitial, which contribute to the 
restenosis following arterial injury (Tigges, et al. 2013). All these studies 
show that these adventitial SPCs do exist and contribute to the SMC 
accumulation during the restenosis after the arterial injury surgery.  
 
Another group of progenitor cell were found in a region called ‘vasculogenic 
zone’, located between the medial and adventitial layer of the human blood 
vessel. These SPCs also participate in vascular structure formation in a 
transplantable tumor model in vivo (Zengin, et al. 2006). Further 
investigations were able to divide these cells into two groups which are 
CD34+ / VEGFR2+ /Tie+/CD31- /cells and CD34-/CD3-
/CD44+/CD90+/CD105+/CD73+ cells,  with the former group of cells though 
to differentiate into the ECs, whilst the latter group are thought to 
differentiate into SMCs(Tilki, et al. 2009). Another study also reported 
similar findings (Torsney, et al. 2011), demonstrating an ability of these 
progenitor cells to differentiate into the multiple mature cells in selective 
culture media in vitro. MSCs were defined with cells as being able to 
differentiate into a variety of cell types with minimal immune-response 
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gene expression profiles. It is ruled by the international cell therapy society 
published in 2006 that the MSCs were defined by CD105+, CD73+ and CD90+, 
but CD45-, CD34-, CD14- or CD11b-, CD79a- or CD19- as well as HLA-DR- 
(Dominici et al. 2006). By this definition, one group have identified a MSC 
population (CD44+/ CD73 + /CD34 -/CD45 -) in adult human arterial 
adventitia which present typical MSC characteristics and exhibit multi-
potency (Klein et al. 2011). Notably, these cells were able to be induced to 
differentiate towards SMCs under TGFβ1 treatment in vitro. However, 
contradictory results by other groups found that CD34+ cells in the 
vasculature also display an MSC-like character. One study discovered a 
group of CD34+/CD31- cells from human saphenous vein. These cells 
expressed mesenchymal antigens such as CD44 and CD90 as well as the 
stem cells marker SOX2, but not the endothelial marker; Von Willebrand 
factor (VWF). Moreover, these cells displayed multiple differentiation 
capacity in vitro, and were able to give rise to osteoblasts, adipocytes, and 
myocytes (Campagnolo, et al. 2010). These data suggest that MSCs are 
mixed and heterogeneous populations with different origins, which make it 
more difficult to direct compare their functions and contributions to disease 
pathology. Despite this, it has become clear that these MSCs are able to 
respond to vessel injury and are involved in several biological processes in 
the vasculature. One study shows that in response to vessel injury, 
adventitial cells are likely to migrate through the tunica media and into the 
intimal site and acquire a SMC-like phenotype resulting in enhanced 
neointimal formation (Kramann, et al. 2016), indicating that MSCs in the 





1.6.3 Sonic Hedgehog (Shh) signalling pathway 
Shh signalling pathway also known as Sonic hedgehog-glioma-associated 
oncogene 1 (Shh-GLI1) signalling and Hedgehog-patched smoothened (Hh-
Ptch- Smo) signalling pathway, is one of the major signal networks which 
plays an important role during the embryonic development as well as the 
cells differentiation. The Shh signalling pathway is a highly conserved signal 
transmission pathway which is frequently active during the development 
for intercellular communication.  In adult tissues, Shh signalling is quiescent 
or poorly active unless some specific stimulation present, for instance, it 
was reported that Shh signalling was active during wound healing (Le, et al. 
2008). Many researchers discovered that Shh signal pathway is widely 
recognized to participate into the development of various tumours as well 
as in tumorigenesis (Katoh, et al. 2009) and embryonic development in 
diverse organisms (Taylor, et al. 2002).Moreover, Shh-GLI1 signalling has 
been extensively implicated in adventitia smooth muscle progenitor cell 
self-renewal and differentiation (Majesky, et al. 2012; Passman, et al. 2008) 
and blood vessel formation (Kolesova, et al. 2008). Shh-/- mice were 
reported had less number of Sca-1+ cells in artery (Koleva, et al. 2005). This 
suggest Shh signalling pathway plays a critical role in AdSPCs and may 
involve in the SMCs differentiation. Shh signalling can be activated though 
two major ways: canonical signalling and non-canonical signalling (Carballo, 
et al.  2018). Canonical signalling activation start with Shh binding to the 
cells membrane receptor 12-ransmembrane protein Patched (Ptch1), once 
Ptch1 interacted with the Shh its inhibitory function of a Smo, a G-protein-
coupled receptor like protein, is abolished. Cytoplasm accumulation of Smo 
will cause the translocation of GLI family protein into the nucleus, which 
triggers target gene transcription. The non-canonical Shh signalling is 
mediated through GLI independent way. The first one is though Smo 
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modulated-Ca2+ influx. The second one is directly interacting, activating 
cyclin B1, leading to cell proliferation and survival (Carballo, et al.  2018). 
Shh signalling pathway could interact with other pathways such as Wnt 
pathway to control stem cells differentiation. Many components could 
participate in and regulate Shh signalling activation.  Supressor of Fused 
(Sufu) has been considered as a negative regulator of the Shh signalling 
pathway. It was said that Sufu could regulate the GLI1 and GLI2 activation 
at several levels (Murone, et al. 2000; Dunaeva, et al. 2003). Moreover, 
some studies found that Sufu could negatively regulate Shh signalling 
through direct binding with GLI1 and retaining GLI1 in the 
cytoplasm(Dunaeva, et al. 2003; Kogerman, et al. 1999). 
   
1.7 RNA interference and small noncoding RNAs 
Multiple mechanisms include DNA/RNA modifications, transcription, post- 
transcription and translation control a given gene regulation. Among them, 
RNA interference (RNAi) is an extensive mechanism used by all eukaryotic 
cells to regulate gene expression via mRNA degradation, translation 
suppress and chromatin remodelling (Zotti, et al. 2018).  
 
1.7.1 Small noncoding RNAs  
Small noncoding RNAs is the primary class of RNA in RNAi process, which is 
usually about 20-30nt in length and play a negative regulate role during the 
gene expression (Ghildiyal, et al. 2009). Because of their origin, structure 
and the role in specific biological processes the small non coding RNAs are 
classified into three classes: genome encoded microRNAs (miRNAs)  
(Lambert, et al. 2019), small interfering RNAs(siRNAs) (Zamore, et al. 2000), 




1.7.2 Small interfering RNAs (siRNAs) biogenesis 
Small interfering RNAs (siRNAs), first discovered from plants and later from 
other species, is transcripted and matured from a longer double –stranded 
RNA, similar to miRNAs. Both miRNAs and siRNAs are cleaved by an RNase 
III enzyme called Dicers, despite that they have very different structure. 
Further research in drosophila found that Dicer family contains two 
different gene called Dicer-1 and Dicer-2. Later study reported that Dicer-1 
is necessary during the miRNA mature, while Dicer-2 is required in dsRNA 
processing into siRNAs (Lee, et al. 2004). siRNAs degrade or inhibit the 
target gene expression by forming a RNA-induced silencing complex (RISC) 
with ribonucleoproteins (Hammond, et al. 2000).  The RISC interacts with 
the antisense strand from the siRNAs to form an active RISC complex. The 
left passenger strand was cleaved by the endonucleases argonaute 2(AGO2). 
After binding to the cognate mRNAs the active RISC complex cleavages and 






Figure 3. SiRNA regulate the gene expression. The ds-RNAs were processed by the Dicer and 
become ds-siRNA, these siRNAs were loaded into RISC and AGO complex. The passage strand 
were cleaved into small pieces, while the guide strand incorporate into RISC complex and lead 
to cleavage/supress the target mRNA.  
 
1.7.3 Piwi-interacting RNAs (piRNAs) biogenesis 
Piwi-interacting RNAs (piRNAs) are the most recently discovered small RNAs. 
It was first discovered in Drosophila in 2001(Aravin, et al. 2001). Later 
studies in other species like fish, files and mammals showed these small 
RNAs were especially associate with Piwi clade of Argonaute protein (a sub-
class of Animal Argonaute protein), and named as Piwi-interacting RNAs 
(piRNAs). The piRNA is the longest small noncoding RNAs with a length of 
25-30nt.PiRNAs can be distinguished from siRNAs or miRNAs since they are 
restrictedly binding with Piwi proteins and do not need Dicer for their 
maturation. 
 
The biogenesis and maturation of piRNAs is still not well understood. Some 
studies suggest that piRNAs are cleaved from the coding and 3’untranslate 
regions of the single-strand precursor RNAs (Vagin, et al. 2006), which is 
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different from siRNAs and miRNAs. The mature piRNAs have a phosphate 
at its 5’ terminus, and similar structure to siRNAs in flies at 3’termini (Kirino, 
et al.  2007). The piwi proteins differ across different species, for instance 
in mice, the piwi family are comprised of MILI, MIWI and MIWI2, while in 
human HILI, HIWI1, HIWI2 and HIWI3 are classified as the piwi family 
proteins (Ghildiyal, et al. 2009).  Two major pathways, primary pathway 
(phased piRNAs pathway) and secondary pathway (Ping-pong cycling) 
(Czech, et al.  2016), have been proposed to control/regulate the 
production and maturation of piRNAs. In the primary pathway, a genomic 
region called piRNAs clusters are transcribed into a long single stranded 
RNAs. Interestingly, not all the mRNA transcripts could produce piRNAs, and 
only 5’ mono-phosphorylated RNAs, a structure is critical for Argonaute 
protein binding, can produce the piRNAs. Once the single strand RNA 
interacted with the PIWI proteins, the RNA transcripts are modified at 3’ 
terminus before they become mature piwi-RNAs (Ozata, et al. 2019). In the 
‘ping-pong’ cycle or secondary pathway, the piRNA- PIWI protein complex 
acts as a cleavage director, which ultimately generate a new piRNA. First, 
the piRNA cluster transcripts are recognized by Argonaute3 protein and 
cleaved to piRNA intermediates. These intermediates are loaded into 
Aubergine (Aub) protein. After then, two nonexclusive ways lead the piRNA 
to different destination. One is cleaved by Zuc at 3’ end and associated with 
PIWI proteins, producing a mature piRNA. In another way, the 3’ end 
subjects to Papi-dependent trimming and Hen1 mediated methylation. The 
methylated piRNA- Aub complex is then modified by dimethyl -arginine 
(sDMA), and later recruited into Krimper -Ago3 protein complex. After 
interacted with Krimper the piRNA were loaded again into Ago3. These 
Ago3-loaded piRNA intermediates are either subjected to cleavage by Zuc 
or trimming and methylation by Hen1 for their maturation. The matured 
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Ago3- piRNA complex are then used as a pre-piRNA precursor for another 
cycle. Notably, mature piRNAs produced by this pathway always contain a 
10-nt complementarity sequence to the director piRNA (Ozata, et al. 
2019)(Figure 4 ). 
 
Figure 4. Piwi-RNA biogenesis. Two different pathways were reported to be involved in piRNA 
production and maturation. Left illustrating primary pathway, while right part describing the 
‘ping-pong’ cycling. In the primary pathway, the long precursor transcripts RNA is cleaved by a 
mitochondrial protein, Zucchini/PLD6. After bound to a PIWI protein, the 3’end of the pre-RNA 
were modified by PNLDC1, a single stranded RNA exonuclease, followed by methalyation by 
Hen1/HENMT1 at the 3’end, producing mature piRNA. The ‘ping-pong’ cycle is much more 
complicate, AGO3 protein binding is associated with cleavage of the piRNA precursor transcript, 
while Aub protein binding is a critical step for transporting the pre-piRNA within the ‘ping-pong’ 
cycle (Ozata, et al. 2019). 
 
The function of piRNAs and Piwi proteins is still not well studied, some 
research suggest piRNAs may play a role during the meiosis (Li, et al. 2013). 
Mammalian piRNAs possess much more complicated functions than their 
counterparts in flies. There are two major mammalian piRNAs, pre-
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pachytene and pachytene piRNAs (Aravin, et al. 2007). Apart a role in 
meiosis, piRNAs have also been implicated in protecting the germline 
double-strand DNA breaks (Aravin, et al. 2001). piRNAs have also been 
reported to mediate post transcriptional transposon silence (Lewis, et al. 
2018; Reuter, et al. 2011). The regulatory mechanisms of given piwiRNA 
vary among different species. For example, in flies, piRNAs recruit the 
dSetdb1 and then promotes H3K9 methylation (Wang, et al. 2011), but it is 
unclear if the mouse nuclear PIWI protein MIWI2 could promote DNA 
methylation. Although the piRNAs was first reported to protect the 
germline cells, their functions in other tissue and cells were also observed. 
For instance, piRNAs play important roles in stem cell maintenance and 
regeneration in melanogaster (Palakodeti, et al. 2008), and in mosquito the 
somatic piRNAs exert a protective effect in the viruses infection(Miesen, et 
al.  2015).  
 
1.7.4 MiRNAs biogenesis 
MiRNAs are a group of highly conserved and endogenous non-coding RNAs 
which were first recognized in 1993 (R. C. Lee, et al. 1993). The lin-4, as the 
first identified miRNA, was proven without any protein coding potntial but 
to inhibit the target gene, lin-14, by direct interacting with the 3’ un-
translation region (3’UTR). (Wightman, et al. 1993). Since then, miRNAs are 
extensively identified in different species, including plants and animals 
(Bartel,et al.  2004).   
 
MiRNA biogenesis processes are starting with primary (pri-miRNA) miRNA 
transcription from miRNA genes by RNA polymerase II (Pol II). The pri-
miRNA transcripts containing a distinctive hairpin structure is loaded into 
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protein complex of Drosha, a type III RNase, and protein DGCR8, within 
which the pri-miRNAs are subjected to multiple cleavages at their 5’and 3’ 
terminals to produce pre-miRNA (miRNA precursor). After loaded into 
exportin 5-RAN/GTP complex the pre-miRNAs are transported from the 
nuclear to cytoplasm, where the RNase III Dicer and TAR RNA binding 
protein (TRBP) work cooperatively to remove the loop from pre-miRNA, 
resulting in a double-strand miRNA (ds-miRNA). The resulting ds-miRNAs 
are loaded into argonaute (AGO) family of proteins, which unwind ds-
miRNA duplex. After then, the guide strand incorporates into the core of 
the RNA-induced silencing complex (RISC), forming a mature miRNA 
regulate complex, and the passenger strand is transported into P-body and 
degraded(Rupaimoole, et al.  2017) (Figure 5). However, recent data shows 
that the passenger strand also has the same function as the guide strand 








Figure 5. MiRNA regulates the gene expression. The pri-RNAs are transcript by polymerase II (Pol 
II) enzyme from genome, and then interacted with the Drosha complex to produce pre-miRNA. 
Pre-miRNAs are transported from the nuclear to cytoplasm by Exportin5-RAN/GTP complex. In 
cytoplasm, pre-miRNA is processed by the Dicer to generate ds-miRNA, which is unwound within 
RISC and AGO complex to produce mature miRNAs. The passage strand is cleaved into small 
pieces within P-body, while the guide strand reloads into RISC complex and binds to the target 
mRNA, supressing the target gene expression.  
 
SiRNAs and miRNAs are very similar in structures and biogenesis, and they 
both could inhibit target gene expression, but through different 
mechanisms. The siRNA requires for full complementary to its target mRNA 
to trigger the target mRNA degradation by different exonucleases. 
Contrastingly, such a requirement is unnecessary for miRNA to supress its 
target gene expression. The first 2-8 nucleotides of miRNAs, recognised as 
‘seed sequence’, is critical for target gene regulation. To regulate target 
gene expression, miRNAs usually bind to one or more miRNA binding sites 
located within the 3’untranslated region (3’ UTR) of target mRNAs through 
their ‘seed sequence’. However, later studies also suggest that miRNAs can 
also regulate target gene expression by interacting with the binding site(s) 
outside 3’ UTR, such as code region and 5’ UTR (Valencia-Sanchez, et al. 
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2006). Since the 3’UTR of each gene contains binding site(s) for multiple 
miRNAs, thus each gene could be regulated by several miRNAs. Meanwhile, 
each miRNA could regulate different target genes.  
 
Two mechanisms for miRNA-mediated gene regulation were reported: 
decaying/degrading mRNAs or repressing the translation efficiency of 
target genes. The former is mediated through endonuclease cleavage of the 
target mRNAs when the ‘seed sequence’ is perfectly matched with its 
binding site(s), while the latter is mediated through silencing/impairing the 
mRNA translation there is an imperfect matching between miRNA and 
target mRNAs. However, one study showed that miR-196 could mediate 
HOXB8 mRNA decay without perfect pairing, suggesting that perfect 
matching between miRNA and its target mRNA is not compulsory for the 
mRNA cleavage induced by some miRNAs (Yekta, et al. 2004). Another 
paper reported that the Argonatue protein 2 (AGO 2), the only one in the 
Argonatue family, is required for miRNA-RISC complex to catalyse mRNA 
cleavage (Meister, et al. 2004). On the other hand, it was first observed that 
lin-4 meditates the lin-14 protein amount but rarely changes the mRNA 
quantity(Lee, et al. 1993), indicating that silencing/impairing mRNA 
translation may come to play, which is largely supported by later studies. 
For instance, miR-15a and miR-16-1 influence the protein Bcl2 expression 
level, but have no effect on Bcl2 mRNA level (Cimmino, et al. 2005). Let-7 
was reported to carry its target mRNAs to polysomes, and consequently 
represses the mRNA translation. Additionally, the mRNAs could be brought 
by miRNA to the P-Bodies (PBs) for storage, which suggest that the PBs is 
not only the site for  mRNAs degradation, but could act as a ware house for 




1.8 MiRNAs and diseases  
More than 1900 miRNAs were discovered so far (miRBase/ 
http://www.mirbase.org/cgi-bin/browse.pl). MiRNAs participate in almost 
every biological process and sometimes act as a critical regulator of 
controlling cell proliferation, death, migration, differentiation and survival. 
Animals absent of miRNAs display embryo development defect in early 
stage (Wienholds, et al. 2003). Another seminal paper showed that during 
the mice embryo development, Dicer1 gene inactivation could induce the 
embryos died at early stage, means that miRNAs as well as other small RNAs 
produced by Dicer1 are critical for maintaining the stem cell amount and 
functions in mouse embryo development(Bernstein, et al. 2003). One study 
with embryonic stem cell (ESCs) showed that miR-214 could promote ESC 
differentiation into SMC-like cells (Wu, et al. 2017). The let-7 family of 
miRNAs could promote ESC differentiation and maintain the cells mature 
statues, while opposite effect was observed with ESCC miRNA families. 
(Melton, et al. 2010). Together, these studies suggest a divergent role for 
any given miRNAs in regulating ESC self-renew and differentiation. Similarly, 
huge number of miRNAs have been implicated in almost every human 
disease, particularly cancers and CVDs.  
 
1.8.1 MiRNAs in cancers 
 Cancer is one of the leading causes of death. Progressive accumulation of 
the genetic and epigenetic alterations of oncogenes and some tumour 
suppressor genes allow the cells to obtain new properties, such as 
uncontrollable cell proliferation and migration. Those are two main 
underlying causes for cancer development and deterioration. The 
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processes for cancer formation and development divide into five steps: 
trigger, promotion, malignant transformation, progression and 
metastasis(Zhang, et al. 2007). MiRNAs have been reported to be involved 
in all these steps. One of the early studies reported that two miRNAs (miR-
15 and miR-16) were down-regulated or missing in chronic lymphocytic 
leukemia (CLL) cells and CLL patients (Calin, et al. 2002).  B cell lymphoma 2 
(Bcl2) plays an anti-death role in eukaryotic cells, and increased level of Bcl2 
protein was observed in many types of cancers, such as leukaemia and 
lymphoma. Both miR-15a and miR-16-1 were found to reduce Bcl2 protein 
expression in B cell CCL and increase apoptosis of the cells isolated from CLL 
patients (Cimmino, et al. 2005). Lung cancer is another common cancer in 
human. One study observed decreased level of let-7 miRNA in human lung 
cancer cells both in vivo and in vitro. This thesis also reported that lower 
let-7 expression in lung cancer patients have a worse prognosis and lower 
survival rate (Takamizawa, et al. 2004). RAS is a well-recognized oncogene. 
One study found that all three RAS genes were negatively regulated by let-
7, and lung tumour tissues express a high level of RAS gene but lower level 
of let-7 gene (Johnson, et al. 2005). Other studies showed that miR-17-92 
cluster was upregulated in lung cancer cells (Hayashita, et al. 2005), and 
miR-372 and miR-373 could promote testicular germ tumour cell 
proliferation and tumour process by targeting P53 signalling (Voorhoeve, et 
al. 2007). Since miRNAs could target multiple genes, they are not always 
function as an oncogene or tumour suppressor in diseases. Take miR-26 as 
an example, one research found that miR-26a expression was dramatically 
increased in glioblastoma multiform (GBM) patients, and phosphates and 
tensin homolog (PTEN)/ Akt signalling pathway was responsible for miR-
26’s oncogenic functions in glioma(Huse, et al. 2009). However, an opposite 
effect was observed in human thyroid carcinomas. By using two thyroid 
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carcinomas cell lines FB-1 and FRO, the authors showed that miR-26a and 
miR-125b could effectively reduce the cell proliferation. These result 
suggest this two miRNAs might negative regulate thyroid cell proliferation 
and present them as tumour suppressor genes in human thyroid 
carcinomas (Visone, et al. 2016). In short, miRNAs play a distinct role in 
different cancers, thus more investigation into the functions of these 
miRNAs could provide a new method to predict the patient’s survival rate 
and treat cancer by modulating the specific miRNAs. For example, MRX, act 
as a miR-34 mimic, could inhibit multiple oncogene signal pathway and 
induce the tumour cell apoptosis, and has now been used in clinical trial for 
treating the primary liver cancer (Farooqi, et al. 2016). Any promising data 
rasied from such a trial would provide a new avenue for us to use miRNAs 
as a novel weapon for fighting cancers. 
   
1.8.2 MiRNAs with other diseases 
Cells or tissue dysregulation predispose disease progression, and miRNA 
dysregulation may play an important role in this initiate step. 
Neurodegenerative disorders (NDDs) are a group of neuronal degenerative 
diseases, characterised as a certain proportion of neuron undergoing 
progressive loss/damage in nervous system (Karnati, et al. 2015). As a 
powerful gene regulator, miRNAs have unsurprisingly been reported to play 
many critical roles in NDD. Take Alzheimer’s disease (AD) as an example, 
Hebert et al observed an increased expression level of BACE1 gene, but 
decreased levels of miR-29a and miR-29b-1 in AD patients. The authors 
further confirmed that BACE1 is one of the target genes of miR-29 subgroup, 
suggesting that dysregulation of miR-29 subgroup may cause increased 
BACE1 protein expression and contribute to AD process (Hebert, et al. 2008). 
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Another research showed that miR-133b level was significant decreased in 
rat brain after Stroke compare with normal group, and the impaired 
expression of miR-133b was reversed by administration of MSCs. Additional 
evidence suggest that miR-133b released by MSCs could transfer to brain 
parenchymal cells and promote neurite outgrowth, which in turn improve 
neuron growth after Stroke(Xin, et al. 2012).  
 
Even nowadays, virus infection still is one of most terrifying diseases. Virus 
infection happens in people’s everyday life, causing from influenza to death. 
Hepatitis C is one the widely reported virus infection, which is caused by 
hepatitis C virus (HCV). After infected, HCVs trigger the liver chronic 
inflammatory process, leading to liver fibrosis and hepatic carcinoma 
(Manns, et al. 2017). Many miRNAs have been implicated in HCV infection 
or hepatitis C. Among them, the liver-specific miR-122 caught the 
researchers’ attention. One research group found that the HCV viral 
replicon RNA level was significant decreased miR-122 inhibition. Further 
investigation revealed that miR-122 could directly interact with HCV RNA 
by binding to its’ 5’ UTR, resulting in HCV genome stabilization and increase 
of the replication of HCV in the liver cells (Jopling, et al. 2005). This research 
implied that the liver-specific miR-122 could be a therapy target in 
controlling HCV infection. Actually, as we all know targeted therapy could 
reduce the drug toxicity in patients and improve the therapeutic effect, 
miR-122 would be a perfect drug target for treating HCV infection. For such 
a purpose, a drug called Miravirsen, a high affinity anti-miRNA drug for miR-
122, has been recently developed. Animals experiment with HCV-infected 
chimpanzees reported that Miravirsen could effectual suppress the miR-
122 expression in vivo and significantly decrease the HCV RNA level after 
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two-week treatment. More importantly, HCV was undetectable after 
treated for 12 weeks(Lindow, et al. 2012). Following these promising data 
generated from pre-clinical studies, Miravirsen has now become the first 
miRNA-target drug used in phase II clinical trials, in which the investigators 
observed that Miravirsen showed a dose dependent effect when used in 
patients with genotype 1 HCV infection, with subcutaneous injection a 
higher dose for 5 weeks resulting in lower or even undetectable HCV RNA 
levels (Janssen, et al. 2013). 
 
Diabetes mellitus (DM) is another very common but serious metabolism 
disease worldwide. Patients with DM is rapidly increased in the past three 
decades, and will continue to increase, with an estimate of 439 million DM, 
as much as 7.7% of world aged 20-79 years old people in the world in 
2030(Chen, et al. 2011). Many studies have reported a critical role for 
miRNAs in DM, and suggested that these newly identified miRNAs could 
provide a new avenue for controlling or treating diabetes(Bhatia, et al. 
2015). Just list one as example, one study reported that miR-103 and miR-
107 could regulate the insulin sensitivity, and over-expression of miR-103 
and miR-107 could induce a dysregulated glucose homeostasis in mice 
(Trajkovski, et al. 2011). The authors further identified Cav1, a regulator of 
insulin receptor, as one of the target genes for these two miRNAs 
(Trajkovski, et al. 2011).  
 
1.8.3 MiRNAs in cardiovascular diseases  
As mentioned previously, CVD is one of the leading causes of morbidity and 
mortality in the world, especially in developed countries. Since discovered, 
these studies have provided clear evidence to support that miRNAs are the 
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key regulators involved in almost all the biological processes, human 
diseases particularly CVD (Wu, et al. 2017; Afzal, et al. 2016; Yang, et al. 
2018) as well as embryo development (Wienholds, et al. 2003; Bernstein, 
et al. 2003). Handful of miRNAs have been implicated in cardiovascular 
system development. For instance, a cardiac specific mRNA, MiR-208, 
produce from the intron region of human and mice α-myosin heavy chain 
(αMHC) genes, has been identified as a key miRNA to control the heart 
functional response to stress and hypothyroidism (van Rooij, et al. 2007). 
Specifically, the authors found that although the animal with miR-208 loss 
did not display any obvious abnormal phenotype in terms of heart 
development, these mice lost their ability to develop a cardiac adaptive 
response to pressure overload (van Rooij, et al. 2007). Other miRNAs, miR-
133 and miR-1 have also been reported to play a role in controlling cardiac 
hypertrophy (Care, et al. 2007).  
 
Apart from cardiac hypertrophy, numbers of miRNAs show a cell/tissues-
specific expression pattern and have been implicated in cardiovascular 
system development and angiogenesis. The first miRNA has been assigned 
a role in these processes is the EC specific miRNA, miR-126 (Nicoli, et al. 
2010). In this zebrafish, miR-126 induced by the flow could active the VEGF 
signalling by repressing spred1, the VEGF signalling inhibitor, and then 
promote angiogenesis (Nicoli, et al. 2010). In the absence of miR-126, 
zebrafish display severe embryonic developmental defects due to lacks of 
vessel integrity and calibre. Interestingly, spred1 overexpression could 
mimic the observed phenotypes in miR-126-deficient zebrafish (Fish, et al. 
2008). On the other hand, the SMC-specific miRNA, miR-145 has been 
recognised as important regulator for SMC development. In this aspect, 
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miR-145 was first reported to promote SMC differentiation from fibroblasts 
(Cordes, et al. 2009). Serum response factor (SRF) is the master regulator 
for SMC differentiation and its phenotype switching. Both miR-143 and miR-
145 expression were induced by SRF activation, suggesting that these two 
miRNAs are the transcriptional downstream targets of SRF signalling, and 
they could play important roles in SMC biology controlled by SRF (Xin, et al. 
2009). MiR-145 deficient VSMCs stopped at synthetic state and less 
neointimal lesion was observed in miR-145 mutant mice (Boettger, et al. 
2009). Apart being a critical regulator for cardiovascular system 
development and angiogenesis, growing evidence has also suggested that 
miRNA dysregulation is the main underlying cause for almost all the CVDs 
such as atherosclerosis, heart failure and hypertension.  
 
Atherosclerosis is a chronic inflammatory diseases of vascular wall starting 
with EC injury and dysfunction (Rudijanto. 2007). MiR-10a was significantly 
decreased in regions of athero-suscetibility with EC dysfunction (Fang, et al. 
2010). Inhibiting miR-10a in ECs result in NF-ƙB signal pathway activation 
and increase of the pro-inflammatory gene expression (Fang, et al. 2010).  
Unsurprisingly, miR-126 was reported to promote EC regeneration and 
repair after injury (Schober, et al. 2014). Additionally, miR-126 
deletion/inhibition resulted in a thicker neointimal lesion, and 
administration of miR-126 mimics could rescue the dysregulated ECs 
caused by hyperlipidaemia (Schober, et al. 2014). MiR-181b is another 
miRNA that plays an important role in modulating the NF-ƙB signal pathway 
and suppressing inflammatory gene expression in vivo after treatment with 
TNFα (Sun, et al. 2012). Interestingly, the SMC-specific miRNA, miR-145 has 
also been reported to play a role in ECs by targeting junctional adhesion 
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molecule-A (JAM-A) (Schmitt, et al. 2014). Additional study showed that 
shear stress could increase miR-143/145 expression in ECs and promote 
SMCs being switched to an athero-protective phenotype, preventing 
atherosclerotic lesion formation (Hergenreider, et al. 2012). These data 
suggest that physiological shear stress could trigger the communication 
between ECs and SMCs through releasing miRNAs, and consequently 
prevent atherosclerosis.  
 
Dysregulated cholesterol metabolism and homeostasis is a critical factor 
underlying atherosclerosis development and progression. Several miRNAs 
have been reported to be involved in the dysregulation of cholesterol 
metabolism and homeostasis, and consequently atherosclerotic plaque 
formation. In this regard, liver-specific miRNA, miR-122 (Jopling, et al. 2005) 
has been identified as a key regulator to control HCV replication as well as 
cholesterol metabolism and homeostasis. Inhibiting the miR-122 in liver 
reduces plasma cholesterol level in mice (Elmen, et al. 2008). Apart from 
miR-122, miR-33 is another miRNA, its role in cholesterol metabolism and 
homeostasis, and atherosclerosis has been extensively studied. MiR-33 is 
located in the intron of Srebp2 gene, a gene belongs to sterol regulatory 
element-binding protein (SREBP) group (Rayner, et al. 2010). As expected, 
miR-33 decreased plasma High-density lipoprotein (HDL) level by targeting 
human ATP-binding cassette transporter A1 (ABCA1) (Rayner, et al. 2010). 
Inflammatory responses and lipid uptake inside the intima by macrophages 
and VSMCs induce plaque development. MiR-155 regulates the 
macrophage inflammatory response though modulating CCL2 gene 
expression and thus activating the NF-ƙB pathway (Nazari-Jahantigh, et al. 
2012). An early study reported a role for miR-21 in controlling VSMC 
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proliferation and apoptosis, and promoting neointimal formation in rat 
carotid artery injury model (Ji, et al. 2007). MiR-26a has also been suggested 
to play a role in VSMC differentiation though regulating TGFβ1 signalling 
pathway (Leeper, et al. 2011). Both abovementioned miRNAs function as 
an inhibitor of SMC differentiation, but an opposite role was reported with 
other miRNAs including miR-145. Moreover, miR-145 was down-regulated 
in human atherosclerosis samples, while overexpression of miR-145 in 
animal models could significantly reduce the plaque size (Lovren, et al. 
2012). These reports suggest that VSMC phenotype switch is finely 
controlled by multiple miRNAs; any change within the miRNA regulatory 
network could break the balance and trigger the disease.  
 
Atherosclerotic angiogenesis (new vessel formation) is developed at the 
later stage of the atherosclerosis. It has been suggested that macrophages 
within atherosclerotic plaque could release cytokines into 
microenvironment, which in turn promote atherosclerotic angiogenesis.  
Neo-vessel formation in the plaque is a very complex process and controlled 
by a complicated regulatory network including many miRNAs. One of such 
miRNAs is miR-222. It has been reported that miR-222 regulates EC 
migration and proliferation through Signal Transducer and Activator of 
Transcription 5A (STAT5A). In vivo experiment further confirmed that 
STAT5A was the target gene of miR-222, and proven that miR-222 could 
reduce the neo-angiogenesis and intra-plaque vessel formation (Dentelli, et 
al. 2010). Neovessel formation in the plaque introduce a new challenge in 
atherosclerosis since the haemorrhage due to the leaky neovessels within 
plaque could attract and bring more inflammatory cells into plaque and 
produce more pro-inflammatory cytokines, which in turn increase plaque 
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vulnerability and cause plaque rupture. At this scenario, the pro-
inflammatory cytokines and other apoptosis factors trigger EC and VSMC 
death which significantly aggravate the plaque instability and result in 
rupture. In this regard, growing evidence has suggested an important role 
for multiple miRNAs in cell apoptosis. Specifically, miR-365 could prevent 
EC from apoptosis induced by ox-LDL via targeting anti-apoptotic gene Bcl-
2 (Qin, et al. 2011). A similar role was observed for miR-21 in hydrogen 
peroxide (H2O2) induced VSMC apoptosis (Lin, et al. 2009). Interestingly, 
miR-221/222 has a pro-proliferation effect in VSMCs (Liu, et al. 2009), but 
an opposite effect was observed in ECs (Dentelli, et al. 2010). MiR-221/222 
expression was after angioplasty, inhibiting these two miRNAs expression 
in the rat carotid artery after injury could reverse neointima formation by 
promoting re-endothelialization of the injured arteries. These findings 
indicate that miRNAs regulate cellular functions in a cell-specific manner 
(Liu, et al. 2012).  
 
Apart from atherosclerosis and neointima SMC hyperplasia, miRNAs have 
also been extensively implicated in other CVDs, such as heart failure (HF) 
and acute myocardial infarction (AMI). Heart failure is a final manifestation 
of CVD which happened when the heart cannot providing enough 
circulatory force to pump sufficient blood maintaining the body’s need 
(Leonard, et al.  2012). The main pathological characteristics of heart failure 
is associate with the damaged cardiac tissue replaced by accumulating ECM 
and activating cardiac fibroblasts, resulting in cardiac fibrosis and 
eventually HF (Mann, et al. 2005). Extensive studies have unraveled the 
great importance for many miRNAs in cardio-myocyte dysfunction, cardiac 
fibrosis and thus HF. Decreased level of miR-133 was observed in both 
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murine model of cardiac hypertrophy and patients with heart diseases (e.g., 
hypertrophic cardiomyopathy and atrial dilatation) (Care, et al. 2007). 
Moreover, many dysregulated serum/plasma miRNAs have been observed 
in patients with symptomatic HF (Sygitowicz, et al. 2015). Specifically, it has 
been reported that the expression levels of circulating miR-423-5p could 
distinguish the HF patients from the non-HF patients, inferring a diagnostic 
role of this miRNA in HF (Tijsen, et al. 2010). Further study demonstrated a 
diagnostic and prognostic potential for another two miRNAs, miR-1254 and 
miR-1306, as evidenced by both miR-1254 and miR-1306 were significantly 
associated with the increased risk of mortality and morbidity in patients 
with HF (Bayes-Genis, et al. 2018).  
 
AMI is another major cause of the high morbidity and mortality rate in 
patients with CVD. Significant changes were observed for the expression 
profiles of miRNAs after AMI. In an animal AMI model, the authors reported 
that the expression level of serum miR-1 peaked at 6 hours post AMI, then 
decreased to normal level after 3 days (Townley-Tilson, et al. 2010).  In 
patients with left ventricular remodeling (LVR) after AMI, both miR-21 and 
miR-146a were significantly increased 5 days post AMI, and their expression 
levels were correlated with AMI traditional biomarkers (Liu, et al. 2015). 
MiR-208a was another miRNA with an expression level peaked at 3 hours 
post AMI, and associated with other AMI traditional biomarkers (Bialek, et 
al. 2015). Compared with miR-1 and miR-208, a more accurate predictive 
value for AMI was observed with miR-499 (Liu, et al. 2015), suggesting miR-
499 released from the damaged cardio myocytes could serve as a potential 
novel biomarker in AMI patients (Liu, et al. 2015; Corsten, et al. 2010). 
Although many miRNAs are dysregulated in AMI, not all of them are 
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specifically expressed in cardiomyocytes, and can be used as AMI 
biomarkers.  
 
1.9 MiR-214 biogenesis 
The human miR-214 gene was first discovered by a computational 
procedure during the sequence comparison in invertebrates (Lim, et al. 
2003). MiR-214 gene is located at the opposite strand of the Dynamin-3 
gene (Dnm3) intron 14, also called Dmn3os (Loebel, et al. 2005). Apart from 
miR-214, miR-199 is also located at this genomic region, which contains a 
vertebrate –specific conserved cluster of the Dnm3 gene (Desvignes, et al. 
2014). Dmn3os is a 7.9kb antisense transcript of the Dmn3 gene, although 
it has a potential open reading frame in the mouse, a similar start site 
cannot be found in human and chicken species, thus Dmn3os was 
considered as a non-coding RNA transcript. Further genomic knock out 
experiment showed that deleting Dmn3os in mice resulted in a lower level 
of miR-199 and undetectable level of miR-214 (Watanabe, et al. 2008). 
Another miRNA, miR-1320, is found to be transcripted from the opposite 
strand of the Dnm3os (Scott, et al. 2012).  It has been reported that the 
transcription of miR-214 expression is regulated by Twist-1, a nuclear 
transcription factor (Thisse, et al. 1988; Gitelman. 1997). Twist -1 promotes 
miR-214/199a2 expression by binding to the E-box within Dnm3 gene intron 
(Lee, et al. 2009). Conversely, it has been shown that several potential NF-
ƙB binding sites are located in the upstream promoter region of the miR-
214/199a2, and miR-214/199a2 are negatively regulated by NF-ƙB 
signalling (Duan, et al. 2012). Moreover, miR-214/199a2 expression is 
transcriptionally regulated by ZEB1, a transcription factor structurally 
similar to Twist-1 and functionally binding to E-boxes (Williams, et al. 2012). 
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Importantly, miR-214 homologs with conserved sequence have been 
discovered in over 20 different species, inferring a crucial role for this 
miRNA in variety of biological functions and diseases (Desvignes, et al.  2014; 
Penna, et al.  2015)(Figure 6). 
 
 
Figure 6.  MiR-214 location and sequence. MiR-214 is located at the opposite strand of the 
Dynamin-3 gene (Dnm3) intron 14, called Dmn3os. Three different miRNAs (miR-214, miR-199, 
and miR-1320) are transcript from this genomic region. The sequences of mouse, rat, human 
and Rhesus macaque miR-214 were included here.  
 
Indeed, spatiotemporal changes of miR-214 expression were observed in 
different organs and tissues during the development. MiR-214 expression 
in embryonic murine heart was rapidly increased at the early 
developmental stage and peaked at E12.5 (Aurora,  et al. 2012). 
Interestingly, DNM3os gene inactivation leads to an abnormal development 
of skeletal and adipose tissues, and DNM3os mutant mice died shortly after 
birth (Watanabe, et al. 2008), suggesting an important role for these 
miRNAs during embryonic development. Indeed, zebrafish study showed 
that miR-214 regulates the skeletal muscle development by targeting the 
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Sufu gene (Flynt, et al. 2007). Additionally, it has been reported that the 
skeletal muscles differentiation from embryonic stem cells is regulated by 
miR-214, and miR-214 exerts such function via modulating Ezh2 gene 
expression (Juan, et al. 2009). These results suggest a role for miR-214 in 
the skeletal muscles differentiation. However, no embryonic lethality and 
abnormal phenotype is observed in global miR-214 knockout mice (Aurora, 
et al. 2012), inferring a redundant role for this miRNA in embryonic 
development. However, a pathological role was confirmed using these 
knockout mice, with an increased level of cardio myocytes apoptosis after 
AMI was determined in these mice (Aurora, et al. 2012).  
 
1.9.1 MiR-214 in cancer  
Functional importance of miR-214 has been first investigated in cancers, 
reported an inhibitory effect of miR-214 on cancer cell  apoptosis(Cheng, et 
al. 2005). However, later studies point-out a contradicting role for miR-214 
in different cancers. Specifically, malignant melanoma, basal cell carcinoma 
and squamous cell carcinoma (SCC) are three major type of skin cancers. 
MiR-214 is upregulate in metastatic melanoma cells and promotes 
melanoma metastasis by increasing the melanoma cell survival, migration 
and invasion (Penna, et al. 2011). On the other hand, miR-214 expression 
was decreased in human SCC cells (Yamane, et al. 2013), with no significant 
change was observed in basal cell carcinoma (Sand, et al. 2012). Moreover, 
miR-214 has an anti-breast cancer effect since miR-214 over-expression 
inhibits breast cancer cell proliferation and migration, but increases cell 
apoptosis (Liu, et al. 2016). Consistent with this finding, lower expression 
level of miR-214 was observed in breast cancer patients (Yi, et al. 2016) 
(Zhang, et al. 2016). However, increased level of miR-214 has been reported 
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in patients with ovarian cancer from two different studies (Yang, et al. 2008) 
(Vaksman, et al. 2011). Furthermore, miR-214 dysregulation has also been 
reported in patients with pancreatic cancer (Cao, et al. 2018), stomach 
cancer (Yang, et al. 2018), lung cancer (Zhang, et al. 2018), bladder cancer 
(Wang, et al. 2015), and colorectal cancers (Wu, et al. 2018). These 
contrasting observations highlight a divergent role for miR-214 in different 
cancers/diseases, with a cellular-context- and/or disease-dependent 
effects on cancer progression. Due to its huge importance in some cancers, 
miR-214 represents a promising drug target in fighting with cancers. In this 
regard, the therapeutic effect of miR-214 on cutaneous T-cell Lymphoma 
(CTCL) has been tested in a pre-clinical study (Kohnken, et al. 2019).  
 
1.9.2 MiR-214 in other diseases 
MiR-214 has also been implicated in other diseases, such as DM, kidney 
disease and neural disease. MiR-214 overexpression prevents diabetic 
nephropathy by reducing oxidative stress in diabetic kidney (Yang, et al. 
2019). However, another study shows that increased expression of miR-214 
in renal tubular cells induce the mitochondrial dysfunction and lead to the 
renal tubular cell death (Bai, et al. 2019). Additionally, decreased serum 
miR-214 level was observed in patients with ankylosing spondylitis. Since 
precise and rapid distinguishing the patients with or without ankylosing 
spondylitis is crucial for the patients prognosis and their quality of life, 
circulating miR-214 could serve as a novel biomarker for diagnosing this 
disease (Hyun Yi Kook, et al. 2019). Moreover, it has been reported that 
inhibiting miR-214 after spinal cord injury reduces oxidative stress, 
promotes neural cell survival and inhibits inflammatory diffusion at the 




1.9.3 MiR-214 in CVDs 
Similar to cancers, a contradicting role for miR-214 in CVD has also been 
documented in literature.  Increased serum miR-214 level was reported in 
patients with HF, and correcting the dysregulated miR-214 expression level 
could reverse the cardiac remodeling in vivo  (Duan, et al. 2015). In this 
thesis, the authors also reported a role for miR-214 in EC function and 
angiogenesis (Duan, et al. 2015). A later study also showed that miR-214 
expression is dramatically decreased in mice after treatment with 
Doxorubicin (DOX), a drug has been widely used for treating cancers with a 
proven side-effect, causing the congestive heart failure (Octavia, et al. 
2012). Interesting, miR-214 expression in these patients displayed a time 
and dose dependent manner (Holmgren, et al. 2016). Above studies suggest 
that miR-214 could be a potential biomarker in HF.  
 
MiR-214 seems to play a more consistent role in ischemic cardiac disease. 
Study showed that miR-214 plays a protective role in AMI by reducing 
cardiomyocyte death and activating cell proliferation signal pathway, which 
in turn reduces the infarct size and improve the heart function. PI3K/Akt 
signalling pathway is one of the most important pathways controlling 
multiple cellular functions such as apoptosis, cell cycle progression, 
proliferation, and growth (Cantley. 2002). Phosphatase and tensin 
homologue (PTEN) reduces the Akt phosphorylation and inhibits the 
PI3K/Akt signal pathway, thus increases cell death in the ischemic cardiac 
tissue (Gericke, et al. 2006; Stambolic, et al. 1998). In cardiomyocytes, miR-
214 promotes Akt phosphorylation and activates PI3K/Akt signalling by 
targeting PTEN. Animal study showed that miR-214 overexpression reduced 
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myocardial infarct size after ischemia/reoxyenation (I/R) through 
promoting Bad protein phosphorylation and increasing Bcl-2 protein level 
(Wang, et al. 2016).  Increasing in reactive oxygen species (ROS) after I/R 
induces the cell apoptosis. Decreased expression of miR-214 was observed 
in cardiomyocytes in response to oxidative stress, and miR-214 
overexpression prevented ROS-induced cell death via modulating PTEN 
expression level. Thus, aforementioned studies have provided clear 
evidence to support a protective role for miR-214 after AMI. MiR-214 exerts 
such an effect by inhibiting PTEN and activing PI3K/Akt pathway. Apart from 
activing cell proliferation signal pathway, miR-214 protects cells from 
apoptosis by also supressing some pro-apoptosis protein expression. Ca2+ 
accumulation in the cardiomyocytes after I/R is another key underlying 
cause of cell death. Sodium/calcium exchanger1 (NCX1) is a Ca2+ transporter. 
Mice with miR-214 inhibition treatment had a higher percentage of cell 
apoptosis after I/R injury and an increased level of NCX1 protein. Further 
evidence confirmed that NCX1 is a target gene of miR-214 in cardiac cells 
(Aurora, et al. 2012). Coronary artery disease (CAD) is another common 
ischemic heart disease, resulting mainly from atherosclerosis. One clinical 
study reported a decreased level of circulating miR-214 in CAD patients, and 
showed that such a decline was associated with the severity of coronary 
artery stenosis (Lu, et al. 2013). Above studies highlight a protective role for 
miR-214 in ischemic cardiac disease, thus correcting the dysregulated miR-
214 in these pathological conditions might provide a novel therapeutic 
strategy to treat ischemic cardiac diseases including AMI and CAD. 
 
 Cardiac hypertrophy precedes HF. Administration of isoproterenol (ISO) 
and phenylephrine (PE) receptor activators into mice are the two well-
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reported animal models of cardiac hypertrophy. It has been shown that 
miR-214 expression was significantly increased in ISO-induced cardiac 
hypertrophy (Hou, et al. 2012). Similar data was reported in another study. 
Interestingly, the authors also reported that miR-214 could down-regulate 
X-box binding protein1 (XBP1) expression, a regulator of unfolded protein 
response involved in variety of signalling which control cell proliferation and 
angiogenesis in ischemic tissues and sustain the normal heart function. In 
vivo data revealed a negative relationship between miR-214 and XBP1 
expression levels, with an increased miR-214 expression and decreased 
XBP1 level was observed in hypertrophic cardiac tissues (Duan, et al. 2015). 
Contrasting to above finding, another study showed that miR-214 
expression was decreased in the hypertrophic cardiac tissues in both Ang-II 
infusion- or transverse aortic constriction (TAC)-induced cardiac 
hypertrophy animal models, and increasing miR-214 level in these mice 
could protect the mice against cardiac hypertrophy (Tang, et al. 2016).  
Above studies support the argument that miR-214 displays a model-
dependent effect in cardiac hypertrophy, which should be more cautious 
when considering its clinical therapeutic effect in the future.  
 
Less attention has been focused on the potential role of miR-214 in 
atherosclerosis and neointima formation. EC dysfunction is regarded as the 
starting point during atherosclerosis development and progression. One 
recent study has reported an increased expression of miR-214 in ECs 
isolated from mice with atherosclerosis, and found that miR-214 over-
expression could inhibit ox-LDL-induced autophagy in young HuVECs (Wang, 
et al. 2018). Moreover, angiogenesis occurs at late stage of atherosclerosis, 
and is one of the main underlying causes of plaque rupture. In this regard, 
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an inhibitory effect of miR-214 on tube formation, EC migration and 
angiogenesis has also been reported (Chan, et al. 2009). Importantly, 
previous study showed that miR-214 could inhibit VSMC proliferation and 
migration, as well as prevent neointima formation in response to injury 
(Afzal, et al. 2016). Taken together, these studies imply a cellular-context- 
and disease-dependent involvement of miR-214 in CVD, and the functional 
importance in arterial remodelling still requires a further investigation.   
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2. Hypothesis and Aims of the PhD Project 
2.1 Hypothesis 
MiR-214 has been implicated in skeletal muscle differentiation (Liu, et al. 
2010; Juan, et al. 2009), angiogenesis(van Mil, et al. 2012a; van Balkom, et 
al. 2013), heart protection from ischemic injury(Aurora, et al. 2012), bone 
formation (Wang, et al. 2013), and arterial remodelling(Afzal, et al. 2016). 
Some previous studies have provided clear evidence that miR-214 plays a 
role in cardiovascular development and disease. Recently, another 
reported also showed that miR-214 modulates SMC proliferation and 
migration by regulating NCAKP1 expression (Afzal, et al. 2016). However, 
little is known about its role in regulating iSMC differentiation from AdSPCs 
and its significance in injury-induced arterial remodelling. 
 
Previous miRNA microarray analysis from Aurora’ research shows that miR-
214 is one of the most up-regulated miRNAs during SMC differentiation 
from ESCs. Moreover, miR-214 has been reported to be highly expressed at 
early murine embryonic stages (E10.5~E12.5) in the heart(Aurora, et al. 
2012), in the vasculature rich adult organs/tissues(Aurora, et al. 2012; van 
Mil, et al. 2012), ECs, and VSMCs (van Mil, et al. 2012). Therefore, I 
hypothesized that miR-214 might play a critical role in iSMC differentiation 




1) To investigate the functional involvement of miR-214 in SMC as well as 
iSMC differentiation from AdSPCs. 
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2) To identify and validate the potential target gene of miR-214 during SMC 
differentiation. 
 3) To delineate the underlying molecular mechanisms of miR-214-
mediated iSMCs differentiation from AdSPCs. 
4) To study whether AdSPC differentiation towards iSMCs is regulated in 
injury-induced arterial remodelling, and the therapeutic potential of in situ 





3. Materials and Methods 
 
3.1 Materials  
Key reagents used in the experimental work of this thesis are listed in Table 
2. 
Table 2. Reagents, kits and materials used in this project 
Reagents Supplier  Catalogue number 
Acrylamide (30%) National Diagnostics EC-890 
Ammonium Persulfate(APS) Thermo Scientific 17874 
Ampicillin Sigma Aldrich 7177-48-2 
Anti-CD31 antibody  Abcam ab28364 
Anti-CD45 antibody  Biolegend 103102 
Anti-DDR2 antibody  Abcam ab221812 
Anti-Nestin antibody  Abcam ab9498 
Anti-GLI1 antibody Abcam ab49314 
Anti-SMαA antibody Abcam ab32575 
Anti-SM-MHC antibody  Abcam ab53219 
Anti-SM22α antibody Abcam ab14106 
Anti-SOX1 antibody  Abcam ab87775 
Anti-SOX10 antibody  Abcam ab216020 
Anti-SOX17 antibody  Abcam ab155402 
Anti- α-tubulin antibody Sigma Aldrich T6074 
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ATP Sigma Aldrich A7699 
bFGF R&D Systems 233-FB-010 
Bromophenol Blue Sigma Aldrich GE17-1329-01 
B-27™ Supplement (50X) Invitrogen 17504044 
Bovine Serum Albumin (BSA) Sigma Aldrich 05479 
Cel-miR-67 agomir  Creative-biogene  
Cell Strainer Sigma-Aldrich CLS431751-50EA 
CellStart Invitrogen  A1014201 
Chick embryo extract  MP Biomedical SKU 092850145 
Chloroform Sigma Aldrich C2432 
Cignal GLI Reporter (luc) Kit Qiagen CCS-6030L 
Collagenase, Type II Gibco 17101015 
Coelenterazine Promega  S2001 
d-luciferin  Goldbio LUCK-100 
Dimethyl sulfoxide (DMSO) Sigma Aldrich D4540 
Dithiothreitol (DTT) Sigma Aldrich D9779 
Donkey Anti-Rabbit IgG H&L 
(Alexa Fluor® 647)  
Abcam ab150075 
dNTP Mix Thermo Fisher R0192 
Dulbecco’s Modified Eagle’s 
Medium (DMEM) 
Sigma Aldrich D6546 
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ECL Plus Western Blotting 
Substrate   
Thermo Scientific 32132 
EcoRI restriction enzyme NEB R3101S 
EquiPhi29™ DNA Polymerase 
(PCR enzyme ) 
Thermo Fisher A39390 
EquiPhi29™ DNA Polymerase 
Reaction Buffer (10X) 
Thermo Fisher B39 
Ethylenediaminetetraacetic 
acid (EDTA) 
Sigma Aldrich E6758 
Formaldehyde Sigma Aldrich 47608 
Fluoromount-G™ Thermo Scientific 00-4958-02 
Gelatin Sigma Aldrich G1890 
GelRed Nucleic Acid Stain  Biotium 41003 
GenElute Mammalian Total 
RNA Miniperp Kit 
Sigma Aldrich RTN350 
GenElute™ Plasmid Miniprep 
Kit 
Sigma Aldrich PFM250 
Glycerol Sigma Aldrich G5516 
Glycine Sigma Aldrich 50046 
Goat Anti-Mouse IgG H&L 
(Alexa Fluor® 488) 
Abcam ab150113 
Goat Anti-Mouse IgG H&L 




Goat Anti-Mouse IgG 
H&L(HRP)  
Abcam ab97040 
Goat Anti-Rabbit IgG H&L 
(HRP) 
Abcam ab205718 
Goat Anti-Rabbit IgG H&L 
(Alexa Fluor® 488)  
Abcam ab150077 
Hanks’ balanced salt solution 
(HBSS) 
Sigma Aldrich H6648 
HEPS  Sigma Aldrich 54457 
IFNγ Mouse ELISA Kit Thermo Scientific KMC4021 
IL-6 Mouse ELISA Kit Thermo Scientific EM2IL6 
Isopropanol Sigma Aldrich W292907 
JM109 competent Promega L2005 
KAPA SYBR FAST qPCR Kit 
Master Mix 
KAPA Biosystems 07959621001 
KOH Sigma Aldrich 720143 
LiCl Sigma Aldrich L4408 
L-Glutamine Gibco 25030081 
MiR-214 mimics Sigma Aldrich HMI0379 
MiR-214 inhibitor Sigma Aldrich HLTUD0379 
MiRNA negative control Sigma Aldrich HMC0002 
MCP-1 Mouse ELISA Kit Thermo Scientific EMMCP1 
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MgSO4.7H2O Sigma Aldrich 63138 
MiRNA mimic,Negative 
control  
Sigma Aldrich HMC0002 
MiRNA Inhibitor, Negative 
Control 
Sigma Aldrich 4464079 
MiR-214 Agomir Creative-biogene  
MiR-214 inhibitor Sigma Aldrich HLTUD0378 
MiR-214 mimic Sigma Aldrich HMI0379-5NMOL 
Mouse IgG control Abcam ab37355 
Murine s100a4 ELISA Kit  Antibody Online ABIN4972603 
NaCl Sigma Aldrich S9888 
NCode VILO miRNA cDNA 
synthesis Kit 
Invitrogen MIRAS-20 
NotI restriction enzyme NEB R3189S 
NP-40 Thermo Scientific 85125 
Paraformaldehyde (PFA) Sigma Aldrich P6148 
pCDH-CMV-MCS-EF1-Puro 
vector 
System Biosciences CD510B-1 
pCMV-Green Renilla Luc 
vector 
Thermo Scientific 16153 
pMCP-1 Plasmid Addgene #40324 




(PVDF) membranes (0.45mm) 
GE Healthcare 10600038 
Phosphate buffered saline 
(PBS) 10× 
Sigma Aldrich P5493 
Pierce™ BCA Protein Assay Kit Thermo Scientific 23225 





Sigma Aldrich V900929 
proteinase K (20 mg/mL) Thermo Scientific 25530049 
Protein G Magnetic Beads Thermo Scientific 88848 
Protease Inhibitors Sigma Aldrich S8820 
PureLink™ Quick Gel 
Extraction Kit 
Invitrogen K210012 
Puromycin Sigma Aldrich P9620 
QuikChange Lightning site- 
Directed mutagenesis Kit 
Agilent 210515 
Rabbit IgG control Abcam ab172730 
Recombinant Mouse TGF-
beta 1 Protein (TGFβ1) 
R&D Systems 7666-MB-005 
Recombinant Mouse TNF-
alpha Protein (TNFα) 
R&D Systems 410-MT-010 
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Reporter Lysis 5X Buffer Promega E3971 
Retinoic acid Sigma Aldrich R2625 
RevertAid Reverse 
Transcriptase Kit 
Thermo Scientific K1691 
RIPA Lysis and Extraction 
Buffer 
Thermo Scientific 89900 
RNaseA Thermo Scientific 12091021 
ShRNA Sufu plasmids Sigma Aldrich SHCLNG- 
NM_015752 
ShRNA Non-Targeting control 
vector 
Sigma Aldrich SHC002 
Sodium dodecyl sulphate 
(SDS) 
Sigma Aldrich L3771 
Sodium Deoxycholate Sigma Aldrich 30970 
Sufu cDNA ORF clone GeneScript NM_001025391 
TAE buffer 50× Sigma Aldrich 1061741000 
tetramethylethylenediamine 
(TEMED) 
Thermo Scientific 17919 
Tips of cross-IT 200x guide 
wire 
Abbott Laboratories 0030281 
TRI-reagent Sigma Aldrich 93289 
Tris Base  Sigma Aldrich T1503 
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Tris-HCl  Sigma Aldrich T3253 
Triton X-100 Sigma Aldrich T8787 
TurboFect Transfection  Thermo Fisher R0533 
T4 DNA Ligase Invitrogen 15224090 
Tweet-20 Sigma Aldrich P7949 
2-mercaptoethanol (β-ME) Sigma Aldrich M3148 
4’,6-diamidino-2-phenylindole 
(DAPI) 
Sigma Aldrich D9542 
 
3.2 AdSPC isolation 
The procedures for mouse aortic AdSPC isolation and culture were followed 
the protocols described in Tang’s study (Tang, et al. 2012), details are 
described below.  
 
The following media were prepared before beginning experiments: 
·GP medium: 50% P/S mixed with 50% L-Glutamine. 
·Tissue collection medium: 89% DMEM mixed with 10% FBS and 1% GP 
medium. 
·Perfusion medium: HBSS mixed with 1% GP medium. 
·Gelatin medium: PBS with 0.1% Gelatin. 
·P/S medium: PBS with 1% P/S. 
·Digestion medium: 1mg/ml and 3mg/ml Collagenase II in DMEM. 
·Elastase medium: 0.744 U/ml Elastase in DMEM. 
·Operation medium: 89% DMEM mixed with 10% FBS and 1% GP medium. 




Before experiments the surgical instruments and culture dishes were 
irradiated with UV light for at least 30min and 12-well plates were coated 
with CellStart for at least 30min. 
 
Asphyxiated mouse with CO2 for at least 2min, sprayed the mouse with 75% 
ethanol thoroughly. Opened the chest carefully without cutting any vessels 
with sterilized forceps and scissors. Perfused the mouse through a cardiac 
puncture at the apex with Perfusion medium. Removed the organs if 
necessary to make sure there is clear enough view of the whole aorta 
before cut it down. Removed the connective tissue around the aorta 
carefully. Cut down the aorta after it is free of fibrous material and fat tissue 
(Approximately 1.5cm long). Placed the aorta into the collection medium 
and keep them on ice before use. 
 
Rinsed the aorta in operation medium quickly and placed it in the 10cm 
culture dishes covering with tissue collection medium. Scraped off as much 
surrounding fat tissue of the artery as possible under microscope. Aortas 
were washed three times with PBS supplemented with 1% P/S. Digested the 
artery with 1 mg/ml Collagenase II in a new dish at 37°C for 15min. Carefully 
put the aorta into the new dish containing collection medium. Adventitia 
were carefully dissected away under a dissecting microscope. Unfolded and 
cut the adventitia layer into cubes as small as possible with scissors. Tissue 
blocks from 10 mice were pooled together.  
 
Transported the cubes and the medium into a 15ml centrifuge tube, spined 
down the cubes at 800rpm for 3min. Incubated the tissue blocks with 3 
mg/ml type II collagenase in DMEM with a 1/5 (w/v) ratio of tissue (g) to 
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enzyme solution (ml). After incubated for 30 min, the same volume of 1 
mg/ml elastase solution was added to the solution contain the tissue and 
collagenase. The tissues were incubated for another 1–2hr until all the 
tissues were digested. Flited the cells with a Cell Strainer (70µm). Spined 
down the cell digestion solution at 800rpm for 3min and suspend cells in 
culture medium. Seeded the cells in pre-coated 12 well plates and culture 
at 37°C in 5% CO2 incubator. (2-3 aortas in one well of 12-well plate) 
 
3.3 AdSPC culture and maintenance 
The following media were prepared before beginning experiments: 
·AdSPC culture medium: DMEM supplemented with 2% chick embryo 
extract, 1% FBS, 1% N2 supplement, 2% B27 supplement, 100nM retinoic 
acid, 50nM β-ME, 1% P/S and 20ng/ml bFGF. 
·Gelatin medium: 0.04% Gelatin in PBS. 
·DMEM medium: DMEM mixed with 10% FBS. 
·Freezing medium: FBS 20% mixed with 70% DMEM and 10% DMSO. 
· SMC differentiation induction medium: DMEM supplemented with 5% FBS 
and 5ng/ml TGFβ1. 
·iSMC differentiation induction medium: DMEM supplemented with 5% FBS, 
5ng/ml TGFβ1 and 50ng/ml TNFα.  
 
AdSPC passaging 
AdSPCs were cultured/maintained in T25/T75 flasks with 5/15ml AdSPC 
culture medium at 37°C under constant supply of 5% CO2. Cells were 
observed every day to check cellular growth and morphology. Cell 
passaging was required once cell reach confluence level of 80-90%. Used 
Gelatin medium to coat the flasks for 30min before experiment. Washed 
the cells with PBS 2-3 times, then added 0.5/1ml Trypsin-EDTA to the 
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T25/T75 flask accordingly, shaked the flasks gently and put flask into the 
incubator for 30sec to 1min. Closely inspected the cell digestion under the 
microscope, Added DMEM medium to stop the digestion once cells start 
detaching from the flasks. Collected the cells with 15ml centrifuge tube and 
spined down the cells at 800rpm for 3min.Suspended the cells in AdSPC 
culture medium and re-plateed cells into pre-coated flasks at a ratio of 1:3. 
 
AdSPCs freezing  
AdSPCs were preserved in freezing medium in -80°C freezers (for short term) 
or in liquid nitrogen (for long term preservation). When the cultured cells 
reach a confluence level of 80-90%, detached cells as described in AdSPC 
passage. Collected the cells with 15ml centrifuge tube and spined down the 
cells at 800rpm for 3min. Discarded the supernatant and re-suspended the 
cells by adding suitable quantity of freezing medium (usually 1 ml for each 
cryovials). Transferred the cells to freezing container and placed in -80°C 
freezers overnight. For longer preservation, the cryovials were transferred 
from -80°C freezers to liquid nitrogen. 
 
AdSPC thawing and recovery 
Took the cryovials containing cells from liquid nitrogen and placed the 
cryovial into the 37°C water bath. After thawing, transferred the cell 
suspension into 15ml centrifuge tube and added 5ml pre-warmed DMEM 
medium into the cell suspension. Centrifuged the cells at 800 ×g for 3min, 
discarded the supernatant and re-suspended the cells with AdSPCs culture 
medium. Transferred the cell suspension into T25/75 flasks pre-coated with 
Gelatine medium and cultured in 37°C incubator with 5% CO2.   
 
SMC or iSMC differentiation from AdSPCs 
99 
 
Undifferentiated AdSPCs (p3~p8) were used for differentiation. For SMC 
differentiation, incubated the cells with SMC differentiation induction 
medium for up to 8 days in different experiments. For iSMC differentiation, 
treated the cells with iSMC differentiation induction medium for 2 to 4 days. 
Differentiation medium was refreshed every other day. 
 
3.4 Genetic material transfection 
Washed the cells one or two times with PBS before treated with trypsin-
EDTA and subsequently neutralized by adding DMEM medium. Collected 
the cells and centrifuge at 800 ×g for 3min, discarded the supernatant and 
re-suspended the cells with 5ml AdSPCs culture medium. Used the 
haemocytometer to count the cells, seeded 1.5x105 cell per well of 6 well 
plate pre-coated with Gelatin medium. Cultured the cells overnight before 
transfection. Clean Eppendorf tubes were labelled for each treatment, 
added 2µg/μl TurboFect Transfection Reagent and 500μl serum free DMEM 
into the Eppendorf tubes. Added 5μl of miR-214 mimics/inhibitor or their 
respective control scramble miRNA mimics/inhibitor into the corresponding 
tube (for plasmid transfection, add 1μg plasmid) for each well of 6-wells 
plate. Mixed the mixture and left at room temperature for 20-30min to 
form the transfection complexes. Refreshed the cells with culture medium 
or treatment medium before transfection. Added the mixture drop by drop 
with circular motion to dispose the transfection mixture as evenly as 
possible. Rocked back-and-forth and side-to-side the 6-well plate 
immediately to evenly distribute the mixture. Incubated the cell for 24-48 




3.5 DNA amplification, purification, and transformation  
DNA product without restriction enzymes site or not enough amount need 
to be amplified by Polymerase Chain Reaction (PCR) before use. Prepared 
the PCR reaction mixture in PCR tubes as shown in Table 3. 
Table 3. PCR reaction mixture components 
components volume 
10× DreamTaq Buffer 5µl 
dNTP mixture 5µl (2mM) 
Forward and reverse 
primers 
0.1-1.0µM 
DNA Polymerase 1.25U 
DNA template X µl (10pg-1µg) 
nuclease free water Up to 50µl 
Total volume 50µl 
 
Placed the PCR reaction mixture PCR tubes into a thermal cycler, ran the 













Table 4. PCR reaction cycler program 
step Temperature(°C) time Number of cycles 
Initial 
Denaturation 
95 5min 1 
Denaturation 95 1min 35 
Annealing 55 (adjust 
according to the 
primer Tm) 
1min 
Extension 72 1min/kb 
Final Extension 72 5-10min 1 
 
Agarose gel was used here to detect the PCR product. 1% agarose gel was 
used in this study. 50ml 1xTAE mixed with 0.5g agarose, then boiled the 
mixture until the solution became clear, cooled the gel mixture to about 
50°C. Added the GelRed Nucleic Acid Stain before poured the gel to the gel 
tank with a comb. Left it for about 30min to solidify the agarose gel. 
Transferred the gel to a gel-running reservoir, full filled the running 
reservoir with the 1x TAE buffer. Loaded about 20 to 30µl of PCR product 
each well along with the 10µl DNA ladder. Ran the gel by apply the electrical 
current of 120V for about 40min.Took the florescent image by using the 
Aphalamager HP system (Alpha Innotech, 3089N IMAGER) at dual 
wavelength ultra violet illumination (365nm or 302 nm) to check the PCR 
result. 
 
The fragment after treatment with restriction enzymes need to be purified 
before use. Ran the DNA agarose gel to separate the different size DNA 
fragments, recycled target DNA fragments. Mixed the digested DNA 
fragments or recycled DNA fragment gel with 300ul Gel Solubilisation Buffer, 
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then pipetted the solution into a column set after the gel dissolved. 
Centrifuged the column at 12,000 ×g for 1min, discarded the flow through 
and placed the column into the wash tube. Added 500µl wash buffer to the 
column, centrifuged the column at 12,000×g for 1min, then discarded the 
flow through. Placed the column back to the wash tube, centrifuged the 
tube at 12,000 ×g for 1 to 2min. Placed the column onto a clean tube and 
added about 50µl elution buffer to the centre of the column. Centrifuged 
the tube at 12,000×g for 1 min and collect the purified DNA fragment. 
 
DNA transformation was conducted following procedures. Added 1μl of 
plasmid DNA (or 10μl ligated DNA) into 30-50μl of JM109 competent cells 
in pre-cold tubes on ice. Gently mixed and incubated the mixture on ice for 
30min.Then, heated the mixture at 42°C for 1min and put it back onto ice 
for 3-5min, left it at room temperate for 5min. Added 500µl of LB medium 
to the mixture and incubated at 37°C for 1hr on a floor shaker at 225rpm. 
After incubation, centrifuged the tube at 3,000×g for 5min and discarded 
the supernatant, 200µl LB broth was used to re-suspended the bacteria and 
spread the mixture onto the surface of the LB plate with ampicillin.  
Incubated the plate at 37°C overnight, transferred small number of bacteria 
from the colonies into a 15ml tube containing 5ml LB solution. Collected the 
bacteria by centrifuged the tube on following day, re-suspended the 
bacterial pellet with 200µl Resuspension Solution. Lysed the re-suspended 
cells with 200µl lysis buffer. Mixed the contents by gentle inversion until 
the mixture becomes clear. Added about 350ul Neutralization/ Binding 
Buffer into the tube inverted the tube for several times. Centrifuged the 
tube at 12,000×g for 10min. Inserted a binding column into a provided 
micro centrifuge tube. Added about 500µl column Preparation solution to 
the column and centrifuge at 12,000×g for 30sec, and discarded the flow-
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through liquid. Added the cleared lysate to the column and centrifuged at 
12,000×g for 1 min. Discarded the flow –through liquid. Added about 750µl 
wash buffer to the column, centrifuged the tube at 12,000×g for 1min and 
discarded the flow –through liquid. Centrifuged the column tube again for 
1 to 2min. Placed the column onto a clean collection tube. Added 50 to 
100µl elution buffer to the centre of the column. Centrifuged the column 
for about 1min and checked the concentration of the plasmid by NanoDrop 
spectrophoto meter (Thermo Scientific, D-2000). 
 
3.6 Stable overexpression or knockdown genes in AdSPCs  
Designed a pair of the pri-miR-214 primers with EcoRI/NotI restrict enzyme 
cleavage sites on genscript websit by following the website instroduction, 
enter the gene sequence on the website and then check the outcome 
primer sequence. https://www.genscript.com/tools/pcr-primers-designer. 
Approximate 688bps of genomic fragment containing mmu-miR-214 
precursor (110bps) and its flanking sequence (293bps and 285bps, 
respectively) was amplified by PCR with specific primer set as shown in table 
13. The steps were present in section 3.5. Treated the insert DNA product 
(pri-miR-214 or Sufu) and pCDH-CMV-MCS-EF1-Puro vector with EcoRI and 
NotI restriction enzymes for about 1hr at 37°C. After digestion, purified the 
product respectively by using the DNA gel extraction kit. Details were 
described in section 3.5. Mixed the vector and insert DNA with a molecular 
ratio of 1:4 to make a 20µl reaction mixture as indicated in the Table 5 and 






Table 5. DNA ligation mixture component 
 
Transformed the ligation product into JM109 competent cells, and evenly 
smeared the transformed bacterial onto LB plate containing ampicillin. 
Incubated the plate at 37°C overnight. At the following day, picked single 
bacterial colonies from the plate and further amplified the plasmid. The 
insert DNA sequences were identified by PCR and double enzymatic 
digestion (EcoRI/NotI), and the resultant plasmids will be verified through 
plasmid DNA sequencing by GCTA Gene Company. 
 
3.7 lentivirus production and infection 
All vectors were verified by DNA sequencing. Control (pCDH or Lenti-GFP), 
Sufu (pCDH-Sufu) or miR-214 (Lenti-miR-214) pseudoviral particles were 
generated using pCDH, pCDH-GFP, pCDH-Sufu, or pCDH-miR-214 and 
packaging plasmids, respectively. Prepared enough 293T cells before 
experiments. Prior to transfection, the 293T cells were cultured in T75 flask 
for about 18hr to 24hr.Mixed the target plasmid with the packaging 
plasmids (pCMV-dR8.2 and pCMV-VSV-G) at the ratio 4:3:1. Added 2µg/μl 
TurboFect Transfection Reagent and 500μl serum free DMEM into the 
Eppendorf tube, mixed gently and then add mixed plasmids into the tube. 
Mixed the solution gently and incubate at the room temperature for about 
Component Blunt Ends 
5×Ligase Reaction Buffer 4µl 
Insert Ends X µl (45-480fmol) 
Vector Ends X µl (15-60fmol) 
T4 DNA Ligase 1 µl (1unit) 
Autoclaved distilled water To 20µl 
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20min.Transfected the cells overnight and refresh the medium next day. 
The 293T culture medium containing the lentivirus was harvested after 48h, 
then filtered and aliquot in 15ml falcon tubes. Keep the lentivirus in the 4 °C 
before use or stored at –80°C for future use. 
 
AdSPCs were plated a day before infection in 6-wells. One transducing unit 
per well of miR-214 overexpression lentivirus or control virus were added 
into each well of the 6-well plate, then kept the infected cells in the 
incubator for one day. Refreshed the cells with t AdSPCs culture medium 
and incubated the cells for another 24hrs before treated with AdSPCs 
culture medium with puromycin (5µg/ml). Survival cells were checked the 
gene expression and subjected to other experiments. 
 
3.8 RNA Extraction and Analysis   
Total RNA Extraction  
Cleaned the working bench with 75% ethanol before collect the cells. 
Prepared enough cells before harvest. Lift the cells using trypsin or cells 
scrappers and transferred the cells into a 15ml centrifuge tube. Centrifuged 
the cells at 800×g for 3min and discarded the supernatant. Washed the cells 
once with PBS and transferred the cells into a new Eppendorf tube. 
Centrifuged the tube at 800×g for 3min and discarded the supernatant to 
obtain cell pellet. Prepared the fresh lysis solution by adding β-ME at a ratio 
of 1:100 to lysis buffer followed the manufacturer instruction. Then added 
250µl to 500µl lysis buffer to the cell pellet. Vortexed the tube until the cells 
were completely dissolved, transferred the mixture to the GenElute 
Filtration Column placed in a 2ml collection tube.Centrifugeed at 13,200 
rpm for 2min at room temperature, discarded the filtration column after 
centrifuge. Added equal volume of 70% ethanol into the flow-through liquid. 
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Mixed and transfer the mixture to a clear GenElute binding column placed 
in 2ml collection tube and centrifuged at 13,200rpm for 30sec. Discarded 
the flow –through liquid. Added 500μl wash buffer 1 to the binding column 
and spin the tube at 13,200rpm for 30seconds. Discarded the flow –through 
liquid. Added 500μl wash buffer 2 to the binding column and spin the tube 
at 13,200rpm for 30sec. Discarded the flow –through liquid and centrifuged 
the binding column again for about 2min. Placed the binding column into a 
clean collection tube and added about 50µl elution buffer to the binding 
column. Centrifuged the tube at 13,200rpm for 30sec to 1min to elute the 
RNA samples. Checked the RNA concentration by NanoDrop spectrophoto 
meter (Thermo Scientific, D-2000). 
 
MiRNA Extraction  
The total RNA including the miRNAs were purified from the cells by using 
the TRI-reagent and DNase I digestion. Collected the cells into a 15ml 
centrifuge tube and prepared cell pellet as described above. Added about 
500µl TRI-reagent into the tube and pipet several times to make sure the 
cells were lysed completely. Left the homogenised samples at room 
temperature for 5min. Added 100µl chloroform into the tube and vortexed 
the tube for 30sec. Left the mixture at room temperature for 5min and then 
centrifuged the samples at 12,000×g for 10min at 4 °C. Carefully collected 
upper colourless supernatant into a new RNase free tube. Added 500µl 
isopropanol to each sample and mix it gently. Incubated the mixture at 
room temperature for 5min, centrifuged the samples at 12,000×g for 10 
min at 4 °C. Carefully discarded the supernatant and washed the pellet with 
500µl cold 75% ethanol. Centrifuged the samples at 8,000 ×g for 5min at 
4°C. Repeated this step once. Carefully discarded the supernatant and air-
dried the RNA pellet for about 10min. Dissolved the RNA samples with 
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RNase free water and mixed the sample gently. Check the RNA 
concentration using NanoDrop spectrophoto meter (Thermo Scientific, D-
2000). 
 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
For each RT-PCR reaction, 2µg purified RNA was used to prepared the 
reaction mixture as list in the Table 6. 
Table 6. The RT-PCR sample reaction mixture 
components Volume 
Total RNA Xµl (2µg) 
Random primer 2µl 
RNase free water Up to 13µl 
Total 13µl 
 
Centrifuged the reaction mixture briefly, placed the reaction tube into the 
thermal cycler, incubate at 65 °C for 5min, and then cool the sample down 
to 4°C in order to open the GC rich secondary structure and increase the 
primer binding effect.  Prepared the master mixture for each RT-PCR 
reaction as shown in Table 7 while the incubation step is running. 
Table 7. The RT-PCR master reaction mixture 
components Volume 
5× Reaction Buffer 4µl 
dNTPs 2µl 
Thermo Scientific RiboLock RNase Inhibitor 0.5µl 
RevertAid Reverse Transcriptase 0.5µl 




Added the master mixture into the sample reaction mixture tube, and 
briefly centrifuge the tube before placed into the thermal cycler. Ran the 
RT programme which is 25°C, 10min for annealing, 42°C, 60min for 
extension, 70°C, 10min for destroying the remaining enzyme, and finally 
cool down the samples to 4°C. 
 
RT-PCR for miRNAs 
NCode VILO miRNA cDNA synthesis Kit was used to generate miRNA cDNA. 
The main difference between these two RT procedures is a synthesize 
poly(A) tail and linker sequence will be added onto all the miRNAs, and a 
common and unique reverse primer is used to generate the cDNAs for all 
the miRNAs from the tailed miRNA population in a single reaction.  
 
Mixed 1µg of template RNA with 4µl of 5×Reaction Mixture and 2µl of 
10×SuperScript Enzyme Mixture, then topped up the volume of mixture to 
20µl by adding DEPC-treated water. Briefly spine down the mixture, then 
incubated the PCR mixture in a PCR thermal cycler by running following 
programme: 37°C for 60min for RT-PCR reaction, 95°C for 5min to terminate 
the reaction, then cool down the sample at 4°C.  
 
3.9 Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) 
If the cDNA samples were kept in the freezer, thawed the sample and kept 
on ice before use. SYBR Green was used as a probe here to detect the cDNA 
quantity. SYBR green binded to newly synthesized double-stranded DNA, 
emitting fluorescence in direct proportion to the number of amplicons 
generated. A threshold line was drawn at the RFU (relative fluorescent unit) 
where there is a significant increase of fluorescence above background 
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fluorescence. The cycle number at which the samples reached this level was 
referred to as the cycle threshold value (CT), thus reflecting the relative 
abundance of the specific mRNA transcripts. Relative gene expression or 
mRNA/miRNA expression level was determined by the relative ratio of 
target gene expression level or miRNA expression level to 18S/GAPDH 
(taken as house-keeping gene for normal mRNAs) or U6 RNA (taken as 
house-keeping gene for miRNAs), respectively. The specific steps for RT-
qPCR were described below. 
Prepared the RT-qPCR master mixture for normal mRNAs following the 
Table 8. 
Table 8. Components and quantity of qPCR reaction for mRNAs 
Components Volume for 1 reaction 
KAPA SYBR FAST qPCR Master Mix 5µl 
Forward primer 1µl (final con 0.2mM ) 
Reverse Primer 1µl (final con 0.2mM ) 
RNase free water 1µl 
Total volume 8µl 
 
Followed Table 9 to prepare miRNA RT-qPCR master mixture. 
Table 9. Components and quantity of RT-qPCR reaction for miRNAs  
Components Volume for 1 reaction 
SYBR GreenER RT-qPCR Master Mix 5µl 
miRNA specific Forward Primer 1µl (final con 0.2mM ) 
Universal Reverse Primer 1µl (final con 0.2mM ) 
RNase free water 1µl 




After mixed, carefully disposed 8μl of the mixture into each well of 384 
wells plate or 96well plate (MicroAmp Optical). Added 2μl of cDNA sample 
(5ng/μl) in to each reaction well and sealed the plate with MicroAmp PCR 
film. Briefly centrifuged the plate and placed the plate to TaqMan Real-Time 
PCR System (Bio-Rad, CFX96 Dx) to run the qPCR reaction. The qPCR 
programme was shown in the Table 10. The results were expressed as 
relative units based on 2-ΔΔCT calculation (Pfaffl and Hageleit 2001) , which 
gives the relative amount of gene normalized to endogenous housekeeping 
gene. 
 
Table 10. The RT-qPCR programmes 




95 10min 1 
Denaturation 95 10sec 40 
Annealing 60  30sec 
Melt curve 60-95 1 min 1 
cooling 4   
 
3.10 Gene cloning and Mutation 
Sufu 3’UTR reporter with miR-214 binding site mutation and SMC gene 
promoters with GLI mutants 
The mutation primers were designed on the website of the company the 
mutation kit was used, Agilent Company, entered the gene sequence and 
the mutation site on the website and then selected the outcome primer 
sequence. All the mutation primers’ sequences were listed in the table 13. 
(https://www.agilent.com/store/primerDesignProgram.jsp) Prepared the 
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mutation reaction as outlined in the Table 11. After briefly centrifuged, 
placed the tube onto the thermal cycling machine.   
 
Table 11. The mutant strand synthesis reaction mixture 
Reaction component Volume 
10× QuikChange Lightning 
Multi reaction buffer 
2.5µl 
QuikSolution 0-0.75µl(titrate for each templat) 
ds-DNA template X µl (100ng) 
mutagenic primers X µl (100ng each primer for 1-3 primer; 
50ng each primer for 4-5 primer) 
dNTP mix 1µl 
QuikChange Lightning Multi 
enzyme blend 
1µl 
double-distilled H20 X µl up to 25µl 
 
Ran the PCR programme as indicated in the Table 12. At the end of 
programme, placed the tube on ice. Added 1µl of Dpn1 restriction enzyme 
directly to the reaction tube. Gently mixed the reaction mixture by pipetting 









Table 12. The mutation PCR programme 
step Temperature(°C) time Number of 
cycles 
1 95 2 min 1 
2 95 20 sec 30 
  55  30 sec 
 65 30sec/kb of plasmid 
length 
3 65 5min 1 
 
Thawed the XL10-Gold ultracompetent cells on ice and added 2µl of the β-
ME into the cells to increaseed the transformation efficiency. Transferred 
1.5µl PCR product into the ultracompetent cells, mixed the transformation 
reaction gently, incubated the reaction on ice for 30min. Heat-pulse the 
tubes at 42°C for 30sec and then put the tube back on ice for 2min. After 
that added 0.5ml LB broth to the tube and incubate it at 37°C for 1 hr on a 
shaker. Spread the product on the agar plates containing the antibiotic 
(ampicillin).  Incubated at 37°C overnight, then transferred small number of 
bacteria from each bacterial colony into 5ml new LB broth, and incubated 
it on a shaker (225-250 rpm) at 37°C for 18hrs. Extract plasmids from the 









Table 13. Primer sets used in the present study 





































AAACGGCTACCACATCCAAG CCTCCAATGGATCCTCGTTA Real-time 
RT-PCR 
 


















































TCCTCTCTCTTGGTCTGGTCT GTCACCCTCTTTGCCTGAGT Real-time 
RT-PCR 
 






























Mus Wisp1 CACAGATGGCTGTGAATGCTG ACCTGTGCACACACTCCTAT Real-time 
RT-PCR 
 






































































































3.11 Luciferase Assay 
For Shh-GLI1 signalling reporter assay, AdSPCs were transfected with GLI 
and (0.15μg/2.5 x 104 cells) pRenilla (15ng/2.5 x 104 cells) mixed reporter 
plasmids were used. For determining the respective SMC gene promoter 
activity, the individual SMC gene promoter vectors (pGL3-SMαA-WT, pGL3-
SM22α-WT, pGL3-SMαA-SRFmut, pGL3-SM22α-SRFmut, pGL3-SMαA-
GLI1mut-1, -2, or -1/2, pGL3-SRF-WT, or pGL3-SRF-GLI1mut) (0.15μg/2.5 x 104 cells) 
and pRenilla (15ng/2.5 x 104 cells) mixed reporter plasmids were used. Wild 
type plasmids were gifts form Xu’s group (Margariti et al. 2009). For mouse 
IL-6 and MCP-1 gene promoter activity, pmIL-6 or pMCP- (0.25μg/2.5 x 104 
cells) and pRenilla (15 ng/2.5 x 104 cells) mixed reporter plasmids were used. 
Dual-Luciferase Reporter Assay System was used for detecting luciferase 
and Renilla (15ng/well) activities, the details were described below.   
 
The cells used for transfection were refreshed with the culture medium 
before adding the plasmid. For luciferase assay, the pRenilla vector was 
transfected together with the report vector or promoter vector into the 
cells. After 48hrs, washed the cells with PBS for one or two times, then 
added 100μl 1×reporter lysis buffer to each well and placed on 2D rocker 
for 30min at room temperature. The plate was then incubated in -80°C 
freezer for at least 2hs followed by thawing on a shaker at room 
temperature for 30min. Transferred the lysis product to 1.5ml Eppendorf 
tube and centrifuged at 13,200 rpm for 10min at 4°C. Prepared the 
Substrate buffer solution: 120mM NaCl and 25mM Tris-HCl mixed in the 
water then fix the pH to7.5.Prepare the luciferase reagent and Renilla 




Table 14. The components for Renilla detection   
Renilla substrate component Volume 
Substrate solution 10ml 
Coelenterazine( 2500ng/ul) 10µl 
Total volume ~10ml 
 
Table 15. The components for luciferase detection   
luciferase reagent component Volume 
H2O 8.7 ml 






Mixed 20µl of the sample supernatant with 100µl of the luciferase or Renilla 
substrate and immediately detect the activity by using a GloMax® 20/20 
Luminometer (Promega, E5311 ). 
 
3.12 Protein Extraction and Analysis 
Prepare buffers before the experiment, 5× SDS Loading Buffer: Tris-Cl 
(0.25M, pH 6.8), SDS (10%), Glycerol (50%), Bromophenol Blue (0.25%), DTT 
(0.5 M). 10× Tris-Glycine Buffer(pH 8.4): Tris Base (30.3g), Glycine (144.1g), 
add water up to 1L. 1× Running Buffer: 10× Tris-Glycine Buffer(100ml), 10% 
SDS (10ml), add water up to 1L. 1× Transfer Buffer: 10 × Tris-Glycine 
Buffer(100ml), methanol  (200ml), add water up to 1L. 10× TBS Buffer: Tris-
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HCl(24g), Tris Base (5.6g), NaCl (88g), add water up to 1L. TBST: 10 × TBS 
(100 ml), Tweet-20 (1ml), Distilled water up to 1L. 
Protein Extraction 
Collected cells by using the Trypsin or scrapper and then centrifuged cells 
at 800 rpm for 5min. Discarded the supernatant and mix the cell pellet with 
100-150µl RIPA Lysis and Extraction Buffer. Placed the samples on ice for 
about 30min, and then sonicated the samples at 4°C for 20sec to disrupt 
cell membrane and facilitate release of protein content. Incubated the 
lysate on ice for another hour while vortexed the lysate every 15min. Then 
centrifuged product at 13,200 rpm for 10min at 4°C. Transferred the 
supernatant to a new tube, measured and adjusted the protein 
concentration by using Pierce™ BCA Protein Assay Kit. Prepared BSA 
standard as shown in the Table 16 below. 
Table 16. The BSA standard diluted method  
Vial Volume of 
diluent(µl) 





A 0 300 of stock 2000 
B 125 375 of stock 1500 
C 325 325 of stock 1000 
D 175 175 of vial B dilution 750 
E 325 325 of vial C dilution 500 
F 325 325 of vial E dilution 250 
G 325 325of vial F dilution 125 
H 400 100 of vial G 
dilution 
25 




Prepared the BCA working Reagent by mix the BCA Reagent A with Reagent 
B at ratio of 50:1. Pipetted 25µl of sample or standard into a microplate well 
then added 200ul reagent mixture into each well. Covered the plate and 
incubate at 37 °C for 30min, measured the absorbance at 562nm on a plate 
reader. Prepared a standard curve by plotting the BSA standard data, used 
this standard curve to determine the protein concentration of the sample.  
 
Western blot  
Western blot is a widely used technique in determining the protein 
expression in cells and tissues. Followed the Table 17 and Table 18 to 
prepare 10% separating and 6% stacking gels first before starting the 
western blot.  
Table 17. Reagents for 10% separate gel 
Reagents Volume 
Double distilled water 1.9ml 
Acrylamide  1.7ml 
Tris-HCl Buffer 1.5M (pH 8.8) 1.3ml 
SDS (10%) 50µl 
APS (10%) 50µl 
TEMED 4µl 













Table 18. Reagent for 5% stacking gel 
Reagents Volume 
Double distilled water 2.1ml 
Acrylamide  0.5ml 
Tris-HCL Buffer 1.5M (pH 6.8) 0.4ml 
SDS (10%) 30µl 
APS (10%) 30µl 
TEMED 3µl 
Total volume ~3ml 
 
Left the gel at room temperature for at least 30 min to solidify the gel 
eventually, remove the comb and then transferred the gel into the gel 
running system chamber. Added 1× running buffer to the chamber to the 
extent that it covers the gel and the sample loading wells. Loaded 10µl 
Prestained Protein Ladder into the first wells, then loaded the protein 
samples (the volume depends on the protein amount and the expression of 
the protein in cells or tissues, usually 20µg to 30µg). 80V voltage was first 
applied for about 20 to 30min to stacking the protein, then followed by 
120V voltage for about 70-90min, until the protein marker with the smallest 
size reached the bottom of gel. 
 
Transferred the protein from gel to membrane by using PVDF membrane. 
Activated PVDF membrane in methanol for about 5 to 10sec before using, 
kept the membrane in pre-cold 1× transfer buffer. After completed the gel 
electrophoresis, transferred the gel onto a pre- washed filter papers and 
then covered the gel with labelled PVDF membrane, removed the air bubble. 
Put the sample into the transfer cassette in correct direction. Filled the 
chamber with 1× transfer buffer. Electro-transferred the protein to 
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membrane for 2 to 3hrs at 100V, kept the transfer chamber at cool 
temperature (on ice). After that removed the membrane from the cassette 
and blocked the membrane with 10% milk diluted in 1× TBST buffer on a 2D 
rocker at room temperature for about 1hr. 
 
Cut the membrane according to the marker guide and incubated the 
membrane with specific antibody prepared in 5% skimmed milk or BSA in 
1× TBST buffer at 4°C overnight. Washed the membrane with 1× TBST buffer 
for 3 times before incubate the membrane with corresponding second 
antibody at room temperature for 1 hour. Washed the membrane with 1× 
TBST buffer for 3 times before incubated with ECL Plus Western Blotting 
Substrate for 2-3 min at room temperature. Placed the membrane into the 
ChemiDoc™ Touch Imaging System (Bio RAD, 12003154) to check the 
protein bands. 
 
3.13 Chromatin Immunoprecipitation (ChIP) Assay 
ChIP assays were performed as previously described (Yang, Chen, et al. 
2019). The details were described below. Prepared buffers followed before 
the experiment. ChIP lysis buffer: HEPES-KOH (50mM, pH7.5), NaCl 
(140mM), EDTA (1mM, pH8), Triton X-100 (1%), Sodium Deoxycholate 
(0.1%), SDS (0.1%), Protease Inhibitors. Low salt wash buffer: SDS (0.1%), 
Triton X-100(1%), EDTA (2mM), Tris-HCl (20mM, pH 8.0), NaCl (150mM). 
High salt wash buffer: SDS (0.1%), Triton X-100(1%), EDTA (2mM), Tris-HCl 
(20mM, pH 8.0), NaCl (500mM). LiCl wash buffer: LiCl (0.25M), NP-40(1%), 
Sodium Deoxycholate (1%), EDTA (1mM), Tris-HCl (10mM, pH 8.0). 
 
Prepared enough cells, at least two confluent 150cm2 dishes (1×107-5×107 
cells per dish) before use. Added formaldehyde directly into the dishes to 
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cross link the protein to the DNA, the final concentration of formaldehyde 
in the dishes is 0.75%. Incubated and rotated gently at room temperature 
for about 10min.Added glycine into the dish to stop the formaldehyde 
cross-linking. The final concentration of glycine in the dish is about 125 mM. 
Incubated and rotate gently at room temperature for about 5 min. Washed 
the cells for two times with 10ml cold PBS. Added 3ml PBS and scrape dishes 
thoroughly with a cells scraper, transferred the cells into 15ml tube. Added 
another 3ml PBS to dishes, and repeat the steps. Centrifuged the cells for 
5min at 4°C, 1,000×g. Discarded the supernatant and re-suspend the cells 
in ChIP lysis buffer (750µl per dish) and then incubated the mixture on ice 
for 10 min. Sonicated the lysate for several times to obtain DNA fragments 
with sizes between 200bp and 1000bp. Different cells require different 
sonication times, for AdSPCs, sonicate the cells for about 38 cycles (each 
cycle: sonicate for 10seconds, cool-down on ice for 30 sec to 1min, with the 
sonication power set about 30%). After sonication, centrifuged the tubes at 
4°C, 8,000×g. Transferred the supernatant to a new tube. Removed 50µl of 
each sonicated sample to check the DNA concentration and fragment size. 
Added 70ul elution buffer to 50µl sample, and then added 4.8µl of 5M NaCl 
and 1µl RNaseA. Incubated the mixture at 65°C while shaking overnight. 
Added 2ul proteinase K into the mixture and then incubated at 60°C while 
shaking for 1 hr. Purified the DNA, then check the DNA concentration and 
fragment size. 
 
Use about 25µg of DNA per each reaction. Diluted each sample with 1:10 
RIPA Buffer.  For each group prepare one sample for specific antibody and 
another one for IgG control. Kept 50µl of sample as input. Added primary 
antibody or IgG control into each sample (1-10µg antibody per 25µg sample) 
and rotate at 4°C for 1hr. Prepared the protein G beads and add 60µl to all 
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samples. Rotation at 4°C overnight. Centrifuged the samples at 2,000×g for 
1min and discarded the supernatant. Washed the sample once in low salt 
wash buffer, once in high salt wash buffer and once in LiCl wash buffer. 
Centrifuged the samples at 2,000×g for 1min and discarded the supernatant 
after each wash. Added about 120µl elution buffer to the samples and 
incubate the sample at 30°C for 15min on a shaker. Centrifuged the tube at 
2,000×g for 1min and transferred the supernatant to a fresh tube. Added 
4.8µl of 5M NaCl and 1µl RNaseA. Incubated the mixture at 65°C on a shaker 
overnight. Added 2µl proteinase K into the mixture and then incubated at 
60°C while shaking for 1hr. Purified the DNA, then check the DNA 
concentration. Relative DNA levels were measured by real-time 
quantitative PCR. 
 
3.14 Immunohistochemcial staining 
Immunocytochemistry for cells 
For immunofluorescent staining, seeded and culture 5,000-10,000 AdSPCs 
into each well of chamber slide until the cells reach 60-70% confluence. 
Discarded the culture medium and washed the chamber slide with PBS for 
2 times. Then added 4% PFA to fix the cells at room temperature for about 
10min. Washed the cells with PBS for 3 times, each time incubated at room 
temperature for 10min. Then, added 0.1% Triton x100 in PBS and 
incubateed the cells at room temperature for about 10 min, washed the 
cells for three times with PBS, 10min each time. Blocked the cells with 5% 
BSA in PBS at room temperature for 1hr. Incubated the cells with primary 
antibody or IgG control at dilution of 1 to 200 in 5% BSA with PBS medium 
at 4°C overnight. Next day, washed the chamber with PBS for 3 times, each 
for 10min. Incubated the cells with secondary antibody conjugated with 
fluorescence at dilution of 1 to 1000 in 5% BSA with PBS medium at room 
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temperature for 1hr in the closed staining container to avoid the light.  
Washed the cells with PBST for 3 times, each time for 10 min. 
Counterstained the cells with DAPI for 10min. Then, washed the cells with 
PBS for 3 times, each for 10 min. Removed the frame of chamber, and the 
slide was mounted with fluoromount-G. Took the images using the EVOS 
images system (ThermoFisher scientific, AMC1000). 
 
Immunohistochemcial Staining for Sections 
Frozen slide and Paraffin embedded section of mouse aorta have a little 
different before blocking. For the paraffin sections, the paraffin covered the 
sample need to be removed before staining. Incubated the paraffin section 
at 60°C for about half an hour, then incubated the sections in xylene for 5 
min to dissolve the paraffin, transferred the sections into 100% ethanol for 
about 5min. After that immersed the slides in to another 100% ethanol for 
about 5min, then transferred the slide into 90% ethanol for about 5min. 
Immersed the sections into 70% ethanol and 50% ethanol for 5min in turn, 
transferred the slides into water for hydration. After hydration, immersed 
the samples into sodium citrate buffer, then placed them into the 100°C 
water bath for about 20min. Cooled the samples to room temperature and 
then washed the slide with PBS for 3 times, each for about 5min before the 
next step. For the frozen slide, put the slide in room temperature for about 
20min before next step.  
 
Added 4% PFA to fix the slides at room temperature for about 10min. After 
fixation, the slides were washed with PBS for 3 times, 10min for each time. 
Then incubated the slides with 0.1% Triton x100 in PBS for permeablization. 
10min later, washed the slides for 3 times with PBS, 10min each time. 
Blocked the slides with 5% BSA in PBS for 1 hr at room temperature. 
125 
 
Meanwhile, prepared the primary antibody with 5% BSA in PBS. After 
blocking, added the primary antibody onto the tissue sections in drop wise 
and incubated the slides at 4°C, overnight. Washed the slides with PBS for 
3 times, each for about 5 min. Incubated the slides with appropriate 
secondary antibody for about 1 hr in a closed container to avoid the light. 
Washed the slides with PBS for 3 times, each for about 5min. Then 
counterstained the slides with DAPI for 10min. After last wash, the slides 
were mounted with fluoromount-G. Take the images using the EVOS images 
system. 
 
3.15 Mouse Femoral Artery Denudation Injury and miR-214 
Agomir Perivascular Delivery 
Animal experiments, anaesthesia and euthanasia 
All animal experiments were conducted according to the Animals (Scientific 
Procedures) Act of 1986 (United Kingdom). All the animal procedures were 
approved by Queen Mary University of London ethics review board (PPL 
number: PB508B78D), and conform to the guidelines from Directive 
2010/63/EU of the European Parliament on the protection of animals used 
for scientific purposes or the NIH guidelines (Guide for the care and use of 
laboratory animals). For mouse carotid artery denudation injury and 
AdSPCs transplantation, anaesthesia was induced using 100% O2/4% 
isoflurane, and was maintained throughout the procedure by the 
administration of 100% O2/2% isoflurane. At the end of protocol, all mice 
were euthanized by placing them under deep anaesthesia with 100% O2/5% 
isoflurane, followed by decapitation. 
 
Main Animal Surgical Procedures 
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Eight-week old C57BL/6 male mice purchased from Charles River 
Laboratories. Fully explored the femoral artery with a clear view, made a 
small incision on the artery, and carefully inserted a 0.25 mm angioplasty 
spring-wire into the artery through the incision. Removal of the 
endothelium of the femoral artery was achieved by 3~5 passages of the 
wire. To investigate the potential function of miR-214 function during the 
neointima formation, the injured femoral arteries were randomly received 
miR-214 or Cel-miR-67 (Negative control) agomir treatment locally.  In Brief, 
after injury, applied about 100μl of 30% pluronic gel containing chemically 
modified and cholesterol conjugated 2.5nmol miR-214 or Cel-miR-67 
agomirs perivascularly to the injured femoral arteries.  
 
For AdSPC transplantation, after injury, 100µl Matrigel mixed with 20µl of 
cell culture medium (vehicle control), or 1x106 AdSPCs infected with Lenti-
GFP or Lenti-miR-214 was applied perivascularly onto the injured arteries 
immediately. Then the wound was closed, and the mice were scarified at 
day 3, day 7, day 14 and day 28 to collected the injured arteries for gene 
expression, immunofluorescence staining, and morphometric analysis, 
respectively. For neointima cell isolation. After removed the adventitial 
layer and the outer portion of the media under the microscope, then cut 
the aorta open in longitude direction and carefully remove the endothelium 
with a cotton swab. After that, cut the aorta into cubes as small as possible. 
Digested the cubes in 1mg/ml collagenase I for 3- 3.5hs, then stopped the 
digestion by add the culture medium. Collected the digested cells and spin 
down at 800rpm for 3min, and re-suspended the cells in culture DMEM 
medium. Seeded the cells into 12 wells plate pre-coated with Gelatine 
medium, and cultured the cells at 37°C in 5% CO2 incubator for 3 days 




Morphometric Analysis and Quantification of Lesion Formation 
The procedures used here were similar to the protocols described in Chen’s 
study (Chen, et al. 2015). The injured femoral arteries were harvested and 
embedded into the paraffin. Cut and collected the sections (5um) at 100um 
intervals, 10 section per segment. Five digitised sections with same 
identification number from five segments/intervals (~0.5mm, 1.5mm, 
2.5mm, 3.5mm and 4.5mm from injury site) of each animal (e.g. I-1/2, III-
1/2, V-1/2 represent the 1st and 2nd section of the 1st, 3rd and 5th 
segment/interval, respectively) were stained with H&E for morphometric 
analysis. 
 
Deparaffinize and hydrate the tissue sections as described previously. After 
deparaffinization and hydration, washed the slides for three times with PBS, 
each time for 5min. Added the Hematoxylin staining solution onto the 
tissue sections and incubate at room temperature for 10min. Washed out 
the staining solution with running water, then added 1% hydrochloric acid 
to remove the extra staining solution from the samples.  Rinsed the slides 
with running water. Added alkaline blueing solution. Rinsed the slides with 
running water. Added Eosin Y staining solution on the top of the sample and 
keep it for 3min at room temperature. After staining, placed the slides into 
95% and 100% ethanol, respectively for 2min each. Clear the slides with 
xylene twice, each time for 4min, then mounted the slide with H&E 
Mounting Media. Used a computerized image analysis system (pixel2, 
Axiovision software) to measure the external elastic membrane (EEL), 
internal elastic membrane (IEL), lumen, media and neointimal areas. At 




3.16 ELISA analysis of S100A4 and other cytokines 
Standard preparation. Reconstituted the standard for IL-6, IFNγ, MCP-1 and 
S100A4 by add distilled water. Mixed the original standard tube before use. 
Prepared seven different tubes for different standard point, S1-7. Pipetted 
225ul of distilled water into each tube, pipetted 225ul of reconstitute 
standard (4ng/mg) into first tube S1 and mix. Pipetted 225ul of dilution 
from S1 to second tube S2 and mix before the next transfer. Repeated serial 
dilution five more times and create S3-S7.  Use distilled water as blank S0. 
Took out the microwell strip from the foil bag and washed each well twice 
with 400 µl Wash buffer. Take care of the microwell surface. After the wash, 
taped the microwell strips on the paper towel to dry the microwell strips 
before use. Immediately added 100µl of Standard dilution prepared before 
to the standard wells after the microwell strips were ready. Then added 
50µl Sample Diluent to the Sample and blank wells. After that added 50µl 
of each sample to the sample wells, and 50µl Sample Diluent into the blank 
well, respectively. Each standard dilution and sample need at least one 
repeat well. Prepared Biotin- Conjugate and Streptavidin-HRP by making a 
1:100 dilution of concentrated Biotin- Conjugate solution or Streptavidin-
HRP Solution with Assay Buffer in a clean tube. Make sure they are used in 
30 mins. Added 50ul of Biotin- Conjugate to all wells. Covered the wells with 
adhesive film and incubate at room temperature for about two hours on 
the shaker. Removed the film and washed the microwell strips for 5 times. 
Pipetted 100 µl diluted Streptavidin-HRP to all wells immediately after wash 
and cover the microwell strip with film; incubate at room temperature for 
one hour with shaking. Washed the strips five times. Added 100ul TMB 
Substrate Solution into all wells, avoid the direct exposure to intense light 
when incubated the wells for 30min at room temperature. Stopped the 
enzyme reaction by quickly added the 100µl Stop Solution into each well. 
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Read the absorbance of each well on spectro-photometer using 450nm as 
the primary wave length (optionally 620 nm as the reference wave length). 
Blank wells were used to adjust the plate reader before determining the 
absorbance of the standards and the samples. 
 
3.17 Human Healthy and Diseased Femoral Arteries Collection  
Samples of human healthy and diseased femoral arterial were collected 
from patients at the First Affiliated Hospital of Zhejiang University (China) 
from June 2013 to August 2017. All these patients were aged from 30 to 80 
years who experienced elective major lower extremity amputation of the 
index leg. Healthy femoral arterial specimens were obtained from patients 
with conditions unrelated to peripheral artery disease such as trauma while 
diseased femoral arterial specimens were obtained from patients with 
peripheral artery disease, which present SMC-rich atherosclerotic lesions 
(identified by hematoxylin and eosin staining). Age- and sex- match were 
required when selected for healthy and diseased groups. Exclusion criteria 
was determined prior to sample collection. For instance, liver failure, 
dialysis because of renal failure, cancer, chemotherapy, and pregnancy, and 
the lack of consent to participate to the study were included in the exclusion 
criteria. All patients were informed and consent by written before sample 
collection. All procedures had local ethical approval and were approved by 
the Research Ethics Committees of the First Affiliated Hospital of Zhejiang 
University (institutional review board approval No. 2013/150). All 
experiments conducted in this PhD thesis followed the principles expressed 
in the Declaration of Helsinki. Patient feature, including demographics, 

















Female sex, No. (%) 7 (23.3) 8 (26.7) 0.776 
Age (years) 55.83 ± 14.05 61.97 ± 14.65 0.103 
Clinical Parameters 
Current smoker, No. 
(%) 
5 (16.67) 9 (30) 0.361 
Former smoker, No. 
(%) 
1 (3.33) 8 (26.67) 0.026* 
Body mass index, 
kg/m2 
23.04 ± 3.51 21.76 ± 3.62 0.201 
Systolic blood 
pressure, mmHg 
137.9 ± 25.53 122.23 ± 19.11 0.009** 
Diastolic blood 
pressure, mmHg 
75.87 ± 12.85 74.77 ± 13.05 0.743 
Heart rate, beats 
/min 
88.67 ± 15.66 84.6 ± 15.05 0.309 
Comorbidities 
Prior stroke, No. (%) 1 (3.33) 4 (13.33) 0.353 
Carotid artery 
disease, No. (%) 
2 (6.67) 2 (6.67) 1 
Coronary artery 
disease, No. (%) 





6 (20) 21 (70) 0.0001*** 
Type II diabetes 
mellitus, No. (%) 
0 (0) 12 (40) NA 
Hyperlipidaemia, No. 
(%) 
4 (13.33) 22 (73.33) <0.0001*** 
Chronic kidney 
disease, No. (%) 
0 (0) 8 (26.67) NA 
Medications 
Aspirin, No. (%) 1 (3.33) 25 (83.33) <0.0001*** 
Statin, No. (%) 0 (0) 21 (70) NA 
ACEI/ARB, No. (%) 3 (10) 9 (30) 0.104 
Clopidogrel, No. (%) 0 (0) 6 (20) NA 
Beta blockers, No. 
(%) 
0 (0) 6 (20) NA 
Cilostazol, No. (%) 0 (0) 9 (30) NA 
Other 
antihypertensive 
medications, No. (%) 
3 (10) 17 (56.67) 0.0003*** 
Other 
antithrombotic 
medications, No. (%) 
2 (6.67) 28 (93.33) <0.0001*** 
P value present in the table is calculated with t-test, Mann-Whitney U Test or Fisher's exact test 
to compare continuous variables (presented with mean ± SD) or categorical variables (presented 
with No. (%)), respectively. NA, not applicable. *<0.05, **<0.01, ***<0.001 
 
3.18 Statistical Analysis 
At least three independent experiments were performed for each 
experiment category (both in vitro and in vivo). Results were expressed as 
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Mean ± SEM. Statistical analysis was performed using Graphpad Prism5. 
Shapiro-Wilk Normality Test was used for checking the normality of the 
data. Two tailed unpaired student’s t-test was used for comparisons 
between 2 groups, or one-way analysis of variance with a post hoc test of 
LSD was applied when more than two groups were compared if the data 
display a normal distribution. Conversely, non-parametric Mann-Whitney U 
Test or Kruskal–Wallis H test was applied for comparing two groups and 
three or more groups, respectively, if the data did not display normal 
distribution or if the number of observations from each group was smaller 
than 5 (n<5). Spearman's rank correlation analyses were conducted to 
characterize the relationships between the gene expression levels of miR-
214 and Sufu in human arterial specimens. Alpha=0.05 was chosen as the 





4.1 Important role for miR-214 in SMC differentiation from 
AdSPCs 
AdSPCs were isolated and passaged as described in the method section.  
Passage 3 AdSPCs were subjected to immunofluorescence staining with 
antibody against Sox1, Sox10, Sox17 and Nestin, typical markers for AdSPCs, 
as well as some mature cells markers (CD45, DDR2, SM-MHC and CD31) 
(Figure 7). Strong green fluorescent signal was observed in antibody against 
the Sox1, Sox10, Sox17 and Nestin in the AdSPCs, while other markers are 





















Figure 7. Immunofluorescence staining with AdSPCs. AdSPCs at passage 3 were subjected to 
immunofluorescence staining with antibody against Sox1, Sox10, Sox17 and Nestin, as well as 
some mature cells markers like CD45, DDR2, SM-MHC and CD31, respectively. Images presented 












To figure out whether AdSPCs could differentiated into SMCs; AdSPCs were 
treated in SMC differentiation medium for day0, day2, day4, day6 and day8. 
Total RNAs and proteins from each group were harvested and subjected to 
RT-qPCR and Western blot. Some cells treated for 8 days were also 
subjected to immunofluorescence staining with antibody against SMαA and 
SM-MHC, respectively (Figure 8). Results shows that SMC markers were 
upregulated by cultured the AdSPCs with SMCs differentiation medium, 
indicate that cells were successfully induced to differentiate towards SMCs 



















Figure 8. SMCs gene expression of undifferentiated AdSPCs and AdSPCs at day 2, 4, 6, 8.Total 
RNAs and proteins harvested from day 0(undifferentiated AdSPCs) and day 2, 4, 6, 8 were 
subjected to RT-qPCR (A) and Western blot (B) analyses, respectively. (C)Day 8 cells were stained 
with antibodies against SMαA and SM-MHC. The data presented here are representative images 














To study the potential involvement of miRNAs in SMC differentiation from 
AdSPCs, I first detected if the expression levels of miR-22, -34a and -214, 
the three top modulated miRNAs during SMC differentiation from 
embryonic stem cells (Yu, et al. 2015), were altered in SMCs differentiation 
from the AdSPCs. The result shows that miR-214 is the most up-regulated 
miRNA among them in this SMC differentiation model (Figure 9A). To study 
if miR-214 could play a role in SMC differentiation from AdSPCs, miR-214 
gain/loss-of-function experiments were conducted in AdSPCs using either 
miR-214 mimics (for miR-214 over-expression) or miR-214 inhibitor (for 
miR-214 knockdown), respectively. As expected, miR-214 expression in 
AdSPCs was significantly increased by miR-214 mimics, but was decreased 
by miR-214 inhibitor (Figure 9B). Importantly, RT-qPCR data showed that 
the expression levels of all four SMC genes (SMαA, SM22α, h1-Calponin and 
SM-MHC) examined here were significantly up-regulated by miR-214 
mimics, but down-regulated by miR-214 inhibitor (Figure 9C). Such 
regulation was confirmed at protein level by Western blot assays (Figure 1D 











Figure 9. An important role of miR-214 in SMC differentiation from AdSPCs. (A) miR-214 was 
significantly up-regulated during SMC differentiation. (B-E) miR-214 modulates SMC marker 
expressions. Day 2 differentiating AdSPCs were transfected with miR-214 mimics, inhibitor or 
respective negative control (miR ctrl), and cultured for 48~72 hours. Total RNA or proteins were 
harvested and subjected to RT-qPCR (B & C) and western blot (D & E) analyses, respectively. The 




4.2 miR-214 inhibits TNFα induced iSMC differentiation from 
AdSPCs    
ISMC in response to vascular injury are likely to secrete inflammatory 
cytokines and express cell adhesion molecules (e.g., IL-8, IL-6, and VCAM-
1), whereby genes that define the contractile SMC phenotype are 
suppressed (Orr, et al. 2010). To mimic iSMCs differentiation/generation 
from AdPSCs in vitro, differentiating AdSPCs were incubated with pro-
inflammatory cytokine TNFα. As expected, SMC differentiation was succeed  
by TGFβ1 as evidenced by induction of two SMC-specific genes (SMαA and 
SM-MHC), while no significant difference was observed with inflammatory 
genes (IFNγ, IL-6, and MCP-1/CCL2) and S100A4, a reported marker for the 
rhomboid SMC (R-SMC) phenotype (Brisset, et al. 2007). Interestingly, 
addition TNFα add into the differentiating AdSPCs primed the differentiated 
SMC into an iSMC phenotype, with decreased expression levels of SMC 
genes, but increased levels of the inflammatory genes and S100A4 (Figure 
10). Importantly, an increased expression level of miR-214 was observed 
during the cells were induced by SMC differentiation medium, while such 
induction was blunted once additional TNFα was added, suggesting a role 
for miR-214 in these processes.  




Figure 10. TNFα inhibit the miR-214 expression while induced inflammatory SMC differentiation 
from AdSPCs. (A-C) AdSPCs were cultured in AdSPC culture medium (Vehicle, Veh), SMC 
differentiation medium (SMC differ) or iSMC differentiation medium (iSMC differ)for 4 days. 
Total RNA, protein and conditioned culture medium were harvested and subjected to RT-qPCR 
(A), Western blot (B), and ELISA analyses (C). The data presented here are representative or 
mean±S.E.M. of five or six independent experiments (n=5 or 6). *P<0.05 (v.s Veh or v.s SMCs 













To explore a potential role of miR-214 in iSMC differentiation from AdSPCs, 
miR-214 mimics was introduced into iSMC differentiation. After 4 days 
differentiation, miR-214 mimics (miR-214) or negative control (miR ctrl) 
were transformed respectively and cultured for 48 hours in the same 
culture medium, total RNA, protein and conditioned culture medium were 
harvested and subjected to RT-qPCR (Figure 10A), Western blot (Figure 11B) 
and ELISA analyses (Figure 11C). RT-qPCR data shows that while TNFα 
incubation significantly inhibited miR-214 expression during the iSMC 
differentiating but such inhibition was completely reversed by the 
transfection of miR-214 mimics (Figure 11A). This result also confirmed by 
Western blot assay (Figure 11B) and ELISA analyses (Figure 11C). 
Importantly, similar trend with SMC gene expression but an opposite trend 
for inflammatory genes and S100A4 to miR-214 expression were observed 
(Figure 11B and 11C). Supporting a notion that miR-214 could rescue 












Figure 11. MiR-214 over-express rescued mature/contractile SMC marker expressions, and 
inhibited TNFα-induced inflammatory cytokine gene expression. AdSPCs were differentiated 
into SMCs (SMC differ) or iSMC (iSMC differ) for 4 days, then these groups were transfected with 
miR-214 mimics (miR-214) or negative control (miR ctrl), and cultured for 48 hours in the same 
culture medium. Total RNA, proteins and conditioned culture medium were harvested and 
subjected to RT-qPCR (A), Western blot (B), and ELISA (C) analysis, respectively. The data 
presented here are representative or mean±S.E.M of five or six independent experiments (n=5 







4.3 Shh-GLI1 signal activation and modulation by miR-214 during 
iSMC differentiation 
AdSPCs transfected with GLI reporter constructs were subjected to three 
different treatments groups: maintained in the AdSPCs culture medium 
group (Vehicle group, Veh), SMC differentiation group and iSMCs 
differentiation group. GLI1 reporter activity assays revealed that Shh-GLI1 
signalling was significantly activated in TGFβ1-induced SMC differentiation, 
but its activity was almost abolished in iSMCs (Figure 12A). Additionally, 
over-expression of miR-214 in iSMCs could reverse GLI1 reporter activity 
which were reveals another luciferase activity assay experiment (Figure 
12B), suggesting that miR-214 could modulate Shh-GLI1 signal pathway 
during iSMC differentiation from AdSPCs.  
 
Figure 12. Luciferase activity assays to examine Shh-GLI signalling activity. A; AdSPCs were 
subject to three different treatment, Vehicle group (Veh), SMC differentiation group (SMC differ) 
and iSMC differentiation group (iSMCs differ). B; SMC differentiation plus miRNA negative 
control group (SMCs differ/miR ctrl), iSMCs differentiation plus miRNA negative control group 
(iSMCs differ/miR ctrl), and iSMCs differentiation plus miR-214 mimic group (iSMCs differ/miR-
214). The data presented here are representative or mean±S.E.M. of five or six independent 
experiments (n=5 or 6). *P<0.05 (v.s veh or v.s SMCs differ/miR ctrl); #P<0.05 (iSMCs differ vs 
SMCs differ or iSMCs differ/miR-214 vs iSMCs differ/miR-214). 
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Future more, such a notion was supported by the gene expression profiles, 
in which data showed that all three main components of the Shh-GLI1 
signalling pathway (Shh, PTCH1, and GLI1), as well as its downstream target 
genes (Wnt1, Wnt4, Wnt9a and WISP1) were significantly activated by 
TGFβ1 treatment, while such activations were dramatically inhibited by 
inclusion of TNFα into the differentiating AdSPCs (Figure 13A). Moreover, 
an opposite phenomenon was observed once miR-214 mimics was 
introduced into iSMCs (Figure 13B). It is well known that canonical Shh-GLI1 
signal activation through releasing GLI1 from cytoplasmic sequestration and 
translocating  into the cell nucleus where it binds to the consensus GLI1-
binding element and regulates these gene expression (Zhu and Lo 2010). 
Western blot assay showed that in iSMCs differentiation model, although 
increased the miR-214 expression, the total amount of the GLI1 did not 
change obviously. In contrast the GLI1 protein level in nuclear was 
significantly modulated and regulated by miR-214 in iSMCs (Figure 13C), 
which was further confirmed by immunofluorescence staining (Figure 13D). 
Taken together, these data demonstrated that Shh-GLI1 signalling pathway 









Figure 13. MiR-214 promotes GLI-1 nuclear translocation. (A-B) RT-qPCR detection of Shh-GLI 
target gene expressio during the SMCs differentiation and iSMCs differentiation. (C-D) GLI1 
translocation in AdSPCs during the iSMCs differentiation. Cells were subjected to Western blot 
analysis (C) immunofluorescence staining against with GLI1 antibody (D). The data presented 
here are representative or mean±S.E.M. of five independent experiments (n=5). *P<0.05 (v.s 


















4.4 Identification of Sufu as the target gene of miR-214 during 
iSMC differentiation from AdSPCs    
Sufu gene expression was detected during the SMC differentiation and 
iSMC differentiation process. Interestingly, an inverse relationship 
observed between the expression levels of Sufu (Figure 14A & 14B) and 
miR-214 (Figure 10A) during SMC and iSMC differentiation from AdSPCs, 
that Sufu expression Sufu was negatively regulated by miR-214. This rise a 
question that the relationship between Sufu and miR-214 during the iSMCs 
differentiation, as demonstrated in miR-214 over-expression (Figure 14C & 
14D) and inhibition (Figure 14E & 14F) experiments, respectively. Moreover, 
Sufu has been reported as a target of miR-214 in zebrafish(Flynt et al. 2007), 
and both mouse and human Sufu 3’UTR harbours miR-214 binding site(s), 
indicating that Sufu is the mRNA target of miR-214 during iSMC 
differentiation from AdSPCs.  
 
To determine miR-214 might directly interact with Sufu gene promoter site 
and therefore regulate the Sufu express in the cells, the 3’UTR of Sufu 
containing the conserved miR-214 binding site was cloned into a luciferase 
reporter. Data from miRNA reporter assay showed that the activity of 
luciferase from construct harbouring the wild-type Sufu 3’UTR was 
significantly inhibited by miR-214 over-expression. I found that the 
conserved miR-214 binding site within Sufu 3’UTR is required for Sufu gene 
repression induced by miR-214 overexpression in iSMCs, since the 
inhibitory effect of miR-214 over-expression on Sufu 3’UTR reporter activity 
was almost abolished once the binding site was mutated (Figure 14G). 
Taken together, these data clearly demonstrated that Sufu is a true mRNA 
target of miR-214 and it is negatively regulated by miR-214 during iSMC 





   
Figure 14. Identify Sufu as the target gene of miR-214 during iSMC differentiation from AdSPCs. 
(A-B) Sufu is closely modulated during iSMC differentiation from AdSPCs. (C-D) miR-214 over-
expression in iSMCs differentiation inhibits Sufu gene expression. (E-F) Up-regulation of Sufu by 
miR-214 inhibition. Total RNAs and proteins were harvested and subjected to RT-qPCR (A,C,E) 
and Western blot (B,D,F) analysis, respectively. (G) The binding site is required for miR-214 
mediated Sufu gene repression. The potential wild type binding site (WT) of miR-214 within Sufu 
gene 3’UTR and its mutant (BSmut) are depicted in this illustration (left).  miR-214 mimics or 
negative control (miR ctrl) were co-transfected into iSMCs with wild type Sufu 3’UTR reporter 
(WT), or miR-214 binding site mutants [miR-214BSmut], respectively. The data presented here 
are representative or mean±S.E.M. of five (A-F) or eight (G) independent experiments (n=5 or 8). 
*P<0.05 (v.s Veh or v.s SMCs differ/miR ctrl); #P<0.05 (iSMCs differ vs SMCs differ or iSMCs 
differ/miR-214 vs iSMCs differ/miR-214). 
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4.5 Sufu mediates SMC gene expression via modulating GLI1 
nuclear translocation 
Sufu gene knockdown and over-expression experiments were conducted in 
the differentiating AdSPCs to study a potential role of Sufu in regulating 
SMC gene expression. Compared to the respective control cells, Sufu 
knockdown significantly up-regulated SMC gene expression at both mRNA 
(Figure 15A) and protein level (Figure 15C). While an opposite effect was 
observed when over-expressing Sufu in the differentiating AdSPCs (Figure 
15B), supporting a notion that Sufu functions as a negative regulator of SMC 
marker gene expression. Such a notion was further confirmed by SMC gene 
promoter activity assays (Figure 15D & 15E). Indicating that Sufu regulates 














Figure 15. Sufu regulated SMC gene expression in AdSPCs differentiation into SMCs. AdSPCs 
were infected with non-target (sh-NT) or Sufu (sh-Sufu) shRNA lentivirus as well as 
control(pCDH-ctrl) or Sufu overexpression(pCDH-Sufu) lentivirus, followed by SMC 
differentiation. Total RNAs and proteins were harvested and subjected to RT-PCR (A-B) and 
Western blot (C) analyses, respectively. (D-E) SMC gene promoter activity were regulated by 
Sufu. AdSPCs infected with sh-NT or sh-Sufu lentivirus as well as pCDH or pCDH-Sufu lentivirus 
were transfected with SMC gene promoters (pGL3-SMαA or SM22α). Cells were treatment with 
SMCs differentiation medium. Two days later, total cell lysates were harvested and subjected to 
luciferase activity assays. The data presented here are representative or mean±S.E.M. of five 










In order to explore the underlying molecular mechanism of SMC gene 
transcriptional regulation by Sufu, AdSPCs were infected with non-target 
(sh-NT) or Sufu (sh-Sufu) shRNA lentivirus, followed by SMC differentiation. 
Whether GLI1 gene expression level is affected by Sufu inhibition was first 
examine and RT-qPCR data showed no significant difference for GLI1 mRNA 
expression level between control and Sufu knockdown AdSPCs (Figure 16A). 
As mentioned previously, Sufu negatively regulates hedgehog signalling 
through direct binding with GLI1 and retaining GLI1 in the cytoplasm, thus 
the cellular location of GLI1 is regulated by Sufu was detected. Data from 
both Western blot and Immunofluorescence staining shows, there was no 
big difference between Sufu knockdown and NT control group when 
comparing the total GLI1 protein, but GLI1 expression were significant 
increase in the nuclear in Sufu knockdown group comparing with the NT 
control group (Figure 16B &16C). These assays revealed that Sufu inhibition 
in the differentiating AdSPCs resulted in nuclear accumulation of GLI1 
protein. 
 
Interestingly, I found two possible GLI1 binding sites within SMαA gene 
promoter. To study the functional importance of these two GLI1 binding 
sites, GLI1 single (GLI1mut-1, or GLI1mut-2) or combinational (BSmut-1/2) 
binding site mutant reporters were constructed and used in Luciferase 
activity assays (Figure 16D). Data from these assays revealed that both GLI1 
binding sites are important for Sufu-mediated SMαA gene suppression 
during iSMC differentiation from AdSPCs (Figure 16E). Finally, chromatin 
immunoprecipitation (ChIP) assay data revealed that GLI1 directly bound to 
the regions spanning around GLI1 binding element of SMαA gene 
promoters, and such binding was dramatically enhanced by Sufu inhibition 
151 
 
(Figure 16F). Altogether, the above data suggest that Sufu represses SMC 




Figure 16. Sufu represses SMC gene expression by modulating GLI1 localisation. (A) GLI1 gene 
expression was not affected by Sufu inhibition. (B-C) Sufu knockdown promotes GLI1 protein 
accumulation in nuclei. (D) The potential wild type binding site (WT) of GLI1 within SMαA gene 
promoter region and its mutants (GLI1 mut). (E) Two GLI1 binding sites within SMαA gene 
promoter region are required for SMαA gene up-regulation by Sufu knockdown in AdSPCs. (F) 
Sufu inhibition increases GLI1 enrichment within SMαA gene promoter. ChIP assays were 
performed using antibodies against GLI1 or normal IgG, respectively. The data presented here 









4.6 Sufu controls SMC gene expression through regulating 
transcription factor SRF  
Luciferase activity assays with pGL3-Luc-SmαA and pGL3-Luc-SM22α 
showed that Sufu knockdown in the differentiating AdSPCs significantly 
activated SMαA and SM22α gene promoter activities (Figure 17A & 17B), 
and its SRF binding element (CArG) mutation in the two reporters almost 
abolished their transcriptional activity in response to Sufu inhibition (Figure 
17A & 17B), suggesting a role for SRF in Sufu-mediated SMC gene regulation. 
I found that Sufu over-expression inhibited SRF gene expression (Figure 
17C), while Sufu knockdown promoted its expression (Figure 17D). A similar 
effect was observed in Luciferase activity assays with an SRF gene promoter 
construct generated in my previous study (Figure17E&F). Moreover, ChIP 
assays showed that the binding capacity of GLI1 to SRF gene promoters was 
significantly enhanced by Sufu knockdown (Figure 17G). Taken together, 
above findings demonstrate that Sufu regulates SMC gene expressions 
during iSMC differentiation from AdSPCs through modulating the binding of 










Figure 17. Sufu regulates SMC gene expressions through modulating the binding of GLI1 to SRF 
gene promoter. (A-B) Serum response factor (SRF) binding sites within SMC gene promoters are 
required for Sufu-mediated SMC gene repression. (C-D) Sufu over-expression inhibited SRF gene 
expression, while Sufu knockdown promoted its expression. (E) GLI1 binding site within SRF gene 
promoter region is necessary for SRF gene up-regulation by Sufu knockdown in AdSPCs. (F) SRF 
gene promoter activity is increased by Sufu inhibition. (G) Sufu inhibition increases GLI1 
enrichment within SRF gene promoter. ChIP assays were performed using antibodies against 
GLI1 or normal IgG, respectively. Data presented here are Mean±S.E.M of five or six independent 












4.7 A regulatory role for Sufu-GLI1 signal axis in inflammatory 
gene expression during iSMC differentiation from AdSPCs  
Sufu-GLI1 signal axis has been reported to play a critical role in intestinal 
inflammatory response, and decreased GLI1 activity predisposes to a 
heightened myeloid response to inflammatory stimuli in inflammatory 
bowel diseases (Lees, et al. 2008). I wondered if this axis also plays a role in 
inflammatory gene expression and iSMC differentiation from AdSPCs. To 
this end, Sufu specific shRNA lentivirus and over-expression vector were 
introduced into iSMCs. Total RNAs and conditioned culture medium were 
harvested and subjected to RT-PCR and ELISA analyses, respectively. RT-
qPCR data showed that Sufu inhibition significantly inhibited the expression 
levels of all three inflammatory genes and S100A4 (Figure 18A), while Sufu 
over-expression exerted an opposite effect (Figure 18B). A similar effect 
was confirmed at protein level in ELISA assays (Figure 18C & 18D) as well as 
at transcriptional level as shown in luciferase activity assays with IL-6 and 
MCP-1/CCL2 gene promoter reporters (pmIL-6 FL and pMCP-Luc) (Figure 
18E & 18F). All these data demonstrate that Sufu serves as a positive 
regulator in inflammatory gene regulation by negative regulating GLI1 





Figure 18. Sufu positively regulates TNFα-induced inflammatory gene expression in AdSPC-
derived iSMCs. (A-D) Inflammatory gene expression in iSMCs was positively modulated by Sufu. 
(E-F) Luciferase activity assays proved that inflammatory gene promoter was positively 
modulated by Sufu. The data presented here are mean±S.E.M. of five or six independent 





4.8  miR-214 over-expression in the injured arteries decreased 
iSMC formation  
To study if miR-214/Sufu axis also play a role in controlling iSMC formation 
during arterial remodelling, 100μl of 30% pluronic gel containing chemically 
modified and cholesterol conjugated 2.5nmol miR-214 or Cel-miR-67 
agomiRs (negative control) was perivascularly applied to femoral arteries 
immediately after injury as described in the method. Two weeks later, 
injured segments of femoral arteries were harvested for H&E staining 
analyses or cell isolation, respectively. An apparent neointima layer was 
observed in the injured arteries with control miRNA treatment, while locally 
enforced expression of miR-214 resulted in a smaller neointima layer 
(Figure 19A). As expected, cells isolated by enzymatic digestion from normal 
media layer (SMCs/Sham) constantly exhibited a spindle-shaped phenotype 
with a classic “hill-and-valley” growth pattern at confluence, while cells 
isolated from the media/neointima layer of the injured arteries displayed a 
phenotype resembling R-SMCs as previously reported(Taylor et al. 2002). 
Interestingly, miR-214 over-expression in the injured arteries reverted the 
injury-induced R-SMC phenotype to classic one (Figure 19B). Data from 
immunofluorescence staining revealed cells with R-SMC phenotype were 
positive for SMαA and IL-6, and miR-214 over-expression significantly 
reduced iSMC formation (Figure 19C&D). Compared to sham procedure or 
injured arteries treated with miR-214 agomiR group, expression levels of 
miR-214 and SMC contractile genes (SMαA and SM-MHC) were significantly 
decreased in the injured arteries treated with control Cel-miR-67 agomiRs 
group, while Sufu (miR-214 target gene), IL-6 and S100A4 (iSMC markers) 
were dramatically increased (Figure 19E). Importantly, perivascular 
transfection with miR-214 agomiR resulted in an increased level of miR-214 
in the injured arteries (Figure 19E), confirming that miR-214 was 
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successfully over-expressed in the injured arteries. Consequently, the 
above-mentioned gene expression profiles induced by vascular injury were 
reversed by miR-214 over-expression. Altogether, above data demonstrate 













Figure 19. MiR-214 decreases iSMCs during arterial remodelling. Mice underwent a sham arterial 
injury procedure serve as control (Sham). SMCs and neointima (NI) cells were isolated from 
media (sham mice) or media/neointima layer and cultured in SMC medium for further 
experiments, respectively. (B) Phase-contrast images were also taken prior to other analyses 
and included here. (C & D) Immunofluorescence staining assay with antibodies against SMαA 
and IL-6. (E) RT-qPCR detection of gene expression. Data presented here are representative 
images or Mean±S.E.M of five independent experiments (n=5). *P<0.05 (versus sham), #P<0.05 
(miR-214 versus Cel-miR-67). 
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4.9 Transplantation of AdSPCs increases adversely arterial 
remodeling in response to injury, while miR-214 over-expression 
in AdSPCs reverses such processes  
To investigate a potential contribution of the Ad-SPC derived iSMCs to 
arterial remodeling, femoral arterial wire injuries were conducted as 
described in method, AdSPCs infected with Lenti-GFP was immediately 
applied and packed around injured vessel. The injured segments of femoral 
arteries were harvested one-week post-transplantation. Triple 
immunofluorescence staining with antibodies against GFP, SMαA and 
S100A4 showed that the transplanted AdSPCs could differentiate into 
iSMCs (cells are positive for GFP, SMαA and S100A4) within the injured 
arterial walls (Figure 20). 
 
Figure 20. Transplanted AdSPCs differentiate toward iSMCs during arterial remodelling. Injured 
segments of femoral arteries were harvested after one week and subject to triple 
immunofluorescence staining with antibodies against GFP, SMαA and S100A4.  White arrows 
within merged image indicate iSMCs derived from transplanted AdSPCs. Data presented here 




To further explore the functional implication of miR-214 in controlling iSMC 
formation and its contribution to vascular remodelling after angioplasty, 
control vehicle, and AdSPCs infected with Lenti-GFP or Lenti-miR-214 were 
transplanted onto the injured vessel, respectively. Compared to vehicle 
control, AdSPC transplantation into the injured arteries resulted in a trend 
of decrease of miR-214 expression, but significant increased expressions of 
Sufu, SMαA, S100A4 and IL-6 genes (Figure 21A), further supporting 
previous observation that the transplanted AdSPCs can acquire an iSMC 
phenotype during injury-induced arterial remodelling. Importantly, locally 
transplanting AdSPCs infected with Lenti-miR-214 dramatically increased 
vascular miR-214 and SMαA levels, but significantly decreased Sufu, S100A4 
and IL-6 expression (Figure 21A). Expectedly, a thick neointima was induced 
by wire injury of the femoral artery after 28 days in the mice treated with 
vehicle control, and a much bigger neointimal thickening was observed in 
the mice received the transplantation of AdSPCs infected with control virus 
which almost two times thicker than the control group (Figure 21B & 21C).  
Taken together, this data confirmed an inhibitory role for miR-214 in iSMC 











Figure 21. MiR-214 over-expression in AdSPCs reverses AdSPCs increases adversely arterial 
remodeling function in response to artery injury. (A) RT-qPCR detection of gene expressions in 
the injured arteries. The data presented in (A) are mean±S.E.M. of five independent experiments 
(femoral arteries from 3 to 5 mice were pooled for each experiment, n=5 experiments).  (B & C) 
Morphometric analysis of the wire injury induced neointima formation. Paraffin sections from 
the indicated groups (n=10 mice for each group) were prepared and subjected to H&E staining 
analyses. Representative images (B) and morphological characteristics including media area, 
neointimal area, neointimal/media (N/M) ratio, and lumen area (C) were presented here. 




4.10 Expression profiles of miR-214 and Sufu in the healthy and 
diseased human vessels  
To further explore the functional relevance of the miR-214/Sufu regulatory 
axis in a clinical setting, the gene expression levels of miR-214 and Sufu, and 
their relationship was examined in healthy and diseased femoral arterial 
specimens. Healthy femoral artery (FA) specimens (n=15) from patients 
without peripheral arterial diseases and diseased FA specimens (n=15) from 
patients with peripheral arterial diseases were collected and subjected to 
RT-qPCR analyses. RT-qPCR experiments were subjected to test gene 
expression levels of miR-214 and Sufu. Result showed about four to five 
times decreased expression level of the miR-214 gene, with an increased 
gene expression level of Sufu in the diseased femoral arteries, compared 
with healthy arteries (Figure 22A). Importantly, a significant inverse 
relationship between miR-214 and Sufu in both healthy and diseased 
femoral arterial specimens were observed in this thesis (Figure 22B). Thus, 
above human specimens’ data provides critical information about the 






Figure 22. Expression profiles of miR-214 and Sufu in the healthy and diseased human arteries. 
(A) Expression levels of miR-214 (relative to U6, %) and its target gene Sufu (relative to 18S, %) 
are shown for each specimen (dots). Bars represent the mean±S.E.M. in each patient group. 
*P<0.05 (Mann-Whitney U Test). (B) Spearman's rank correlation analyses were carried out to 
characterize the relationships between the gene expression levels of miR-214 and Sufu in 
healthy and diseased FA specimens. The solid line indicates the fitted linear regression line; the 
dotted line indicates 95% CI level. R is Spearman's correlation coefficient between the 







SMC accumulation and phenotypic transition are the critical steps for 
vascular remodelling in response to vascular injury. Traditionally it is 
thought that the accumulation of SMCs in the neointima results from 
migration of resident SMCs from the arterial media into the intima where 
SMCs undergo proliferation. Nevertheless, recently research found that 
there are a large number of vascular SPCs in the vascular wall, which could 
take part into the iSMCs formation/accumulation in atheroma as well as the 
restenotic lesions. An early study reported that SPC infusion could reduce 
the size of atherosclerotic lesions and promote a switch in the plaque 
phenotype towards a more stable one by reducing macrophage invasion 
and increasing SMC and collagen content in the plaques (Zoll, et al. 2008). 
Similar observation was reported in a later study that transplanted AdSPCs 
contribute to venin-graft atherosclerosis in apoE-deficient mice (Chen, et al. 
2013). A new concept was raised by Li and colleagues (Tang, et al. 2013) 
that vascular disease is likely a stem cell disease. Such a notion was also 
supported by works conducted by Grudzinska et al (Grudzinska, et al. 2013). 
They showed that local inflammation in transplanted vessels exerts an 
effect on surrounding tissue and vessels that leads to phenotypic 
modulation of SMCs in adjacent vessels. However, those cells did not 
migrate to the intima and did not contribute to the intimal hyperplasia. 
Instead, AdSPCs were found to be a prominent source of host-derived cells 
in the lesion. Therefore, abovementioned evidence supports a notion that 
both vascular SPCs and SMCs may play important roles in vascular disease, 
and their contributions to vessel remodelling are highly dependent on the 
models used and the extent of vessel injury. In the current study, I 
attempted to address such unmet challenges by uncovering a novel role for 
miR-214 in modulating SMC differentiation and iSMC generation from 
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AdSPCs in vitro and in vivo. Specifically, I find that miR-214 is one of the 
most up-regulated miRNAs during SMC differentiation from AdSPCs 
induced by TGFβ1, and demonstrate that miR-214 plays a critical role in this 
process. Additionally, addition of TNFα into the differentiating SMCs could 
prime them into an iSMC phenotype, and importantly miR-214 over-
expression reverse this priming process. Moreover, this study has provided 
clear evidence to suggest that miR-214-Sufu-GLI1 axis is one of key signal 
pathways that are responsible for iSMC differentiation/generation from 
AdSPCs. Mechanistically, this study has confirmed that Sufu is the authentic 
downstream target of miR-214 during iSMC differentiation from AdSPCs, 
and have identified Sufu as a novel transcriptional repressor of SMC 
contractile genes but an important transcriptional activator of 
inflammatory genes, respectively. This ex vivo and in vivo data has shown 
for the first time that AdSPCs can be induced to differentiate into iSMCs 
within injured arteries, and that ectopic expression of miR-214 in AdSPCs 
that are transplanted into the injured arteries can reverse the process of 
iSMC differentiation from AdSPCs and prevent post-angioplasty restenosis. 
Importantly, this research also provides clear evidence to support a 
potential role for miR-214 and Sufu in human atherosclerosis. 
 
MiRNAs are endogenous, highly conserved, and single short strand non-
coding RNAs. They have been reported as important regulators for stem cell 
differentiation (Shenoy, et al. 2014; Kane, et al. 2014) and are emerging as 
the novel therapeutics or clinical biomarkers for cardiovascular diseases 
(Barwari, et al. 2016; Gareri, et al. 2016). Although handful miRNAs have 
been recently reported to play a role in modulating SMC differentiation 
from stem cells and controlling multiple processes of vascular diseases 
(Yang, et al. 2018; Yu, et al. 2015; Cheng, et al. 2009), further extensive 
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investigations are warranted to fully elucidate the exact role of individual 
miRNAs in SMC differentiation and their significance in cardiovascular 
development and arterial remodelling. MiR-214 is a member of the miR-
199a-214 cluster encoded by a large noncoding RNA, DNM3os, which is 
transcribed in the opposite strand of the DNM3 gene (Watanabe, et al. 
2008). Inconsistent involvements of miR-214 in cancer progression (Chen, 
et al. 2014; Penna, et al. 2011), and cardiac cell functions and associated 
diseases (Aurora, et al.  2012; Chen, et al. 2015)have been well-documented 
in the literature. The possible reasons for such discrepancies are likely due 
to the fact that different cell systems and animal models were used among 
these studies, suggesting that miR-214 plays a divergent role in various 
diseases and the functional implication of miR-214 is cell context-
dependent. A function implication for miR-214 in mature vascular SMC 
functions and injury-induced arterial remodelling has been reported in 
previous study which reported that miR-214 control both vascular SMC 
proliferation and migration, two critical cellular events in vascular 
neointimal lesion formation, and enforced expression of miR-214 in the 
injured arteries reduces neointima SMC hyperplasia by modulating vascular 
SMC proliferation (Afzal, et al.  2016). In this thesis, the aim was to provide 
new perspectives on the role for miR-214 in injury-induced arterial 
remodelling. Firstly, this thesis addressed the novel concept that AdSPCs 
are an additional cellular source for neointima SMCs, whereas in previous 
studies the main focus has been on the traditional concept of mature 
vascular SMC phenotypic modulation. Secondly, this thesis first observed 
that miR-214 is the most up-regulated miRNA during SMC differentiation 
from AdSPCs, and demonstrated that miR-214 plays an important role in 
SMCs differentiation from AdSPCs. Moreover, this project has confirmed an 
additional function for miR-214 that miR-214 could revert iSMC phenotype 
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into a contractile phenotype in vitro and in vivo even in the presence of 
strong inflammatory stimuli. Thirdly, this thesis has been able to delineate 
a novel underlying mechanism for iSMC differentiation/generation from 
AdSPCs, I found that Shh-GLI1 signalling pathway was activated and 
modulated by miR-214 during iSMC differentiation, and the location but not 
the total protein level of GLI1 was modulated by miR-214 in AdSPC-derived 
iSMCs. Moreover, this project demonstrates that Sufu is the target gene of 
miR-214 during iSMC differentiation from AdSPCs, and that Sufu regulates 
gene expression through controlling the cellular locations of GLI1 protein.  
Specifically, it demonstrates that Sufu is the true target gene of miR-214 in 
the context of iSMCs and injury-induced arterial remodelling. Sufu exerts its 
functions by releasing GLI1, the nuclear transcriptional effector of Shh 
signal pathway, and allowing GLI1 to translocate into nuclei to regulate 
relevant target gene expression. Finally, these findings are also able to 
translate from mice into men by documenting the gene expression profiles 
of miR-214 and Sufu, as well as their relationships in both healthy and 
diseased human arteries. 
  
One of the new findings in this thesis is that I have successfully established 
a reliable cellular model to study iSMC differentiation/generation from 
AdSPCs. Apart from the classical ‘contractile’ to ‘synthetic’ phenotypic 
modulation, extensive evidence also suggests that vascular SMCs can be 
primed to another distinct phenotype, that is ‘proinflammatory’ phenotype 
or iSMCs, in response to vascular injury or inflammatory stimuli. These 
iSMCs contribute to vascular disease progression and are a pervasive 
feature in atherosclerotic lesion formation (Orr, et al. 2010) and arterial 
remodelling (Herring, et al. 2016). However, the majority of previous 
studies used mature vascular SMCs as a cellular model to study iSMCs and 
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relevant signal pathways (Ackers-Johnson, et al. 2015; Liu, et al. 2015; 
Alexander, et al. 2012). Although the existence and functional importance 
of stem/progenitor cell-derived SMCs in vascular diseases has been 
increasingly recognised by vascular biology researchers, there has been a 
lack of a suitable cellular model to study AdSPC-derived iSMCs and the 
molecular mechanisms involved. In this thesis, I tested the hypothesis that 
exposure of the differentiating AdSCPs/SMCs to inflammatory stimuli could 
induce an iSMC phenotype from AdSPCs. Indeed, I found that inclusion of 
TNFα into the SMC differentiation medium could guide AdSPC-derived 
SMCs to adopt an iSMC phenotype, which is associated with decreased 
expression levels of SMC contractile genes and increased expression levels 
of inflammatory genes. As expected, iSMCs also secrete inflammatory 
cytokines IFNγ, IL-6 and MCP-1/CCL2. Interestingly, AdSPC-derived iSMCs 
also express high level of S100A4, the reported marker for R-SMCs (Brisset, 
et al. 2007). S100A4 belongs to S100 family of calcium binding proteins and 
was reported involved in tumour metastasis. S100A4 was found up regulate 
during the oncogenic transformation(Garrett, et al. 2006), this may explain 
that S100A4 are increased in the rhomboid SMC. Although the iSMCs used 
here morphologically resemble R-SMCs (Hao, et al. 2002), it would be 
difficult to draw any assumption that iSMCs are same as or similar to R-
SMCs, or simply representing another distinct SMC phenotype, without 
being side-by-side comparison in terms of their functionalities, pathological 
contributions to vascular diseases, and global gene/protein expression 
profiles.  
 
Another new finding in this thesis is that Sufu is the functional target gene 
of miR-214 in the context of iSMC differentiation from AdSPCs. Although 
multiple miR-214 target genes have been reported in various cellular 
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contexts and diseases, for example; NCKAP1 (Afzal, et al. 2016), N-RAS (Liu 
et al. 2010), ITCH (Chen, et al. 2015a), TFAP2C (Penna, et al. 2011), FGFR1 
(Chen, et al. 2014), Quaking (van Mil, et al. 2012a), and Ncx1 (Aurora, et al. 
2012), none of them has been shown to play a role in iSMC differentiation 
from AdSPCs. However, I have demonstrated that the Sufu is a novel target 
gene of miR-214 which has a role in regulation of iSMCs differentiation from 
AdSPCs. The Shh pathway is a pivotal morphogenic driver during embryonic 
development and a key regulator in determining residential vascular stem 
cell fate (Mooney, et al. 2015). Several components of Shh-GLI1 signal 
pathway (e.g., Shh, patched-1, patched-2, and GLI1) has been reported to 
play critical roles in development of the adventitia and maintenance of the 
resident vascular stem/progenitor cells in the artery wall (Passman,  et al. 
2008; Kramann, et al. 2015). Importantly, Sufu is a well-known negative 
regulator of hedgehog signalling. It serves as a docking protein to retain the 
nuclear effector protein of Shh signalling, GLI1, in the cytoplasm, preventing 
it being shuttered into nuclei to trigger the transcriptional program 
(Dunaeva, et al. 2003; Kogerman, et al. 1999), indicating a role for Sufu in 
vascular stem/progenitor cell development and differentiation. Despite this 
possibility, no such evidence reported in the existing literature, and the 
mechanism through which Sufu (or Shh- GLI1 signal axis) is modulated in 
the context of SMC differentiation from AdSPCs remains elusive. In the 
current study, I demonstrated for the first time that Shh- GLI1 signal axis is 
activated during iSMC differentiation from AdSPCs, Sufu is negatively 
regulated by miR-214, and that Shh- GLI1 signal axis is closely modulated by 
miR-214/Sufu in iSMCs. Furthermore, I observed that change the 
expression of Sufu in AdSPCs indeed changed the activity of SMCs gene 
promoter. Apart from Sufu that has been identified and validated as a bona-
fide miR-214 mRNA target in iSMCs in this thesis, NCKAP1 also reported  as  
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another target gene of miR-214 in a previous study (Afzal, et al. 2016). 
However, no evidence to support the NCKAP1 is the functional target gene 
during iSMC differentiation from AdSPCs. Such a discrepancy further 
supports the notion that any given miRNAs play divergent roles under 
various physiological and pathological conditions by targeting distinct 
target gene(s), and/or that the miRNAs regulate their target genes in a 
cellular context dependent manner. One of novel mechanistic findings in 
the present study is that this research provided clear evidence to support 
that Sufu could serve as a negative or positive regulator of SMC and 
inflammatory gene expression, respectively. I demonstrate that Sufu is an 
important iSMC differentiation mediator by transcriptional regulation of 
SMC specific genes (SMαA and SM-myh11), SMC transcriptional factor SRF, 
and inflammatory genes (IFNγ, IL-6 and MCP-1/CCL2). This data showed 
that Sufu exerts such a transcriptional regulation through modulating GLI1 
nuclear translocation. Data generated from luciferase activity and ChIP 
assays provide multiple lines of evidence to support such mechanism.  
 
Since the discovery of miRNA there has been considerable research focused 
on this promising small non-coding RNA. Currently, there are about 20 
ongoing miRNA clinical trials involved in different human diseases. 
Significantly, the first miRNA therapy drug called miraviresen, based on 
miR-122, is currently in clinical trial for HCV infection treatment 
(Chakraborty, et al. 2017). Comparing with other disease, there is no report 
on microRNA-based therapy in cardiovascular disease. Although many 
preclinical works have proved that miR-214 could be a promising 
therapeutic for protecting cardiac myocytes (Tang, et al. 2016), reducing 
cardiac fibrosis (Zhu,  et al. 2016) as well as arterial remodelling(van Mil, et 
al. 2012; Afzal, et al. 2016), little data reveals the function of miR-214 in 
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clinical research. By collecting the femoral artery specimens from patients, 
my research not only discovered the significant inverse relationship 
between miR-214 and Sufu in both healthy and diseased femoral arterial 
specimens, but also revealed that miR-214 expression levels are obviously 
decreased in the diseased femoral arteries, compared with healthy arteries. 
This provides promising evidence for future clinical research on CVD 
including arterial remodeling. Therefore, findings from this thesis and 
previous one support an important role for miR-214 in iSMC 
differentiation/generation from AdSPCs, vascular SMC biology, and arterial 




In the current study, I focused on the regulatory role of miR-214 in AdSPCs 
differentiating into inflammatory smooth muscle cells, atherosclerosis and 
arterial remodelling. This project successfully uncovered the functional 
involvements of miR-214 in iSMC differentiation/generation from 
residential AdSPCs as well as in vascular remodelling after injury. During this 
research, I first observed that GLI1 transport into the nuclear in miR-214 
overexpressing AdSPCs during the iSMCs differentiating. The newly 
identified target gene Sufu is at least partially responsible for miR-214-
mediated iSMC differentiation. Specifically, these data have shown that: 1) 
Sufu negatively regulates SMC gene promoter activity; 2) GLI1 binding site(s) 
within SMαA and SRF gene promoters are required for these gene 
transductions regulated by Sufu; 3) GLI1 nuclear accumulation and its 
binding to the promoter DNA of SMC-specific genes (SMαA and SRF) was 
modulated by Sufu; and 4) the promoter activity of inflammatory genes (IL-
6 and MCP-1/CCL2) is positively regulated by Sufu in iSMCs.  Therefore, the 
findings presented in this thesis suggest that modulating miR-214-Sufu- 
GLI1 axis could be a potential therapeutic for various vascular diseases such 
as atherosclerosis and post-angioplasty restenosis (Figure 23). 
 
In conclusion, this PhD study has successfully uncovered a functional role 
for miR-214 in iSMC differentiation/generation from residential AdSPCs as 





Figure 23. MiR-214-Sufu- GLI1 axis modulate iSMC differentiation from AdSPCs. Sufu block Shh-
GLI1 signalling pathway by interact with GLI1 and inhibit GLI1 translocated into the nuclear. MiR-













7. Limitations and Future Plan 
7.1 Study Limitations 
The major limitation of this PhD study would be the fundamental 
differences between mouse model used in this thesis and the clinical 
settings of patients with post-angioplasty restenosis or in stent restenosis. 
Although the vascular injury model used here has been widely used to 
mimic the pathological processes of neointima SMC hyperplasia and 
explore underlying molecular mechanisms of arterial remodelling, this 
model does not completely mimic the conditions prevailing at the micro-
environmental level after stent implantation and hence cannot provide us 
the best way to study the underlying factors at such micro level. Moreover, 
both atherosclerosis and post-angioplasty neointima formation are mainly 
incurred at later stages in life, hence the cellular and molecular responses 
to different inflammatory stimuli are somehow different than in normal 
young individual. This would represent the 2nd major difference between 
the animal model (8-week old adult C57BL/6 mice used in this thesis) and 
the clinical condition (aged human population). Furthermore, 
hyperlipidemia is considered as a major predisposing factor for 
atherosclerosis and neointima formation by triggering endothelial 
dysfunction and accelerating the pathological processes. The normal lipid 
profiles could be counted as 3rd major difference between the animal model 
and the patients’ actual conditions which normally presents high levels of 
cholesterol and triglycerides. Finally, although the wire-injury-induced 
neointima formation is nicely mimicking with post-angioplasty restenosis, 





7.2 Future plan 
Despite we have comprehensively demonstrated that miR-214 is critical 
regulator in iSMC differentiation and potential therapeutic drug target for 
treating the patients with post-angioplasty restenosis or in stent restenosis, 
during the course of study we came across some new findings and 
limitations as discussed in the above section, all of them warrant further 
investigation. 
 
First, through combined efforts, we have beautifully elaborated the 
underlying molecular mechanisms of SMC gene regulation mediated by the 
miR-214/Sufu/GLI1 axis, however the evidence to support such a regulatory 
role of this axis in inflammatory gene expression is less clear. Further 
investigation to confirm a regulator role of miR-214 in inflammatory gene 
expression would expand the therapeutic potential of miR-214 from CVD to 
other inflammatory diseases, such as asthma, chronic obstructive 
pulmonary disease, tuberculosis, rheumatoid arthritis, periodontitis, 
hepatitis, ulcerative colitis and Crohn's disease.  
 
Second, although the main focuses of this PhD study are exploring the 
functional involvement of miR-214 iSMC differentiation from AdSPCs, the 
potential importance of this miRNA in other cellular functions including 
AdSPC migration, proliferation and apoptosis cannot be simply ignored, 
since all of them have been implicated in injury-induced neointima 
formation and other CVDs. 
 
Third, as it has been repeatedly mentioned within previous sections that 
given miRNA could target multiple downstream genes in one or more 
pathophysiological conditions, it would be important for us to further 
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examine if there is additional target gene(s) (apart from Sufu) that would 
also play a role in iSMC differentiation from AdSPCs regulated by miR-214. 
Fourth, since atherosclerosis is the main underlying cause of ischemic 
diseases, unravelling a role for miR-214 in atherosclerosis would be 
paramount to moving this thesis close to clinical application. 
 
Last but most importantly, more rigorous preclinical studies using a more 
clinically relevant model (such as stent implantation in porcine coronary 
artery with hyperlipidemia), would be required for further validating the 
findings presented in this thesis before one could consider its clinical 
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